

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 960 107 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:

02.10.2002 Bulletin 2002/40

(51) Int Cl.7: **C07D 305/14, A61K 31/335,
C07D 409/12**

(21) Application number: **97954044.0**

(86) International application number:
PCT/US97/22152

(22) Date of filing: **05.12.1997**

(87) International publication number:
WO 98/028288 (02.07.1998 Gazette 1998/26)

(54) 6-THIO-SUBSTITUTED PACLITAXELS

IN 6-POSITION DURCH THIO SUBSTITUIERTE PACLITAXELE

PACLITAXELS A SUBSTITUTION THIO EN 6

(84) Designated Contracting States:
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE**

(30) Priority: **24.12.1996 US 33419 P
23.01.1997 US 36351 P**

(43) Date of publication of application:
01.12.1999 Bulletin 1999/48

(73) Proprietor: **Bristol-Myers Squibb Company
Wallingford, CT 06492-7660 (US)**

(72) Inventors:
• **STAAB, Andrew, J.
Middletown, CT 06457 (US)**
• **KADOW, John, F.
Wallingford, CT 06492 (US)**

• **VYAS, Dolatrai, M.
Madison, CT 06443 (US)**
• **WITTMAN, Mark, D.
Cheshire, CT 06410 (US)**
• **MASTALERZ, Harold, A.
Guilford, CT 06437 (US)**

(74) Representative: **Josif, Albert, Dr.-Ing. et al
Baaderstrasse 3
80469 München (DE)**

(56) References cited:
• **TETRAHEDRON LETTERS, 1995, Vol. 36, No. 17,
LIANG et al., "Synthesis and Biological
Evaluation of Paclitaxel Analogs Modified in
Ring C", pages 2901-2904.**


Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description**Field of the Invention**

- 5 [0001] The present invention concerns antitumor compounds. More particularly, the invention provides novel paclitaxel derivatives, pharmaceutical formulations thereof, and their use as antitumor agents.

Background Art


- 10 [0002] Taxol® (paclitaxel) is a natural product extracted from the bark of Pacific yew trees, *Taxus brevifolia*. It has been shown to have excellent antitumor activity in *in vivo* animal models, and recent studies have elucidated its unique mode of action, which involves abnormal polymerization of tubulin and disruption of mitosis. It has recently been ap-
 15 proved for the treatment of refractory advanced ovarian cancer and breast cancer; and studies involving other cancers have shown promising results. The results of paclitaxel clinical studies are reviewed by numerous authors, such as by Rowinsky and Donehower in "The Clinical Pharmacology and Use of Antimicrotubule Agents in Cancer Chemothera-
 20 peutics," *Pharmac. Ther.*, 52:35-84, 1991; by Spencer and Faulds in "Paclitaxel, A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in the Treatment of Cancer," *Drugs*, 48 (5) 794-847, 1994; by K.C. Nicolaou et al. in "Chemistry and Biology of Taxol," *Angew. Chem., Int. Ed. Engl.*, 33: 15-44, 1994; by F.A. Holmes, A.P. Kudelka, J.J. Kavanaugh, M. H. Huber, J. A. Ajani, V. Valero in the book "Taxane Anticancer Agents Basic
 Science and Current Status" edited by Gunda I. Georg, Thomas T. Chen, Iwao Ojima, and Dolotrai M. Vyas, 1995,
 25 American Chemical Society, Washington, DC, 31-57; by Susan G. Arbuck and Barbara Blaylock in the book "TAXOL® Science and Applications" edited by Mathew Suffness, 1995, CRC Press Inc., Boca Raton, Florida, 379-416; and also in the references cited therein.
- [0003] A semi-synthetic analog of paclitaxel named Taxotere® (docetaxel) has also been found to have good anti-
 30 tumor activity. The structures of paclitaxel and Taxotere® are shown below along with the conventional numbering system for molecules belonging to the class; such numbering system is also employed in this application.



Taxol®: R = Ph; R' = acetyl
 Taxotere®: R = t-butoxy; R' = hydrogen

SUMMARY OF THE INVENTION

- 40 [0004] This invention describes novel antitumor compounds in which the C-6 position of the taxane core is linked by a direct bond to a sulfur atom. This invention relates to novel antitumor compounds represented by formula I, or phar-
 45 maceutically acceptable salts thereof
- [0005] A compound of formula I, or a pharmaceutically acceptable salt thereof



wherein:

R is aryl, substituted aryl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₃₋₆ cycloalkyl, or heteroaryl;

R^B is -NHC(O)-aryl, -NHC(O)-substituted aryl, -NHC(O)-heteroaryl, -NHC(O)OCH₂Ph, -NHC(O)O-(C₁₋₆ alkyl), or -NHC(O)O-(C₃₋₆ cycloalkyl);

R^D is hydroxy, -OC(O)R^X, -OC(O)OR^X, OP(O)(OH)₂, OCH₂OP(O)(OH)₂, -OCH₂OCH₂OP(=O)(OH)₂, OP(O)(OH)₂ base, OCH₂OP(O)(OH)₂ base, -OCH₂OCH₂OP(=O)(OH)₂ base, -(OCH₂)_mOC(=O)CH(Rⁿ)NR'₆R'₇, -OCOCH₂CH₂NH₃⁺HCOO⁻, -OCOCH₂CH₂COOH, -OCO(CH₂)₃COOH, -OC(O)(CH₂)_aNR^FR^G, where a is 0-3, -OC(O)CH₂CH₂C(O)OCH₂CH₂OH or -OC(O)-Z-C(O)-Rⁱ;

R^X is benzoyl, acetyl, phenylacetyl, formyl, mono-, di-, and trihaloacetyl.

Z is -CH₂CH₂-, -CH₂CH₂CH₂-, -CH=CH-, 1,2-cyclohexane or 1,2-phenylene;

Rⁱ is -OH, -OH base, -NR'₂R'₃, -OR'₃, -SR'₃, or -OCH₂C(O)NR'₄R'₅;

R'₂ is -H or -CH₃;

R'₃ is -(CH₂)_jNR'₆R'₇ or (CH₂)_nN⁺R'₆R'₇R'₈X⁻, where j is 1-3;

R'₄ is -H or -C₁₋₄ alkyl;

R'₅ is -H, -C₁₋₄ alkyl, benzyl, hydroxyethyl, -CH₂CO₂H or dimethylaminoethyl;

R'₆ and R'₇ are independently -H, -CH₃, -CH₂CH₃, benzyl or R'₆ and R'₇ together with the nitrogen of NR'₆R'₇ form a pyrrolidino, piperidino, morpholino, or N-methylpiperizino group;

R'₈ is -CH₃, -CH₂CH₃ or benzyl;

X⁻ is halide;

base is NH₃, (HOC₂H₄)₃N, N(CH₃)₃, CH₃N(C₂H₄)₂NH, NH₂(CH₂)₆NH₂, N-methylglucamine, NaOH or KOH;

R^F and R^G are independently -H or -C₁₋₃ alkyl, or R^F and R^G taken together with the nitrogen of NR^FR^G form a pyrrolidino, piperidino, morpholino or N-methylpiperizino groups;

Rⁿ is -H, -CH₃, -CH₂CH(CH₃)₂, -CH(CH₃)CH₂CH₃, -CH(CH₃)₂, -CH₂phenyl, -(CH₂)₃NH₂, -(CH₂)₄NH₂, -CH₂CH₂COOH, -(CH₂)₃NHC(=NH)NH₂, the residue of the amino acid proline, -OC(O)CH=CH₂, -C(O)CH₂CH₂C(O)NHCH₂CH₂SO₃⁻Y⁺ or -OC(O)CH₂CH₂C(O)NHCH₂CH₂CH₂SO₃⁻Y⁺;

Y⁺ is Na⁺ or N⁺(Bu)₄;

R² is phenyl or substituted phenyl;

R⁴ is C₁₋₄ alkyl, C₃₋₅ cycloalkyl or -O-(C₁₋₄ alkyl);

L is O or S;

R⁶ and R^{6'} are independently hydrogen, -SH, -S-[C₁₋₆ alkyl(OH)_m], -S-ethenyl, -S-substituted ethenyl, -S(O)_nCH₂CN, -S(O)_nCH₂C(O)Q, -SCH₂ halogen, -SC(O)-[C₁₋₆ alkyl(OH)_m], -SC(O)O(C₁₋₆ alkyl), -SC(O)N(W)₂, -SC(S)-(C₁₋₆ alkyl), -SC(S)O(C₁₋₆ alkyl), -SC(S)N(W)₂, -S(O)_n-[C₁₋₆ alkyl(OH)_m], -S(C₁₋₆ alkyl)₂⁺X⁻, -S(O)₂OH, -S(O)₂NH[C₁₋₆ alkyl(OH)_m], -S(O)₂N[C₁₋₆ alkyl(OH)_m]₂, -S-S-[C₁₋₆ alkyl(OH)_m], -S-S-substituted phenyl, -S(O)-CN, -S(O)₂-CN, -SCH₂O[C₁₋₆ alkyl(OH)_m], -SCH(C₁₋₆ alkyl)O[C₁₋₆ alkyl(OH)_m], -SCH₂OCH₂OCH₃, -SCH₂S [C₁₋₆ alkyl(OH)_m], -SCH₂S(O)[C₁₋₆ alkyl(OH)_m], -SCH₂S(O)₂[C₁₋₆ alkyl(OH)_m], -S-heteroaryl or -SCN; with the proviso that R⁶ and R^{6'}

are not both hydrogen;

m is 0, 1, 2 or 3;

n is 0, 1, or 2;

S-substituted ethenyl is -S-C(R^H)=C(R^J)(R^K), wherein two of R^H, R^J and R^K are each H and the other of R^H, R^J and R^K is C₁₋₃ alkyl, CN, COOC₁₋₃ alkyl, S(O)₂CH₃ or C(O)CH₃;

W is H or C₁₋₆ alkyl;

Q is -[C₁₋₆ alkyl(OH)_m], -O(C₁₋₆ alkyl), -OCH₂CCl₃, -N(W)₂ or -C(O)OH;

R⁷ is hydrogen, hydroxy or when taken together with R¹⁹ forms a cyclopropane ring;

R⁹ and R^{9'} are independently hydrogen or hydroxy or R⁹ and R^{9'} together form an oxo (keto) group;

R¹⁰ is hydrogen, hydroxy or -OC(O)-(C₁₋₆ alkyl);

R¹⁴ is hydrogen or hydroxy; and

R¹⁹ is methyl or when taken together with R⁷ forms a cyclopropane ring.

[0006] A preferred embodiment are compounds with the structure I or pharmaceutically acceptable salts thereof

5 wherein:

R is phenyl, p-fluorophenyl, p-chlorophenyl, p-hydroxyphenyl, p-tolyl, isopropyl, isopropenyl, isobutenyl, isobutyl, cyclopropyl, furyl, or thienyl;

10 R² is phenyl;

L is O;

R⁶ is hydrogen;

15

R⁶ is -SH, -S-[C₁₋₆ alkyl(OH)_m], -S-ethenyl, -S-substituted ethenyl, -S(O)_nCH₂CN, -S(O)_nCH₂C(O)Q, -SCH₂ halogen, -SC(O)-[C₁₋₆ alkyl(OH)_m], -SC(O)O(C₁₋₆ alkyl), -SC(O)N(W)₂, -SC(S)-(C₁₋₆ alkyl), -SC(S)O(C₁₋₆ alkyl), -SC(S)N(W)₂, -S(O)_n-[C₁₋₆ alkyl(OH)_m], -S(C₁₋₆ alkyl)₂⁺ X⁻, -S(O)₂OH, -S(O)₂NH[C₁₋₆ alkyl(OH)_m], -S(O)₂N[C₁₋₆ alkyl(OH)_m]₂, -S-S-[C₁₋₆ alkyl(OH)_m], -S-S-substituted phenyl, -S(O)-CN, -S(O)₂-CN, -SCH₂O[C₁₋₆ alkyl(OH)_m], -SCH(C₁₋₆ alkyl)O[C₁₋₆ alkyl(OH)_m], -SCH₂OCH₂OCH₃, -SCH₂S[C₁₋₆ alkyl(OH)_m], -SCH₂S(O)[C₁₋₆ alkyl(OH)_m], -SCH₂S(O)₂(C₁₋₆ alkyl(OH)_m), -S-heteroaryl or -SCN;

20

m is 0, 1, 2 or 3;

25

n is 0, 1, or 2;

W is H or C₁₋₆ alkyl;

R⁹ and R^{9'} together form an oxo (keto) group;

30

R¹⁰ is hydroxy or -OC(O)CH₃; and

R¹⁴ is hydrogen.

35 [0007] Another preferred embodiment are compounds with the structure I or pharmaceutically acceptable salts thereof
of
wherein:

40 R⁶ is -SH, -S-[C₁₋₆ alkyl(OH)_m], -S(O)_n-[C₁₋₆ alkyl(OH)_m], -S-ethenyl, -S-substituted ethenyl, -SCH₂CN, -S(O)CH₂CN, -SCH₂C(O)Q, -SC(O)-[C₁₋₆ alkyl(OH)_m], -SCH₂O[C₁₋₆ alkyl(OH)_m], -SCH(C₁₋₆ alkyl)O[C₁₋₆ alkyl(OH)_m], -SCH₂OCH₂OCH₃, -SCH₂S[C₁₋₆ alkyl(OH)_m], -SCH₂S(O)(C₁₋₆ alkyl(OH)_m), -SCH₂S(O)₂(C₁₋₆ alkyl(OH)_m), or -SCN.

45 [0008] Another preferred embodiment are compounds with the structure I or pharmaceutically acceptable salts thereof
of
wherein:

R^B is -NHC(O)-Ph or -NHC(O)C-(C₁₋₆ alkyl);

50

R^D is hydroxy;

R⁴ is methyl;

55 R⁶ is -S-[C₁₋₆ alkyl(OH)_m], -S-ethenyl, -S-substituted ethenyl, -SCH₂CN, -S(O)CH₂CN, -SCH₂C(O)Q, -S(O)(C₁₋₆ alkyl), -SC(O)-[C₁₋₆ alkyl(OH)_m], -SCH₂OCH₃, -SCH₂OCH₂OCH₃, -SCH₂S(C₁₋₆ alkyl), -SCH₂S(O)(C₁₋₆ alkyl), or -SCN; and

R⁷ is hydrogen or when taken together with R¹⁹ forms a cyclopropane ring.

[0009] Another preferred embodiment are compounds with the structure I or pharmaceutically acceptable salts thereof wherein:

5 R⁷ is hydrogen; and

R¹⁹ is methyl.

10 [0010] Another preferred embodiment are compounds with structure I or pharmaceutically acceptable salts thereof wherein:

R is phenyl;

15 R⁶ is -S-methyl, -S-ethyl, -S-ethenyl, -SCH₂CN, -S(O)CH₂CN, -SCH₂C(O)-(C₁₋₆ alkyl), -S(O)-(C₁₋₆ alkyl), -SC(O)-[C₁₋₆ alkyl(OH)_m], -SCH₂OCH₃, -SCH₂OCH₂OCH₃, -SCH₂SCH₃, -SCH₂S(O)(CH₃), or -SCN; and

R¹⁰ is -OC(O)CH₃.

20 [0011] Another preferred embodiment are compounds with structure I or pharmaceutically acceptable salts thereof wherein:

R is phenyl or substituted phenyl;

25 R^B is -NHC(O)Ph or -NHC(O)O(C₁₋₆ alkyl);

R^D is hydroxy;

R² is phenyl;

30 R⁴ is methyl;

L is O;

35 R^{6'} is hydrogen;

R⁶ is -SH, -S(C₁₋₃ alkyl), -SCN, -S-ethenyl, -SCH₂CN, -SCH₂CH₂OH, -SCH₂(O)-[C₁₋₆ alkyl (OH)_m] or -S-(2-thienyl);

R⁷ is hydrogen;

40 R⁹ and R^{9'} together form an oxo (keto) group;

R¹⁰ is -OC(O)CH₃ or OH;

45 R¹⁴ is hydrogen; and

R¹⁹ is methyl.

[0012] Another preferred embodiment are compounds with structure I or pharmaceutically acceptable salts thereof wherein:

50 R is phenyl, p-chlorophenyl, p-methylphenyl, p-fluorophenyl or p-hydroxyphenyl.

55 [0013] Another aspect of the present invention provides a method for inhibiting tumor in a mammalian host which comprises administering to said mammalian host an antitumor effective amount of any of the aforementioned compounds of formula I.

[0014] Yet, another aspect of the present invention provides a pharmaceutical formulation which comprises an antitumor effective amount of any of the aforementioned compounds of formula I in combination with one or more pharmaceutically acceptable carriers, excipients, diluents or adjuvants.

DETAILED DESCRIPTION

[0015] In the application, unless otherwise specified explicitly or in context, the following definitions apply. The numbers in the subscript after the symbol "C" define the number of carbon atoms a particular group can contain. For example "C₁₋₆ alkyl" means a straight or branched saturated carbon chain having from one to six carbon atoms; examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, n-pentyl, sec-pentyl, isopentyl, and n-hexyl. Depending on the context, "C₁₋₆ alkyl" can also refer to C₁₋₆ alkylene which bridges two groups; examples include propane-1,3-diyl, butane-1,4-diyl, 2-methylbutane-1,4-diyl, etc. "C₂₋₆ alkenyl" means a straight or branched carbon chain having at least one carbon-carbon double bond, and having from two to six carbon atoms; examples include ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, pentenyl, and hexenyl. Depending on the context, "C₂₋₆ alkenyl" can also refer to C₂₋₆ alkenediyl which bridges two groups; examples include ethylene-1,2-diyl (vinylene), 2-methyl-2-butene-1,4-diyl, 2-hexene-1,6-diyl, etc. "C₂₋₆ alkynyl" means a straight or branched carbon chain having at least one carbon-carbon triple bond, and from two to six carbon atoms; examples include ethynyl, propynyl, butynyl, and hexynyl.

[0016] "Aryl" means aromatic hydrocarbon having from six to ten carbon atoms; examples include phenyl and naphthyl. "Substituted aryl" means aryl independently substituted with one to five (but preferably one to three) groups selected from C₁₋₆ alkanoyloxy, hydroxy, halogen, C₁₋₆ alkyl, trifluoromethyl, C₁₋₆ alkoxy, aryl, C₂₋₆ alkenyl, C₁₋₆ alkanoyl, nitro, amino, cyano, azido, C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, and amido. "Halogen" means fluorine, chlorine, bromine, and iodine.


[0017] "Heteroaryl" means a five- or six-membered aromatic ring containing at least one and up to four non-carbon atoms selected from oxygen, sulfur and nitrogen. Examples of heteroaryl include thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl, thiatriazolyl, oxatriazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, tetrazinyl, and like rings.

[0018] "Hydroxy protecting groups" include, but is not limited to, ethers such as methyl, t-butyl, benzyl, p-methoxybenzyl, p-nitrobenzyl, allyl, trityl, methoxymethyl, methoxyethoxymethyl, ethoxyethyl, tetrahydropyranyl, tetrahydrothiopyranyl, dialkylsilyl ethers, such as dimethylsilyl ether, and trialkylsilyl ethers such as trimethylsilyl ether, triethylsilyl ether, and t-butyl dimethylsilyl ether; esters such as benzoyl, acetyl, phenylacetyl, formyl, mono-, di-, and trihaloacetyl such as chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl; and carbonates such as methyl, ethyl, 2,2,2-trichloroethyl, allyl, benzyl, and p-nitrophenyl. Additional examples of hydroxy protecting groups may be found in standard reference works such as Greene and Wuts, *Protective Groups in Organic Synthesis*, 2d Ed., 1991, John Wiley & Sons, and McOmie; and *Protective Groups in Organic Chemistry*, 1975, Plenum Press.

[0019] "Ph" means phenyl; "ipr" means isopropyl; "DAST" means diethylamino sulfur trifluoride.

[0020] The substituents of the substituted alkyl, alkenyl, alkynyl, aryl, and heteroaryl groups and moieties described herein, may be alkyl, alkenyl, alkynyl, aryl, heteroaryl and/or may contain nitrogen, oxygen, sulfur, halogens and include, for example, lower alkoxy such as methoxy, ethoxy, butoxy, halogen such as chloro or fluoro, nitro, amino, and keto.

[0021] The term "taxane" or "taxane core" refers to moieties with a framework of the structure:



[0022] The cyclopropane group which can be constituted from R⁷ and R¹⁹ of formula I can alternatively be referred to as "7b,8b-methano" group as in Tetrahedron Letters, Vol 35, No 43, pp 7893-7896 (1994) or as "cyclopropa" group as in U.S. Patent No. 5,254,580 issued October 19, 1993.

[0023] The new products that have the general formula I display a significant inhibitory effect with regard to abnormal cell proliferation, and have therapeutic properties that make it possible to treat patients who have pathological conditions associated with an abnormal cell proliferation. The pathological conditions include the abnormal cellular proliferation of malignant or non-malignant cells in various tissues and/or organs, including, non-limitatively, muscle, bone and/or conjunctive tissues; the skin, brain, lungs and sexual organs; the lymphatic and/or renal system; mammary cells and/or blood cells; the liver, digestive system, and pancreas; and the thyroid and/or adrenal glands. These pathological conditions can also include psoriasis; solid tumors; ovarian, breast, brain, prostate, colon, stomach, kidney, and/or testicular cancer, Kaposi's sarcoma; cholangiocarcinoma; choriocarcinoma; neuroblastoma; Wilm's tumor, Hodgkin's disease; melanomas; multiple myelomas; chronic lymphocytic leukemias; and acute or chronic granulocytic lymphomas. The novel products in accordance with the invention are particularly useful in the treatment of non-Hodgkin's

lymphoma, multiple myeloma, melanoma, and ovarian, urothelial, oesophageal, lung, and breast cancers. The products in accordance with the invention can be utilized to prevent or delay the appearance or reappearance, or to treat these pathological conditions. In addition, the compounds of formula I are useful in treating and/or preventing polycystic kidney diseases (PKD) and rheumatoid arthritis.

[0024] The compounds of this invention can be made by techniques from the conventional organic chemistry repertoire. Schemes I - XII, which depict processes that compounds within the scope of formula I can be made, are only shown for the purpose of illustration and are not to be construed as limiting the processes to make the compounds by any other methods.


[0025] The procedures for preparing taxane derivatives which contain a hydroxy group at C-6 and which are deoxygenated at C-7 are disclosed in our colleague's co-pending application Serial Number 60/019,493 filed June 6, 1996; the disclosure of which is herein incorporated by reference in its entirety. Schemes I and II illustrate the chemistry from this application which is utilized to synthesize 7-deoxy-6- α -hydroxy-paclitaxel analogs. Although the protecting group used to protect the 2' hydroxy group in the sidechain in this scheme is a trialkyl silyl ether, other protecting groups which are well known in the taxane art could be utilized.

[0026] The preparation of a diol intermediate is shown in Scheme I. The starting material is a taxane analog suitably protected to leave the most reactive hydroxy group at C-7. Compound 1 in Scheme I is protected at the 2' hydroxy group at the sidechain with a triethylsilyl ether. The preparation of intermediates such as 1 are now well known in the art. The synthesis of diol 4 utilizes precursor 6,7-olefin analogs 3 which is also now well known in the art. Compound 3 can be formed directly from intermediate's 1 upon treatment with a reagent such as DAST as described in the U.S. patent 5,380,751. The synthesis of olefin 3 described in Scheme I proceeds through the 7-trifluoromethanesulfonate (triflate) intermediates 2 which are prepared as shown in step A. Elimination of the triflate (step B) provides the desired olefins 3. The preparation of 7-O triflates and their conversion into cyclopropanes and olefins has been divulged by Johnson, R.A., *et al.*, *Taxol chemistry. 7-O-Triflates as precursors to olefins and cyclopropanes. Tetrahedron Letters*, 1994, 35(43): p. 7893-7896 & by the same authors in WO 94/29288.


[0027] The olefin 3 is then hydroxylated with Osmium tetroxide (step C) which is used in either stoichiometric quantities or catalytically in the presence of a cooxidant such as N-methyl morpholine-N oxide (NMO). A patent application on such diol intermediates which includes some methods of its preparation has been published: Roth *et. al.* 6,7 EP 0 600 517 A1. A protected taxane diol intermediate has also been described in the literature by Liang *et. al.* *Tetrahedron Letters* 1995, 36(17) 2901-2904. and *ibid.* 1995, 36(43) 7795-7798. The osmium reagent only reacts from the face of the double bond which is down or α as the taxane core is depicted in this document. Thus this reaction provides only one stereoisomer.

[0028] The preferred approach to the initial 7-deoxy-substituted taxanes is shown in Scheme II. An advantage of this approach is it avoids the need for a selective protection of the starting 6,7 diol 4. A new cyclic thiocarbonate 5 is formed (step D) upon reaction with thiocarbonyldiimidazole (or alternatively thiophosgene could be used) under standard conditions of amine base and optional inert solvent. Other standard organic chemistry bases could also be utilized. Reduction of the thiocarbonate 5 (step E) with most preferably, a trialkyl germane such as tri-n-butyl germane provides the C-7 deoxy compound 6 with little, if any, competitive formation of the C-6 deoxy material. Alternatively, a trialkyl tin hydride could be utilized in place of the germanium reagent. The use of the tin hydride reagent also results in competitive deoxygenation at C-10 which produces mixtures which must be separated. The tin reagent is the method of choice for producing C 7 and 10 deoxy -6-substituted analogs if these are the desired targets. The use of trialkyl germane to suppress an unwanted side reaction is notprecedented. This reagent has been studied by physical chemists in other radical reactions. J. W. Wilt *et.al.* *J. Am. Chem. Soc.* 1988, 110, 281-287. The product of step E is a 7-deoxy-6- α -hydroxy intermediate 6 which is protected at the sidechain. The above reactions are demonstrated in Example 1.


Scheme I




Scheme I continued



Scheme II




Scheme III



[0029] Scheme III illustrates the preparation of the C-6 trifluoromethanesulfonate (triflate or Tf) **7** from the C-6 hydroxy compound **6**. The conversion is carried out as shown in Step f using Triflic anhydride and 4-N,N-Dimethylamino pyridine (DMAP) as a catalyst. Although other amine bases could be utilized, the conditions described in the experimental are preferred. While a number of nonprotic organic solvents can be utilized successfully for this reaction, the preferred solvent is dichloromethane.


[0030] Scheme IV, step G illustrates a direct displacement of the trifluoromethanesulfonate of Compound **7** to produce the methyl sulfide **8**. Lithium or potassium mercaptides could also be utilized. Although a number of organic solvents such as DMSO, DMF, THF, dioxane or others could be utilized for this transformation, the preferred solvent is DMF. The mercaptide derived from methyl mercaptan is depicted in this scheme, but mercaptides derived from other alkyl and aromatic thiols can be used similarly. The products from this reaction can be purified using preparative HPLC or chromatography. Although the trifluoromethanesulfonate derivative is used in this reaction sequence, the corresponding p-tolylsulfonate or methanesulfonate derivatives could be used similarly.

Scheme IV




[0031] As shown in step H of Scheme 4, the 2' triethylsilyl protecting group present in sulfide 8 can be removed using aqueous HCl in acetonitrile to provide 9 which is a compound claimed in this invention. These are standard conditions for removing silyl protecting groups from taxanes and other standard conditions such as fluoride sources could also have been utilized.

Scheme V




[0032] As shown in Scheme V, the triflate intermediate 7 reacts quite efficiently with the potassium salt of thioacetic acid in DMF to provide the thioester analog 10. The salts of other thio acids could be utilized similarly. Other solvents as discussed above can also be employed. An alternative synthesis of thioester 10 could be realized by reacting alcohol 6 with thioacetic acid in the presence of DEAD (diethyl azodicarboxylate) and triphenylphosphine. These and other variations of the Mitsunobu reaction (J. Med. Chem. 1994, 37, 674) could be employed. Step J describes the standard deprotection step to produce analog 11 which is a compound claimed in this patent and which has useful antitumor properties.

Scheme VI




- [0033] Scheme VI, step K depicts the ammonolysis of the thioester at position 6 of **10** to produce the C-6 mercaptan **12**. Although other hydrolysis conditions such as aqueous base in the presence of an organic cosolvent can be utilized the depicted ammonolysis is the preferred method. As shown in step L, standard deprotection produces **13** which is a compound with useful antitumor properties.
- [0034] Mercaptan intermediate **12** can be alkylated or acylated with typical electrophiles to produce new analogs. For example Scheme VII illustrates the formation of methyl sulfide **8** via alkylation (step M). Deprotection as already described in step H of Scheme IV produces sulfide **9**. This is the preferred method for synthesizing methyl sulfide **9**. Other thiol alkylation conditions which are well known in the art could also be used to accomplish similar reactions.

Scheme VII




[0035] Scheme VIII, step N illustrates the reaction of thiol 12 with ethylene oxide in the presence of catalytic DBU to produce the 2-hydroxyethyl sulfide derivative 14. Standard removal of the 2' protecting group provides hydroxy sulfide 15 which is a compound with useful antitumor properties.

Scheme VIII




[0036] Reaction of triflate 7 (Scheme IX) with potassium thiocyanate in a suitable solvent such as DMF at an elevated temperature of approximately 100° provided the thiocyanate intermediate 16 as well as the deprotected compound 17. Standard deprotection provided 17, which is a compound with useful antitumor properties.

Scheme IX




[0037] As shown in Scheme X and Scheme XI C-6 sulfide derivatives can be oxidized to produce either sulfoxides (both diastereoisomers) or sulfones. Using 1 eq. of MCPBA (Step R) produces sulfoxide 18 which can be deprotected to provide 19. It is likely that reversing the sequence of these steps could also result in the same outcome. Similarly, as shown in Scheme XI, use of two equivalents of oxidizing agent (step T) results in the formation of a sulfone 20 which after deprotection provides the target compound 21. Other peracids or standard oxidizing agents for sulfur should work similarly.

Scheme X




step R


~1 eq. MCPBA,
-35° to -45°, CH₂Cl₂.




step S

HCl/CH₃CN


Scheme XI




step T

-2 eq. MCPBA,
0°, CH₂Cl₂.

step U

HCl/CH₃CN

Scheme XII



[0038] The examples shown in Schemes I-XI describe compounds containing a paclitaxel sidechain. It is well known in the art that chemistry that works with a paclitaxel sidechain works with other standard sidechains or on baccatin III analogs which contain a suitably protected C-13 hydroxy group. Examples of suitable C-13 protecting groups include trialkylsilyl, TROC, or phenoxy acetate.

[0039] Scheme XII illustrates the preparation of a taxane analog having a modified paclitaxel side chain.

[0040] Some of the schemes refer to a hydroxy protecting group, preferably trialkylsilyl group. It is to be understood that hydroxy protecting group may be a carbonate or ester group $-\text{C}(\text{O})\text{OR}^x$ or $-\text{C}(\text{O})\text{R}^x$. Thus when such a group is employed as a hydroxy protecting group, it may either be removed to generate the free hydroxy protecting group or it may remain as a part of the final product.

[0041] By now there are many publications teaching the introduction of a wide variety of groups onto a taxane core. By using these well established methods or obvious variants thereof, the starting taxanes of formula VII, or hydroxy protected analogues thereof, can be readily made. For example, for transforming C4-acetoxy into other functional

groups see, S. H. Chen et al., *J. Organic Chemistry*, 59, pp 6156-6158 (1994) and PCT application WO 94/14787 published July 7, 1994; for converting C2-benzoyloxy to other groups see, S.H. Chen et al, *Bioorganic and Medicinal Chemistry Letters*, Vol. 4, No. 3, pp 479-482 (1994); K.C. Nicolaou et al., *J. Am. Chem. Soc.*, 1995, 117, 2409 and European Patent Application 617,034A1 published September 28, 1994; for modifying C10-acetyloxy see, K.V. Rao et al., *J. Med. Chem.*, 38, pp 3411-3414 (1995), J. Kant et al., *Tetrahedron Letters*, Vol. 35, No. 31, pp 5543-5546 (1994); and U.S. Patent No. 5,294,637 issued March 15, 1994; for making C10 and/or C7 unsubstituted (deoxy) derivatives see, European Patent Application 590,267A2 published April 6, 1994 and PCT application WO 93/06093 published April 1, 1993; for making C-10 epi hydroxy or acyloxy compounds see PCT application WO 96/03394; for making C-10 deoxy-C-10 alkyl analogs see PCT application WO95/33740; for making 7b,8b-methano, 6a,7a-dihydroxy and 6,7-olefinic groups see, R. A. Johnson, *Tetrahedron Letters*, Vol. 35, No 43, pp 7893-7896 (1994), U.S. Patent No. 5,254,580 issued October 19, 1993, and European Patent Application 600,517A1 published June 8, 1994; for making C7/C6 oxirane see, X. Liang and G.I. Kingston, *Tetrahedron Letters*, Vol. 36, No. 17, pp 2901-2904 (1995); for making C7-epi-fluoro see, G. Roth et al, *Tetrahedron Letters*, Vol 36, pp 1609-1612 (1995); for forming C7 esters and carbonates see, U.S. Patent No. 5,272,171 issued December 21, 1993 and S. H. Chen et al., *Tetrahedron*, 49, No. 14, pp 2805-2828 (1993); for 9a- and 9b-hydroxy taxanes see, L. L. Klein, *Tetrahedron Letters*, Vol 34, No 13, pp 2047-2050 (1993), PCT application WO 94/08984 published April 28, 1994, U.S. Patent No. 5,352,806 issued October 4, 1994, PCT application WO 94/20485 published September 15, 1994, and G.I. Georg et. al., *Tetrahedron Letters*, Vol 36, No 11, pp 1783-1786 (1995). Substituents containing a sulfur atom attached to the taxane core have been reported in European Publication 0604910A1 published on July 6, 1994 and PCT Application WO 96/00724 published on January 11, 1996. However, such sulfur atoms are not directly bonded to the taxane core as are the compounds herein invented.

DESCRIPTION OF SPECIFIC EMBODIMENTS

[0042] The specific examples that follow illustrate the syntheses of the compounds of the instant invention, and is not to be construed as limiting the invention in sphere or scope. The method may be adapted to variations in order to produce the compound embraced by this invention but not specifically disclosed. Further, variations of the methods to produce the same compound in somewhat different manner will also be evident to one skilled in the art.

[0043] In the following experimental procedures, all temperatures are understood to be in Centigrade (C) when not specified. The nuclear magnetic resonance (NMR) spectral characteristics refer to chemical shifts (δ) expressed in parts per million (ppm) versus tetramethylsilane (TMS) as reference standard. The relative area reported for the various shifts in the proton NMR spectral data corresponds to the number of hydrogen atoms of a particular functional type in the molecule. The nature of the shifts as to multiplicity is reported as broad singlet (bs or br s), broad doublet (bd or br d), broad triplet (bt or br t), broad quartet (bq or br q), singlet (s), multiplet (m), doublet (d), quartet (q), triplet (t), doublet of doublet (dd), doublet of triplet (dt), and doublet of quartet (dq). The solvents employed for taking NMR spectra are acetone- d_6 (deuterated acetone), DMSO- d_6 (perdeuterodimethylsulfoxide), D_2O (deuterated water), $CDCl_3$ (deuteriochloroform) and other conventional deuterated solvents. The infrared (IR) spectral description include only absorption wave numbers (cm^{-1}) having functional group identification value.

[0044] Celite is a registered trademark of the Johns-Manville Products Corporation for diatomaceous earth.

[0045] The abbreviations used herein are conventional abbreviations widely employed in the art. Some of which are: DAB (deacetylbaicatin III); MS (mass spectrometry); HRMS (high resolution mass spectrometry); Ac (acetyl); Ph (phenyl); v/v (volume/volume); FAB (fast atom bombardment); NOBA (m-nitrobenzyl alcohol); min (minute(s)); h or hr(s) (hour(s)); DCC (1,3-dicyclohexylcarbodiimide); BOC (t-butoxycarbonyl); CBZ or Cbz (benzyloxycarbonyl); Bn (benzyl); Bz (benzoyl); Troc (2,2,2-trichloroethoxycarbonyl), DMS (dimethylsilyl), TBAF (tetrabutylammonium fluoride), DMAP (4-dimethylaminopyridine); TES (triethylsilyl); DMSO (dimethylsulfoxide); THF (tetrahydrofuran); HMDS (hexamethyldisilazane); MeOTf (methyltriflate); NMO (morpholine-N-oxide); (DHQ)₂PHAL (hydroquinine 1,4-phthalazinediyl diether). Tf = triflate = trifluoromethanesulfonate; LRMS (low resolution mass spectrometry); ESI (electrospray ionization); MCPBA (meta-chloro-peroxybenzoic acid).

[0046] Also isometric substituent orientations on the taxane molecule are indicated as "a" or "α" meaning in the down position from the planar position of the taxane molecule (e.g. 6a- or 6α- or 6-alpha); "b" or "β" means the up position for the substituent relative to the taxane molecular plane (e.g. 7b- or 7β- or 7-beta).

Preparation of Starting Materials (Scheme I)

2'-O-(triethylsilyl)-paclitaxel [1]

[0047] Paclitaxel (15g, 17.57 mmol) was dissolved in a solution of 60mL of pyridine and 60mL of dichloromethane and then the mixture was cooled to 0°C. Triethylsilyl chloride (11.8mL, 70.3 mmol) and the reaction was stirred for 90 min at 0°. The reaction was diluted with ethyl acetate, washed successively with water and then brine, dried over

[0048] Paclitaxel (146.0 mg, 0.17 mmol) was dissolved in dry N,N-dimethylformamide (1 mL). To this solution imidazole (116.1 mg, 1.7 mmol) and t-butyltrimethylsilyl chloride (128.8 mg, 0.85 mmol) were added successively and the mixture was stirred at 60°C for 1 hour. The reaction mixture was then diluted with ethyl acetate (2 mL), followed by water. The aqueous layer was washed with additional ethyl acetate (2 X 2 mL). The combined organic layers were then washed with water and brine, dried over sodium sulfate, and evaporated to give crude product. Purification of the crude product by preparative TLC (silica gel, 7:3 hexane : ethyl acetate) furnished 2'-O-(t-butyltrimethylsilyl)-paclitaxel (157 mg, 95% yield). ¹H NMR (CDCl₃, TMS, 400 MHz) δ 8.13 (d, 2H, J = 7.0), 7.73 (d, 2H, J = 7.0), 7.62-7.23 (m, 11H), (157 mg, 95% yield). ¹H NMR (CDCl₃, TMS, 400 MHz) δ 8.13 (d, 2H, J = 7.0), 7.73 (d, 2H, J = 7.0), 7.62-7.23 (m, 11H), 7.06 (d, 1H, J = 8.9, H_{NH}), 6.28 (t, 2H, J = 8.9, H₁₀, H₁₃), 5.74-5.67 (m, 2H, H₃, H₂), 4.97 (d, 1H, J = 7.7, H₅), 4.65 (d, 1H, J = 2.2, H₂), 4.50-4.40 (m, 1H, H₇), 4.32 (d, 1H, J = 8.4, H₂₀), 4.21 (d, 1H, J = 8.4, H₂₀), 3.83 (d, 1H, J = 7.1, H₃), 2.57 (s, 3H, -CH₃), 2.54 (m, 1H, H₆), 2.45-2.35 (m, 2H, 7-OH, H₁₄), 2.22 (s, 3H, -CH₃), 2.10 (m, 1H, H₁₄), 1.89 (s, 3H, -CH₃), 1.85 (m, 1H, H₆), 1.68 (s, 3H, -CH₃), 1.23 (s, 3H, -CH₃), 1.12 (s, 3H, -CH₃), 0.80 (s, 9H), -0.05 (s, 3H), -0.3 (s, 3H). LRFABMS *m/z* calcd for C₄₇H₅₂NO₁₅ [MH]⁺ 968, found 968.

[0049] The alcohol **1** (17g, 17.5 mmol) and DMAP (8.55g, 70mmol) was dissolved in dichloromethane and then the mixture was cooled to 0°C. Trifluoromethanesulfonic anhydride (3.39mL, 20.1 mmol) was added via syringe and then reaction was allowed to warm to ambient temperature. The reaction was stirred for 2 hours, was diluted with ethyl acetate, washed successively with water and then brine, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The crude material was purified by flash chromatography over silica gel using 2:1 hexane/ethyl acetate as eluent to provide 17.6g (91%) of the title compound.

[0050] 2'-O-(*t*-butyldimethylsilyl)paclitaxel **[1a]** (180.0 mg, 0.19 mmol) was dissolved in dry CH₂Cl₂ (2 mL). To this solution 4-dimethylaminopyridine (61.0 mg, 0.5 mmol) and trifluoromethanesulfonyl chloride (50 mL, 0.5 mmol) were added successively at 0°C and the mixture was stirred at room temperature for 1 hour. Then to this solution additional 4-dimethylamino pyridine (61.0 mg, 0.5 mmol) and trifluoromethanesulfonyl chloride (50 mL, 0.5 mmol) were added successively and the mixture was stirred at room temperature for additional 1.5 hours. The reaction mixture then was diluted with EtOAc (4.0 mL) and the precipitate was filtered off on Celite. The solvent was evaporated, and the residue was purified by preparative TLC (silica gel, 6:4 hexane : EtOAc) to furnish 2'-O-(*t*-butyldimethylsilyl)-7-O-trifluoromethanesulfonylpaclitaxel (187.0 mg, 92% yield). ¹H NMR (CDCl₃, TMS, 400 MHz) δ 8.12 (d, 2H), 7.73 (d, 2H), 7.60 (t, 1H), 7.53-7.30 (m, 10H), 7.09 (d, 1H, *J* = 8.9, H_{NH}), 6.62 (s, 1H, H₁₀), 6.25 (t, 1H, *J* = 9.2, H₁₃), 5.76 (q, 1H, *J* = 8.9, 2.6, H₃), 5.74 (d, 1H, *J* = 7.0, H₂), 5.49 (dd, 1H, *J* = 7.5, 10.1, H₇), 4.94 (d 1H, *J* = 8.6, H₅), 4.67 (d, 1H, *J* = 2.0, H₂), 4.37 (d, 1H, *J* = 8.5, H₂₀), 4.22 (d, 1H, *J* = 8.5, H₂₀), 3.97 (d, 1H, *J* = 7.0, H₃), 2.85 (m, 1H, H₆) 2.60 (s, 3H, -CH₃), 2.39 (m, 1H, H₁₄), 2.19 (s, 3H, -CH₃), 2.18 (m, 2 H, H₆, H₁₄), 2.08 (s, 3H, -CH₃), 1.89 (s, 3H, -CH₃), 1.22 (s, 3H, -CH₃), 1.18 (s, 3H, -CH₃), 0.8 (s, 9H), -0.02 (s, 3H), -0.29 (s, 3H). ¹³C NMR (CDCl₃, TMS, 100 MHz) δ 200.97, 171.89, 171.16, 169.34, 167.71, 167.42, 141.75, 138.77, 134.66, 134.45, 133.48, 132.46, 130.84, 129.52, 129.47, 129.40, 129.38, 128.65, 127.59, 127.00, 86.39, 83.68, 80.64, 79.25, 76.94, 75.77, 75.74, 74.92, 71.69, 57.97, 56.23, 47.55, 43.75, 36.32, 34.67, 26.76, 26.23, 26.13, 23.47, 22.01, 21.29, 18.75, 14.87, 14.80, 11.538, -4.54, -5.20. LRFABMS *m/z* calcd for C₅₄H₆₅NO₁₆F₃SiS [MH]⁺ 1100, found 1100.

[0051] The triflate **2** (17.6g, 16mmol) was dissolved in 75 mL of dry THF and then 12.18g (80mmol) of DBU was added. The reaction was heated at reflux for 2 hours and then diluted with ethyl acetate. The organic layer was washed five times with water and then brine, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The crude product was dissolved in methylene chloride and then 16 mmol of imidazole and 8 mmol of triethylsilyl chloride were added. The reaction was stirred for 1.5h at ambient temperature, diluted with ethyl acetate, washed with two portions of water, dried over anhydrous magnesium sulfate and concentrated in vacuo. The crude material was purified by flash chromatography over silica gel using 2:1 hexane/ethyl acetate as eluent to provide 15.0g (99%) of the title compound.

2'-O-(tertbutyldimethylsilyl)-6,7-dehydropaclitaxel [3a]

[0052] To a stirred solution of 2'-(*t*-butyldimethylsilyl)-7b-trifluoromethanesulfonylpaclitaxel [2a], (202.0 mg, 0.18mmol) in dry dichloromethane (1.0 mL) was added 1,8-diazabicyclo (5,4,0) undec-7-ene (DBU, 300.0 mL, 2.0 mmol). The mixture was kept stirring at 40°C for 4 hours. The reaction mixture then was diluted with ethyl acetate (2.0 ml) and washed with diluted HCl, diluted NaHCO₃ solution, water and brine. The aqueous layer was extracted with additional ethyl acetate (2 X 2 mL). The combined organic layers were dried over sodium sulfate and evaporated to give crude product. Purification of the crude product by preparative silica gel TLC (7:3 hexane : ethyl acetate) furnished two compounds: 2'-(*t*-butyldimethylsilyl)-6,7-dehydropaclitaxel [3a] (150.0 mg, 86%) and 6,7-dehydropaclitaxel (21.3 mg, 13.9%). Spectroscopic data for 3a: ¹H-NMR (CDCl₃, TMS, 400 MHz) δ 8.12 (d, 2H), 7.73 (d, 2H), 7.60 (t, 1H), 7.53-7.30 (m, 5H), 7.07 (d, 1H, *J* = 8.9, H_{NH}), 6.24 (s, 1H, H₁₀), 6.25 (t, 1H, *J* = 9.2, H₁₃), 6.08 (dd, 1H, *J* = 9.9, 5.6, H₆), 5.87 (d, 1H, *J* = 9.9, H₇), 5.86 (d, 1H, *J* = 6.5, H₂), 5.72 (d, 1H, *J* = 8.6, H₃), 5.12 (d 1H, *J* = 5.5, H₅), 4.65 (d, 1H, *J* = 2.0, H₂), 4.45 (d, 1H, *J* = 8.1, H₂₀), 4.34 (d, 1H, *J* = 8.1, H₂₀), 4.03 (d, 1H, *J* = 6.5, H₃), 2.58 (s, 3H, -CH₃), 2.44 (m, 1H, H₁₄), 2.22 (s, 3H, -CH₃), 2.18 (m, 2 H, H₆, H₁₄), 1.88 (s, 3H, -CH₃), 1.83 (s, 3H, -CH₃), 1.24 (s, 3H, -CH₃), 1.14 (s, 3H, -CH₃), 0.79 (s, 9H), -0.05 (s, 3H), -0.32 (s, 3H). ¹³C NMR (CDCl₃, TMS, 100 MHz) δ 205.44, 171.32, 769.56, 169.39, 166.91, 166.87, 141.60, 140.03, 138.27, 134.06, 133.67, 133.61, 131.76, 130.19, 129.16, 128.80, 128.73, 128.71, 128.69, 127.92, 126.96, 126.3b, 126.126, 81.22, 81.12, 76.31, 75.82, 75.64, 75.12, 71.23, 60.36, 55.65, 55.40, 35.98, 26.29, 25.49 23.14, 22.12, 22.02, 20.744, 20.46, 18.09, 14.62, 14.17, -5.28, -5.89. LRFABMS *m/z* calcd for C₅₃H₆₄NO₁₃Si [MH]⁺ 950, found 950.

2'-O-(triethylsilyl)-6a-hydroxy-7-*epi*-paclitaxel [4]

[0053] The olefin 3 was dissolved in 180mL of acetone and 22.5 mL of water. NMO (4.06g, 34.74 mmol) and OsO₄ (0.200g, 0.79 mmol) were added and the reaction was stirred for 12 days. Silica gel was added and the reaction was concentrated in vacuo to provide a near free flowing powder which was placed on top of a flash chromatography silica gel column. Elution with 1:1 hexane/ ethyl acetate provided 13.35g (86%) of the desired diol.

2'-O-(tertbutyldimethylsilyl)-6a-hydroxy-7-*epi*-paclitaxel [4a]

[0054] To a solution of 2'-O-(*t*-butyldimethylsilyl)-6,7-dehydropaclitaxel [3a], (60.0 mg, 0.063 mmol) in THF (500 mL, 10 drops H₂O) were added osmium tetroxide (2.5 wt. 2.5% solution in 2-methyl-2-propanol, 150 mL, 0.015 mmol) and 4-methyl morpholine-N-oxide (NMO, 50 mg, 0.42 mmol). The mixture was kept stirring at room temperature for 4 hours. Additional osmium tetroxide solution (150 mL, 0.015 mmol) was then added to the reaction mixture to accelerate the reaction. The reaction mixture was kept stirring at room temperature for additional 5 hours. To the reaction solution was added sodium bisulfite (25 mg) and the mixture was stirred for 10 minutes, then diluted with EtOAc (1 mL), filtered through Celite, and washed with H₂O and brine. The aqueous layer was extracted with additional EtOAc (2 X 2 mL). The combined organic layers were dried over Na₂SO₄ and evaporated. Isolation of the residue on preparative TLC plate (silica gel, 1:1 hexane : EtOAc) furnished starting material (7.2 mg, 12%) and a more polar compound 2'-O-(*t*-butyldimethylsilyl)-6a-hydroxy-7-*epi*-paclitaxel [4a] (48.0 mg, 78% yield). ¹H NMR (CDCl₃, TMS, 400 MHz) δ 8.15 (d, 2H), 7.70 (d, 2H), 7.64-7.26 (m, 6H), 7.07 (d, 1H, *J* = 8.8, H_{NH}), 6.83 (s, 1H, H₁₀), 6.29 (t, 1H, *J* = 8.8, H₁₃), 5.79 (q, 1H, *J* = 8.8, 2.4, H₃), 5.74 (d, 1H, *J* = 7.6, H₂), 4.71 (d, 1H, *J* = 12.0, H₇-OH), 4.68 (d, 1H, *J* = 2.0, H₅), 4.66 (bs, 2H, H₂₀), 4.36 (s, 1H, H₂), 4.18 (m, 1H, H₆), 3.87 (d, 1H, *J* = 7.6, H₃), 3.70 (q, 1H, *J* = 5.2, 12.0, H₇), 2.90 (d, 1H, *J* = 8.2, H₆-OH), 2.62 (s, 3H, -CH₃), 2.42-2.10 (m, 2H, H₁₄), 2.18 (s, 3H, -CH₃), 1.90 (s, 3H, -CH₃), 1.62 (s, 3H, -CH₃), 1.18 (s, 3H, -CH₃), 1.12 (s, 3H, -CH₃), 0.78 (s, 9H), -0.03 (s, 3H), -0.3 (s, 3H). HRFABMS *m/z* calcd for C₄₇H₅₂NO₁₅ [MH]⁺ 870.3337, found 870.3336.


Example 1

Preparation of 7-deoxy-6a-hydroxypaclitaxel[6]-(Scheme II)

5 [0055]

10

15




20

[0056] The diol 4 (1.773g, 1.809 mmol), thiocarbonyldiimidazole(0.996 g, 5.427 mmol), DMAP(0.618 g, 5.065 mmol) were dissolved in 50 mL THF and allowed to stir overnight. The reaction was diluted with EtOAc, washed with NaHCO₃, and brine. The solution was dried over MgSO₄, filtered, and concentrated. The residue was chromatographed over silica gel (1:1 hexane/ethyl acetate) to yield 1.646 g of product 5 (89%).

25

30




35

40

ESILRMS M+NH₄⁺ calcd. for C₅₄H₆₃O₁₅N₂S Si: 1043. Found: 1043.
 Anal. calcd. for C₅₄H₆₃O₁₅N₂S Si: C, 63.20; H, 6.19; N, 1.36. Found: C, 63.04; H, 6.22; N, 1.33.
 IR(KBr) 3438(br.), 2958, 1746, 1717, 1282, 1236 cm⁻¹.
¹H NMR (CDCl₃, 300 MHz) δ 8.15(d, J= 7.2 Hz, 2H), 7.74(d, J= 7.2 Hz, 2H), 7.63-7.32(m, 11H), 7.12(d, J= 9.0 Hz, 1H), 6.87(s, 1H), 6.25(br. t., 1H), 5.83(d, J= 6.9Hz, 1H), 5.70(d, J= 9.0, 1H), 4.97(d, J= 11.4 Hz, 1H), 4.87(s, 1H), 4.72(m, 2H), 4.39(d, J= 8.1 Hz, 1H), 4.22(d, J= 8.1 Hz, 1H), 4.00(d, J= 6.9 Hz, 1H), 2.57(s, 3H), 2.43-2.35(m, 1H), 2.21(s, 3H), 2.16-2.08(m, 1H), 2.03(m, 4H), 1.87(s, 3H), 1.21(s, 3H), 1.17(s, 3H), 0.79(m, 9H), 0.44(m, 6H).
 [0057] The thiocarbonate 5 (0.200 g, 0.196 mmol), AIBN(cat.), (aza-isobutyronitrile (catalytic)) and Bu₃GeH(0.479 g, 1.96 mmol) were dissolved in 3 mL toluene under Argon. The reaction mixture was frozen, dried *in vacuo*, and thawed three times to remove O₂. The reaction was heated to 85°C for 1 hr. The reaction mixture was concentrated and chromatographed over silica gel (1.5:1 hexane/ethyl acetate) to yield 0.137 g of product 6 (72%).

45

50



55


ESILRMS M+H calcd for C₅₃H₆₅O₁₄N Si: 968. Found: 968.
 Anal. calcd. for C₅₃H₆₅O₁₄NSi·H₂O: C, 64.55; H, 6.85; N, 1.42. Found: C, 64.49; H, 6.82; N, 1.41.
 IR(KBr) 3442(br.), 2956, 1734, 1486, 1372, 1244, 710 cm⁻¹.

¹H NMR (CDCl₃, 300 MHz) δ 8.13(d, J= 8.7 Hz, 2H), 7.72(d, J= 8.4 Hz, 2H), 7.62-7.33(m, 11H), 7.10(d, J= 8.7 Hz, 1H), 6.45(s, 1H), 6.24(t, J= 8.7 Hz, 1H), 5.71-5.64(m, 2H), 4.80(s, 1H), 4.66(d, J= 2.1 Hz, 1H), 4.31(d, J= 8.4 Hz, 1H), 4.18-4.14(m, 2H), 3.78(d, J= 7.5 Hz, 1H), 2.54(s, 3H), 2.48-2.39(m, 1H), 2.20(s, 3H), 2.17-2.08(m, 1H), 2.02(d, J= 9.0 Hz, 2H), 1.90(s, 4H), 1.77(s, 1H), 1.71(s, 3H), 1.19(s, 3H), 1.10(s, 3H), 0.79(m, 9H), 0.41(m, 6H).


Example 1a

Preparation of 2'-O-(tertbutyldimethylsilyl)-6a-hydroxy-7-deoxypaclitaxel[6a]-(Scheme II)

[0058]



[0059] A solution of (4a) (12.70 g, 12.9 mmoles) in anhydrous THF (300.0 mL) was treated with dimethylaminopyridine (4.73 g, 38.71 mmoles) and 1,1'-thiocarbonyl-diimidazole (7.0 g, 38.71 mmoles). After 3 days, the crude reaction mixture was poured into ethyl acetate (500 mL) and washed with a saturated solution of NaHCO₃ (2x100 mL) followed by brine (2x50 mL). The mixture was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. Purification by column chromatography on silica eluting with 60%-50% hexanes/ethyl acetate afforded 12.9 g (97.4% yield, 92.7% pure by HPLC analysis) of compound 5a as an off-white, amorphous powder which exhibited the following physical properties: LRMS (ESI): 1084.5 ((M+NH₄+ACN)⁺, 35%), 1043.5 ((M+NH₄)⁺, 45%), 1026.5 ((M+1)⁺, 100%).




[0060] A solution of compound 5a (13.4 g, 13.03 mmoles) in anhydrous THF (65.0 mL) was degassed three times using a vacuum freeze/thaw technique. The mixture was heated to reflux under an argon atmosphere and was treated with a solution containing tributylgermanium hydride (20.0 g, 81.65 mmoles) and AIBN (257.1 mg, 1.56 mmoles) in anhydrous THF (15.0 mL) dropwise *via* syringe over a 5 min. period. After 64 mins., the reaction mixture was allowed to cool to ambient temperature and concentrated *in vacuo*. The residue was dissolved in acetonitrile (300 mL) and washed with heptane (2x100 mL) and then concentrated *in vacuo*. Purification by column chromatography on silica eluting with 60%hexanes/ethyl acetate afforded 7.9 g (69.7% yield based on recovered starting material) of compound 6a as an off-white, amorphous powder which exhibited the following physical properties: ¹H NMR (CDCl₃, 300 MHz) δ 8.20 (d, 2H, J= 7.1 Hz), 7.78(d, 2H, J= 7.1 Hz), 7.68-7.34(m, 11H), 7.13(d, 1H, J= 9.0 Hz), 6.52(s, 1H), 6.31(t, 1H, J= 9.0 Hz), 5.80(dd, 1H, J= 8.9, 1.6), 5.71 (d, 1H, J=7.4 Hz), 4.87(s, 1H), 4.70(d, 1H, J= 2.1 Hz), 4.36(d, 1H, J= 8.4 Hz), 4.25-4.11(m, 2H), 3.86(d, 1H, J= 7.3 Hz), 2.71-0.25(m, 39H, incl. singlets at 2.64, 2.25, 1.97, 1.77, 1.25, 1.17, 0.00, -0.25 3H each and at 0.84 9H) ¹³C NMR (CDCl₃, 75.469 Mhz) δ: 205.05, 171.36, 170.64, 169.63, 167.19, 167.01, 140.92, 138.38, 134.19, 133.78, 133.38, 131.88, 130.34, 129.25, 128.92, 128.85, 128.82, 128.08, 127.09, 126.49, 92.89, 83.91, 79.14, 75.49, 75.35, 73.97, 71.29, 70.90, 55.71, 53.34, 45.04, 44.20, 43.06, 36.20, 26.23, 25.61, 23.06, 21.82, 18.24, 15.32, 14.65
IR(KBr) 3442(br.), 2953, 2858, 1731, 1719, 1485, 1371, 1244, 839, 710 cm⁻¹.

LRESIMS m/z Calcd. for $C_{53}H_{65}NO_{14}Si$ [M-H]⁻ 967. Found 967

Example 2

2'-O-(triethylsilyl)-7-deoxy-6 α -trifluoromethanesulphonyloxypaclitaxel [7]

[0061]



[0062] The alcohol 6 (0.950 g, 0.98 mmol) and DMAP (0.479 g, 3.92 mmol) were dissolved in 10 mL of dichloromethane and cooled to 0°C under nitrogen. Triflic anhydride (198 μ L, 1.18 mmol) was added via syringe, and the reaction was allowed to stir at 0°C for 10 min. The crude reaction mixture was placed directly onto a vacuum funnel containing a 1.5 inch plug of silica gel wet with hexanes, and eluted with (3:1 hexanes / ethyl acetate) to provide the triflate 7 (0.842 g 78%) as a white powder.

¹H NMR (CDCl₃ 300 MHz) δ : 8.13 (d, 2H), 7.72 (d, 2H), 7.50-7.25 (m, 11H), 7.10 (d, 1H, J = 9.1, H_{NH}), 6.41 (s, 1H, H₁₀), 6.25 (t, 1H, J = 8.6 H₁₃), 5.73 (d, 1H, J = 9.0, H₃), 5.64 (d, 1H, J = 7.5, H₂), 5.22 (dd, 1H, J = 11.7, 7.5, H₆), 4.98 (s, 1H, H₅), 4.68 (d, 1H, J = 2.0, H₂), 4.33 (d, 1H, J = 8.5, H₂₀), 4.26 (d, 1H, J = 8.6, H₂₀), 3.89 (d, 1H, J = 7.4, H₃), 2.58 (s, 3H, Ac), 2.50-2.40 (m, 2H), 2.21 (s, 3H, Ac), 2.19-2.04 (m, 2H), 1.92 (s, 3H, H₁₈), 1.71 (s, 3H, H₁₉), 1.21 (s, 3H, H₁₆), 1.10 (s, 3H, H₁₇), 0.78 (m, 9H), 0.43 (m, 6H).

¹³C NMR (CDCl₃, 75.469 MHz) δ : 203.94, 171.47, 170.26, 169.58, 167.06, 167.01, 141.57, 138.39, 134.12, 133.93, 133.08, 131.87, 130.30, 128.97, 128.83, 128.77, 128.11, 127.09, 126.44, 88.38, 87.31, 84.00, 79.06, 75.05, 75.00, 73.93, 71.12, 55.66, 52.57, 44.41, 42.97, 40.16, 36.28, 26.19, 22.85, 21.86, 20.77, 15.56, 14.62, 14.40, 6.57, 4.42.


LRESIMS m/z Calcd. for $C_{54}H_{64}F_3NO_{16}SSi$ [M-H]⁻ 1099, found 1099.

IR (cm⁻¹): 3442.61, 2957.67, 1748.72, 1735.68, 1725.17, 1245.93, 1225.00, 1143.23, 925.19, 710.48.

Example 2a

2'-O-(tertbutyldimethylsilyl)-7-deoxy-6 α -trifluoromethanesulphonyloxypaclitaxel [7a]

[0063]




[0064] A solution of 2'-*tert*-butyldimethylsilyl-6 α -hydroxy-7-deoxypaclitaxel (6a) (7.90 g, 8.16 mmoles) in anhydrous DCM (82.0 mL) was cooled to 0°C and treated with dimethylaminopyridine (3.98 g, 32.63 mmoles) and trifluoromethanesulfonic anhydride (1.65 mL, 9.79 mmoles). After 10 mins. the crude reaction mixture was columned through a short pad of silica gel eluting with 75% hexanes/ethyl acetate to provide 7.56 g (84.2%) of compound 7a as a white, amorphous powder which exhibited the following physical properties: ¹H NMR (CDCl₃, 300 MHz) δ 8.12 (d, J = 7.0 Hz, 2H), 7.70 (d, J = 7.0 Hz, 2H), 7.61-7.24 (m, 11H), 7.05 (d, J = 9.1 Hz, 1H), 6.40 (s, 1H), 6.25 (t, J = 8.6 Hz, 1H), 5.75

(d, $J = 9.1$ Hz, 1H), 5.64 (d, $J = 7.3$ Hz, 1H), 5.20 (dd, $J = 7.6$ Hz, $J = 11.5$ Hz, 1H), 4.97 (s, 1H), 4.64 (d, $J = 2.1$ Hz, 1H), 4.28 (dd, $J = 8.5$ Hz, $J = 19.2$, 2H), 3.88 (d, $J = 7.3$ Hz, 1H), 2.60 (s, 3H), 2.54-2.37 (m, 2H), 2.19 (s, 3H), 2.16-2.02 (m, 2H), 1.94 (s, 1H), 1.91 (s, 3H), 1.72 (s, 3H), 1.19 (s, 3H), 1.09 (s, 3H), 0.77 (s, 9H), -0.07 (s, 3H), -0.31 (s, 3H); LRMS (ESI): 1117.5 ($(M+NH_4)^+$, 25%), 1100.5 ($(M+1)^+$, 100%). ^{13}C NMR ($CDCl_3$, 75.469 MHz) δ : 203.96, 171.31, 170.34, 169.59, 167.06, 167.01, 141.59, 138.29, 134.16, 133.97, 133.09, 131.92, 130.34, 129.01, 128.97, 128.89, 128.83, 128.12, 127.08, 126.44, 88.41, 87.29, 84.03, 79.13, 75.36, 75.07, 73.95, 71.08, 55.64, 52.61, 44.46, 42.99, 40.21, 36.33, 26.22, 25.60, 22.93, 21.90, 20.79, 18.25, 15.59 and 14.72
IR (cm^{-1}): 3443.26, 2954.41, 2935.16, 1752.33, 1734.72, 1725.90, 1246.20, 1227.94, 1143.48, 925.48, 838.88, 710.31.

Example 3

2'-O-(triethylsilyl)-7-deoxy-6 β -thiomethylpaclitaxel [8]

[0065]



[0066] Triflate 7 (0.80 g, 0.73 mmol) was mixed with sodium thiomethoxide (0.05 g, 0.73 mmol) under nitrogen and cooled to 0°C. DMF (5 mL) was added and the solution was stirred at 0°C for 20 min. Additional sodium thiomethoxide (0.005 g, 0.07 mmol) was added and stirring was continued for another 20 min. The reaction was diluted with ethyl acetate, washed with water, then brine and dried over $MgSO_4$. Concentration and sequential chromatography over silica gel (hexanes / ethyl acetate 2:1) followed by reversed phase C18 silica gel (acetonitrile / water 3:1) provided 0.04 g of the thiomethyl ether 8 5.5%.

[0067] Alternate procedure: Thiol 13 (0.535g, 0.54 mmol) was dissolved in benzene (10mL) and cooled to 5°C. Methyl iodide (37 μ L, 0.60 mmol) and DBU (99 μ L, 0.66 mmol) were added and the reaction was stirred 15 minutes at 0°C. The precipitated salts were filtered off and washed with benzene. The filtrate was stripped to a residue and chromatographed on silica gel (hexanes / ethyl acetate 2:1) to provide 0.507 g of the thiomethyl ether 8 94%.


1H NMR ($CDCl_3$ 300 MHz) δ : 8.05 (d, 2H, $J = 7.2$ H_{arom}), 7.64 (d, 2H, $J = 7.2$, H_{arom}), 7.54-7.17 (m, 11 H, H_{arom}), 7.03 (d, 1H, $J = 8.9$, H_{NH}), 6.40 (s, 1H, H_{10}), 6.14 (t, 1H, $J = 8.6$, H_{13}), 5.65 (overlapping doublets, 2H, $H_3 + H_2$), 4.90 (d, 1H, $J = 6.3$, H_5), 4.60 (d, 1H, $J = 1.7$, H_2), 4.25 (d, 1H, $J = 8.0$, H_{20}), 4.04 (d, 1H, $J = 7.9$, H_{20}), 3.65 (d, 1H, $J = 6.8$, H_3), 3.33 (m, 1H, H_6), 2.44 (s, 3H, H_{S-CH_3}), 2.30 (m, 2H), 2.13 (s, 3H, H_{4-Ac}), 2.08-2.07 (m, 1H), 1.99 (s, 3H, H_{10-Ac}), 1.82 (s, 3H, H_{CH_3}), 1.81 (s, 3H, H_{CH_3}), 1.78-1.74 (m, 1H), 1.12 (s, 3H), 1.04 (s, 3H), 0.72 (t, 6H), 0.45-0.24 (m, 9H)

^{13}C NMR ($CDCl_3$, 75.469 MHz) δ : 205.03, 171.58, 170.14, 169.84, 167.12, 140.85, 138.45, 134.13, 133.71, 133.51, 131.87, 130.27, 129.33, 128.81, 128.78, 128.05, 127.10, 126.52, 85.41, 80.43, 78.83, 75.84, 75.56, 74.95, 73.97, 71.33, 55.74, 53.07, 43.39, 43.15, 41.85, 40.36, 35.92, 26.16, 22.91, 21.85, 20.86, 16.98, 14.97, 14.54, 6.57, 4.43
ESILRMS Calcd. for $C_{54}H_{67}NO_{13}SSi$ [M-H] $^-$ 997. Found 997.

IR (cm^{-1}): 3441.39, 2956.35, 1747.79, 1732.04, 1716.84, 1484.09, 1371.64, 1267.01, 1241.71, 1108.90, 1069.79, 710.65

Example 4**7-deoxy-6 β -thiomethylpaclitaxel [9]**

[0068]




[0069] Triethylsilyl ether **8** (0.812 g, 0.81 mmol) was dissolved in acetonitrile (10 mL), cooled to 0°C and treated with 1M HCl (1.63 mL, 1.63 mmol) for 30 minutes. The reaction mixture was concentrated to a residue under vacuum, diluted with acetonitrile and stripped to a residue again. The crude material was chromatographed over silica gel (hexanes/ethyl acetate 1:1). The pure fractions were stripped to a residue, dissolved in a minimal amount of methylene chloride and precipitated with hexanes. This suspension was stripped to a solid residue under vacuum to provide the hydroxy thioether **9** (0.541 g) in 76% yield.

¹H NMR (CDCl₃ 300 MHz)δ: 8.12 (d, 2H, _{arom.}), 7.72 (d, 2H, _{arom.}), 7.63-7.30 (m, 11H, _{arom.}), 7.07 (d, 1H, J = 9.0, NH), 6.44 (s, 1H, H₁₀), 6.17 (t, 1H, J = 8.6, H₁₃), 5.79 (d, 1H, J = 9.0, H₃), 5.72 (d, 1H, J = 6.7, H₂), 4.96 (d, 1H, J = 5.8, H₅), 4.78 (s, 1H, H₂), 4.31 (d, 1H, J = 8.0, H₂₀), 4.10 (d, 1H, J = 8.0, H₂₀), 3.74 (d, 1H, J = 6.6, H₃), 3.69 (d, 1H, J = 4.8, OH), 3.37 (m, 1H, H₆), 2.37 (s, 3H, _{4Ac}), 2.36-2.27 (m, 2H), 2.21 (s, 3H, _{10Ac}), 2.06 (s, 3H, _{S-Me}), 1.89 (s, 3H, H₁₈), 1.86-1.79 (m, 2H), 1.74 (s, 3H, H₁₉), 1.29-1.22 (m, 1H), 1.19 (s, 3H, H₁₆), 1.12 (s, 3H, H₁₇).
¹³C NMR (CDCl₃, 75.469 MHz)δ: 204.62, 172.38, 170.53, 169.77, 167.13, 166.97, 140.32, 138.10, 133.92, 133.81, 133.73, 132.02, 130.23, 129.23, 129.03, 128.77, 128.37, 127.13, 127.11, 85.61, 80.46, 78.68, 75.65, 73.99, 73.39, 72.08, 54.94, 53.11, 43.19, 43.08, 41.51, 39.86, 35.77, 26.28, 22.55, 21.30, 20.86, 17.39, 14.78, 14.63.
 LRESIMS m/z Calcd. for C₄₈H₅₃NO₁₃S [M-H]⁻ 883, found 883.
 IR (cm⁻¹): 3432.18, 2923.28, 1731.96, 1716.03, 1662.18, 1485.68, 1371.89, 1270.91, 1240.56, 1069.82, 1024.85, 968.05, 711.09
 Elemental calcd. for C₄₈H₅₃NO₁₃S: C, 65.22; H, 6.04; N, 1.58; S, 3.63. Found: C, 65.38; H, 6.28; N, 1.47; S, 3.44.

Example 5**2'-O-(triethylsilyl)-7-deoxy-6 β -thioacetoxypaclitaxel [10]**

[0070]



[0071] The triflate **7** (1.00 g, 0.91 mmol) was cooled to -10°C and treated with a solution of potassium thioacetate (0.21 g, 1.82 mmol) in 5 mL DMF also at -10°C. The solution was allowed to warm to room temperature, and stirred for 1.5 hours. The reaction was diluted with ethyl acetate, washed with brine and dried over MgSO₄. Concentration followed by radial chromatography over silica gel (hexanes/ethyl acetate 1.5 : 1) provided (0.893 g, 94%) of the thioacetate **10**.

¹H NMR (CDCl₃ 300 MHz)δ: 7.93 (d, 2H), 7.56 (d, 2H), 7.51-7.05 (m, 11H), 6.90 (d, 1H, J = 8.9, H_{NH}), 6.26 (s, 1H,

H₁₀), 6.03 (t, 1H, J = 8.4 Hz, H₁₃), 5.50 (overlapping, 2H, H₃+H₂), 4.76 (d, 1H, J = 7.8, H₅), 4.49 (d, 1H, J = 2.0, H₂), 4.23 (t, 1H, J = 7.6, H₆), 4.12 (d, 1H, J = 8.1, H₂₀), 3.91 (d, 1H, J = 8.1, H₂₀), 3.53 (d, 1H, J = 7.0, H₃), 2.47 (dd, 1H, J = 14.24, 9.1), 2.33 (s, 3H, H_{SAc}), 2.20 (m, 1H), 2.08 (s, 3H, H_{4Ac}), 1.99 (s, 3H, H_{10Ac}), 1.99-1.89 (m, 1H), 1.72 (s, 3H, H₁₈), 1.61-1.51 (overlapping, 4H, contains H₁₉), 1.00 (s, 3H, H₁₆), 0.91 (s, 3H, H₁₇), 0.61 (m, 9H), 0.24 (m, 6H)

¹³C NMR (CDCl₃, 75.469 MHz) δ: 205.10, 194.36, 171.55, 170.02, 169.63, 167.20, 167.02, 140.93, 138.47, 134.16, 133.74, 133.17, 131.83, 130.28, 129.26, 128.86, 128.78, 128.16, 128.05, 127.10, 126.50, 84.09, 80.11, 79.01, 75.59, 74.96, 74.07, 71.24, 60.45, 55.74, 53.01, 44.57, 43.06, 42.38, 38.67, 35.99, 30.20, 26.11, 22.79, 21.73, 21.10, 20.81, 15.59, 14.57, 14.26, 6.58, 4.44.


LRESIMS m/z Calcd. for C₅₅H₆₇NO₁₄SSi [M-H]⁻: 1025, found 1025.

IR (cm⁻¹): 3495.03, 2955.20, 2878.09, 1749.43, 1732.71, 1715.71, 1702.74, 1667.92, 1241.35, 1119.88, 1071.07, 709.56

Example 6

2'-O-(tertbutyldimethylsilyl)-7-deoxy-6β-thioacetoxypaclitaxel [10a]

[0072]



[0073] A solution of 2'-*tert*-butyldimethylsilyl-6- α -trifluoromethanesulfonyl-7-deoxy-paclitaxel (xx) (2.36 g, 2.14 mmols) in anhydrous DMF (25.0 mL) was cooled to -25°C using an immersion cooler and treated with potassium thioacetate (501.4 mg, 2.05 mmols) in anhydrous DMF (10 mL). The temperature increased to -23°C during the course of the addition. The immersion cooler was turned off, and the mixture was stirred for 5 hrs., as it warmed to ambient temperature. The reaction mixture was poured into water (200 mL) overlaid with ethyl acetate (300 mL). The aqueous phase was extracted with ethyl acetate (250 mL). The combined organic extracts were washed with brine (100 mL), dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. Purification by column chromatography on silica eluting with 75% hexanes/ethyl acetate afforded 1.98 g (90.0%) of compound with formula xx as a white, amorphous powder which exhibited the following physical properties: LRMS (ESI): 1024.4 ((M-1)⁻, 100%).


¹H NMR (CDCl₃, 300 MHz) δ: 8.18 (d, 2H), 7.76 (d, 2H), 7.66-7.32 (m, 11H), 7.10 (d, 1H, J = 9.0), 6.50 (s, 1H), 6.30 (t, 1H, J = 8.6), 5.80-5.73 (m, 2H), 5.01 (d, 1H, J = 7.7), 4.70 (d, 1H, J = 2.1), 4.51-4.45 (m, 1H), 4.36 (d, 1H, J = 8.1), 4.15 (d, 1H, J = 8.2), 3.78 (d, 1H, J = 7.1), 2.76-0.26 (m, 41H, include singlets at 2.61, 2.32, 2.23, 1.97, 1.86, 1.57, 1.04, 0.00, -0.26 3H each and at 0.83 9H)

¹³C NMR (CDCl₃, 75.469 MHz) δ: 205.11, 197.67, 171.39, 170.12, 169.63, 167.25, 166.96, 140.96, 138.39, 134.20, 133.77, 133.20, 131.86, 130.32, 129.28, 128.90, 128.84, 128.81, 128.05, 127.08, 126.49, 84.19, 80.16, 79.09, 75.64, 75.32, 74.09, 71.20, 55.71, 53.04, 44.55, 43.10, 42.35, 38.70, 36.05, 30.23, 26.15, 25.61, 22.86, 21.80, 20.82, 18.23, 15.73 and 14.66

IR (cm⁻¹): 3442.20, 2954.03, 2931.14, 1748.69, 1732.16, 1717.89, 1314.57, 1241.75, 1128.23, 1108.41, 1069.85, 971.04, 838.26, 710.67.

Example 7**7-deoxy-6 β -thioacetoxypaclitaxel [11]**

[0074]




[0075] Triethylsilyl ether **10** (0.842 g, 0.82 mmol) was dissolved in acetonitrile (30 mL), cooled to 0°C and treated with 1M HCl (1.64 mL, 1.64 mmol) for 40 minutes. The reaction mixture was concentrated to a residue under vacuum and purified via radial chromatography using hexanes / ethyl acetate 1:1 as eluent. The pure fractions were stripped to a residue, dissolved in a minimum amount of methylene chloride and precipitated with hexanes. This suspension

was stripped to a solid residue under vacuum to provide the hydroxy thioacetate **11** (0.578 g) in 76% yield.
¹H NMR (CDCl₃ 300 MHz)δ: 8.13 (d, 2H_{arom.}), 7.72 (d, 2H_{arom.}), 7.63-7.31 (m, 11H_{arom.}), 7.03 (d, 1H, J = 9.0, H_{NH}), 6.42 (s, 1H, H₁₀), 6.19 (t, 1H, J = 8.6, H₁₃), 5.79 (dd, 1H, J = 8.9, 2.4, H₃), 5.68 (d, 1H, J = 7.0, H₂), 4.93 (d, 1H, J = 7.5, H₅), 4.78 (d, 1H, J = 2.4, H₂), 4.40 (m, 1H, H₆), 4.30 (d, 1H, J = 8.1 H₂₀), 4.08 (d, 1H, J = 8.1, H₂₀), 3.73 (d, 1H, J = 7.0, H₃), 3.63 (br, 1H, OH), 2.60 (dd, 1H, J = 14.6, 8.8), 2.38 (s, 3H, S_{Ac}), 2.32 (d, 2H), 2.27 (s, 3H, Ac), 2.20 (s, 3H, Ac), 1.80 (s, 6H, H₁₈ + H₁₉), 1.73 (dd, 1H, J = 14.9, 2.5), 1.25 (br, 1H, OH), 1.19 (s, 3H, H₁₆), 1.12 (s, 3H, H₁₇)
¹³C NMR (CDCl₃, 75.469 MHz)δ: 204.84, 194.28, 172.63, 170.34, 169.62, 167.16, 167.07, 140.46, 138.09, 133.81, 133.71, 133.50, 132.02, 130.26, 129.24, 129.08, 128.82, 128.76, 128.39, 127.12, 127.08, 84.28, 80.13, 78.86, 75.70, 75.47, 74.13, 73.30, 72.18, 54.98, 53.06, 44.44, 43.02, 41.99, 38.60, 35.87, 30.21, 26.25, 22.47, 21.34, 20.82, 15.86,

14.61

LRESIMS m/z Calcd. for C₄₉H₅₃NO₁₄S [M+H]⁺ 912, found 912IR (cm⁻¹): 3436.11, 2946.38, 1731.81, 1720.30, 1695.57, 1665.13, 1371.88, 1240.79, 1107.89, 711.43Elemental calcd. for C₄₉H₅₃NO₁₄S: C, 64.53; H, 5.86; N, 1.54; S, 3.52. Found: C, 64.12; H, 6.13; N, 1.46; S, 3.28.**Example 8****2'-O-(triethylsilyl)-7-deoxy-6 β -thio-paclitaxel [12]**

[0076]



[0077] Thioacetate **10** (1.76g, 1.71 mmol) was dissolved in ethanol (150 mL) and degassed under vacuum with stirring for 5 minutes. Anhydrous ammonia gas was then slowly bubbled into the reaction flask for 1.5 hours. During this time the progress of the reaction was monitored by TLC (hexanes / ethyl acetate 1:1). When no more starting material remained, the excess ammonia was gently stripped off under vacuum. Concentration to a residue followed by radial chromatography (hexanes / ethyl acetate 2:1) provided the free thiol **12** (1.16 g) in 68.9% yield.

¹H NMR (CDCl₃ 300 MHz)δ: 8.12 (d, 2H_{arom.}), 7.72 (d, 2H_{arom.}), 7.61-7.28 (m, 11H_{arom.}), 7.09 (d, 1H, J = 8.9 H_{NH}), 6.43 (s, 1H, H₁₀), 6.22 (t, 1H, J = 8.7, H₁₃), 5.71 (m, 2H, H₃+ H₂), 4.82 (d, 1H, J = 5.9, H₅), 4.67 (d, 1H, J = 2.0, H₂)

4.31 (d, 1H, J = 8.0, H₂₀), 4.08 (d, 1H, J = 8.0, H₂₀), 3.73 (d, 1H, J = 6.7, H₃), 3.60 (m, 1H, H₆), 2.81-2.51 (m, 4H, contains H_{4-Ac}), 2.39-2.26 (m, 1H), 2.19-2.09 (m, 4H, contains H_{10-Ac}), 1.98-1.88 (m, 7H, contains H₁₈+H₁₉), 1.19 (s, 3H, H₁₆), 1.10 (s, 3H, H₁₇), 0.94-0.87 (m, 1H), 0.79 (t, 9H), 0.52-0.31 (m, 6H).

¹³C NMR (CDCl₃, 75.469 MHz)δ: 204.78, 171.56, 170.11, 169.76, 167.11, 167.05, 141.02, 138.49, 134.16, 133.75, 133.45, 131.84, 130.27, 130.13, 129.03, 128.78, 128.75, 128.04, 127.10, 126.51, 86.10, 79.98, 78.82, 75.75, 74.98, 74.86, 73.95, 71.25, 55.74, 53.27, 44.83, 43.14, 42.88, 35.94, 33.80, 26.17, 22.87, 21.84, 20.84, 17.67, 14.58, 6.58, 4.37.


LRESIMS m/z Calcd. for C₅₃H₆₅NO₁₃SSi [M+H]⁺ 984, found 984.

IR (cm⁻¹): 3442.01, 2956.12, 1745.88, 1732.46, 1718.19, 1667.90, 1484.36, 1271.54, 1240.63, 1069.86, 970.22, 710.50.

Example 9

2'-O-(tertbutyldimethylsilyl)-7-deoxy-6b-thiopaclitaxel (12a)

[0078]



[0079] Thioacetate (6.55 g, 6.38 mmol) was dissolved in ethanol (351 mL) and degassed under house vacuum with stirring for 20 minutes, then backfilled with nitrogen. Anhydrous ammonia gas was then slowly bubbled into the reaction flask for 1 hour. The excess ammonia was gently stripped off under vacuum. Concentration to a residue followed by chromatography on silica gel (hexanes/ethyl acetate 4:1, 3:1) to provide 5.65 g of the free thiol as a white solid in 91% yield

¹H NMR (CDCl₃, 300 MHz)δ: 8.19 (d, 2H), 7.79 (d, 2H), 7.76-7.33 (m, 11H), 7.11 (d, 1H, J = 9.0), 6.50 (s, 1H), 6.30 (t, 1H, J = 8.7), 5.79 (m, 1H, J = 6.9), 4.90 (d, 1H, J = 5.9), 4.70 (d, 1H, J = 2.1), 4.38 (d, 1H, J = 8.0), 4.16 (d, 1H, J = 7.4), 3.79 (d, 1H, J = 6.7), 3.72-3.62 (m, 1H), 2.62-0.29 (m, 39H, include singlets at 2.62, 2.26, 1.95, 1.94, 1.26, 1.16, 0.00, -0.29, 3H each and at 0.84 9H)


¹³C NMR (CDCl₃, 75.469 MHz)δ: 204.79, 171.41, 170.22, 169.78, 167.16, 167.01, 141.03, 138.38, 134.18, 133.80, 133.47, 131.90, 130.31, 129.26, 128.88, 128.84, 128.06, 127.09, 126.49, 86.14, 80.02, 78.88, 75.81, 75.33, 74.90, 73.95, 71.20, 55.71, 53.31, 44.86, 43.16, 42.92, 35.97, 33.84, 26.20, 25.61, 22.95, 21.89, 20.86, 18.23, 17.72, 14.69

LRESIMS m/z Calcd. for C₅₃H₆₅NO₁₃SSi [M+H]⁺ 983, found 983.

IR (cm⁻¹): 3442.10, 2953.51, 2931.34, 1746.52, 1732.37, 1718.10, 1668.17, 1484.54, 1371.86, 1270.11, 1241.06, 1127.17, 1108.70, 1070.00, 970.46, 710.62

Example 10**7-deoxy-6 β -thio-paclitaxel [13]**

[0080]



[0081] Triethylsilyl ether **12** (0.277 g, 0.28 mmol) was dissolved in acetonitrile (5 mL), degassed under vacuum and cooled to 0°C. 1M HCl (0.56 mL, 0.56 mmol) was added and the reaction was stirred for 40 minutes. Concentration followed by chromatography over silica gel (hexanes / ethyl acetate 1:1) provided the product **13** as a white solid (172 mg, 71%).

¹H NMR (CDCl₃ 300 MHz)δ: 8.06 (d, 2H, *arom.*), 7.68 (d, 2H, *arom.*), 7.58-7.24 (m, 11H, *arom.*), 7.02 (d, 1H, J = 8.8, H_{NH}), 6.34 (s, 1H, H₁₀), 6.10 (t, 1H, J = 8.6, H₁₃), 5.73 (d, 1H, J = 8.3, H₃), 5.66 (d, 1H, J = 6.6, H₂), 4.75 (d, 1H, J = 5.4, H₅), 4.72 (s, 1H, H₂), 4.25 (d, 1H, J = 7.9, H₂₀), 4.02 (d, 1H, J = 8.0, H₂₀), 3.67 (d, 1H, J = 6.5, H₃), 3.50 (m, 1H, H₆), 2.39 (dd, 1H, J = 15.1, 9.1), 2.31 (s, 3H, _{4Ac}), 2.23 (s, 1H), 2.21 (s, 1H), 2.15 (s, 3H, _{10Ac}), 1.89-1.74 (m, 7H, contains H₁₈), 1.66 (s, 3H, H₁₉), 1.13 (s, 3H, H₁₆), 1.05 (s, 3H, H₁₇).


¹³C NMR (CDCl₃, 75.469 MHz)δ: 204.39, 172.34, 170.55, 169.73, 167.10, 166.96, 140.45, 138.10, 133.88, 133.73, 132.02, 130.22, 129.19, 129.04, 128.80, 128.77, 128.37, 127.13, 127.11, 86.47, 80.04, 78.62, 75.59, 75.00, 73.97, 73.41, 72.00, 54.93, 53.33, 44.39, 43.07, 42.71, 35.80, 33.75, 26.29, 22.52, 21.31, 20.85, 18.03, 14.66.

LRESIMS *m/z* Calcd. for C₄₇H₅₁NO₁₃S [M+H]⁺ 870, found 870.

IR (cm⁻¹): 3424.76, 1732.65, 1719.50, 1659.96, 1485.84, 1239.78, 1107.76, 1070.11, 969.58, 711.14

Example 11**2'-O-(triethylsilyl)-7-deoxy-6 β -(2-hydroxyethyl)thio-paclitaxel [14]**

[0082]



[0083] Thiol **12** (1.40 g, 1.42 mmol) was dissolved in benzene (30 mL) and degassed under house vacuum for 20 minutes, then backfilled with nitrogen. This solution was then saturated with ethylene oxide gas via a subsurface feed tube, and treated with DBU (21.7 μ L, 0.14 mmol) for 2 hours. The reaction mixture was then concentrated to a residue and chromatographed over silica gel (hexanes / ethyl acetate 1.5:1) to provide the hydroxyethyl thioether **14** (1.18 g, 80.8%) as a white solid.

¹H NMR (CDCl₃ 300 MHz)δ: 8.14 (d, 2H, *H_{arom.}*), 7.74 (d, 2H, *H_{arom.}*), 7.64-7.30 (m, 11H, *H_{arom.}*), 7.11 (d, 1H, J = 8.9, H_{NH}), 6.45 (s, 1H, H₁₀), 6.24 (t, 1H, J = 8.8, H₁₃), 5.72 (m, 2H, H₂ + H₃), 4.94 (d, 1H, J = 6.4, H₅), 4.69 (d, 1H, J = 2.0, H₂), 4.36 (d, 1H, J = 8.0, H₂₀), 4.14 (d, 1H, J = 8.0, H₂₀), 3.74 (d, 1H, J = 6.8, H₃), 3.65 (m, 2H), 3.56 (m, 1H, H₆), 2.67-2.58 (m, 2H), 2.54 (s, 3H, _{4Ac}), 2.51-2.34 (m, 2H), 2.22 (s, 3H, _{10Ac}), 2.19-2.04 (m, 2H), 1.90 (s, 3H, H₁₈), 1.89 (s, 3H, H₁₉), 1.22 (s, 3H, H₁₆), 1.12 (s, 3H, H₁₇), 0.81 (t, 9H), 0.54-0.34 (m, 6H).

^{13}C NMR (CDCl_3 , 75.469 MHz) δ : 205.00, 171.54, 170.20, 169.87, 167.12, 167.04, 141.03, 138.47, 134.15, 133.76, 133.44, 131.84, 130.27, 129.24, 128.84, 128.78, 128.76, 128.04, 127.09, 126.50, 85.45, 80.30, 78.90, 75.74, 75.57, 74.96, 74.14, 71.25, 61.39, 55.73, 52.89, 43.52, 43.13, 41.63, 40.68, 35.95, 35.72, 26.18, 22.88, 21.88, 20.86, 17.07, 14.54, 6.57, 4.43.

LRESIMS m/z Calcd. for $\text{C}_{55}\text{H}_{69}\text{NO}_{14}\text{SSi}$ $[\text{M}+\text{H}]^+$ 1027, found 1027.


IR (cm^{-1}): 3441.09, 2955.74, 2877.85, 1747.01, 1731.81, 1716.67, 1667.63, 1484.78, 1242.11, 1108.45, 970.12, 711.01.

Elemental calcd. for $\text{C}_{55}\text{H}_{69}\text{NO}_{14}\text{SSi}$: C, 64.24; H, 6.76; N, 1.36; S, 3.12. Found: C, 64.57; H, 7.16; N, 1.31; S, 3.07.

Example 12

7-deoxy-6 β -(2-hydroxyethyl)thio-paclitaxel **15**

[0084]



[0085] Silyl ether **14** (1.11 g, 1.08 mmol) was dissolved in acetonitrile (50 mL), cooled to 0°C and treated with 1M HCl (2.16 mL, 2.16 mmol) for 5 minutes. The reaction mixture was stripped to a residue under vacuum, dissolved in acetonitrile and stripped to a residue again. This residue was taken up in a minimal amount of CH_2Cl_2 and passed through a short plug of silica gel (hexanes/ethyl acetate 1:3) to provide the alcohol **15** (0.685 g, 69%) as a white solid.

^1H NMR (CDCl_3 , 300 MHz) δ : 8.11 (d, 2H, H_{arom}), 7.72 (d, 2H, H_{arom}), 7.63-7.30 (m, 11H, H_{arom}), 7.08 (d, 1H, $J = 8.9$, H_{NH}), 6.39 (s, 1H, H_{10}), 6.16 (t, 1H, $J = 8.5$, H_{13}), 5.77 (dd, 1H, $\text{H}_{3'}$), 5.70 (d, 1H, $J = 6.7$, H_2), 4.90 (d, 1H, $J = 5.9$, H_5), 4.77 (d, 1H, $J = 2.5$, H_2), 4.31 (d, 1H, $J = 8.1$, H_{20}), 4.10 (d, 1H, $J = 8.3$, H_{20}), 3.71 (d, 1H, $J = 6.7$, H_3), 3.65 (m, 2H), 3.52 (br, 1H, H_6), 2.71-2.41 (br, 3H), 2.36 (s, 3H, $\text{H}_{4\text{Ac}}$), 2.28 (d, 2H, $J = 8.9$), 2.20 (s, 3H, $\text{H}_{10\text{Ac}}$), 1.85 (s, 3H, H_{18}), 1.74 (s, 3H, H_{19}), 1.29-1.22 (m, 2H), 1.19 (s, 3H, H_{16}), 1.11 (s, 3H, H_{17}).

^{13}C NMR (CDCl_3 , 75.469 MHz) δ : 204.68, 172.47, 170.53, 169.88, 167.08, 140.53, 138.09, 133.83, 133.72, 132.02, 130.23, 129.21, 129.04, 128.79, 128.75, 128.37, 127.11, 85.67, 80.31, 78.70, 75.66, 75.59, 74.19, 73.35, 72.08, 61.50, 54.99, 52.93, 43.30, 43.07, 41.20, 40.46, 35.82, 35.51, 31.65, 26.29, 22.71, 22.54, 21.41, 20.87, 17.45, 14.62, 14.18.

LRESIMS m/z Calcd. for $\text{C}_{49}\text{H}_{55}\text{NO}_{14}\text{S}$ $[\text{M}+\text{H}]^+$ 913, found 913.


IR (cm^{-1}): 3425.97, 2932.16, 1732.38, 1716.61, 1652.17, 1486.96, 1372.16, 1241.40, 1107.79, 1069.54, 969.11, 711.17.

Elemental calcd. for $\text{C}_{49}\text{H}_{55}\text{NO}_{14}\text{S}$: C, 64.39; H, 6.06; N, 1.53; S, 3.51. Found: C, 64.55; H, 6.49; N, 1.43; S, 3.35.

Example 13

2'-O-(triethylsilyl)-7-deoxy-6 β -thiocyanato-paclitaxel [16] and 7-deoxy-6 β -thiocyanato-paclitaxel [17]

5 [0086]



10
15
20
25
30

[0087] Triflate **7** (1.09 g, 0.99 mmol) and potassium thiocyanate (0.195 g, 2.0 mmol) were dissolved in DMF (10 mL) and heated to 80-100°C for 5 minutes. The DMF was stripped off under vacuum, and the residue was taken up in a minimum amount of CH₂Cl₂. This suspension of products and salts was passed through a plug of silica gel using hexanes / ethyl acetate 2:1 to elute the fast moving product, followed by hexanes / ethyl acetate 1:3 to elute the slower moving product. Separate radial chromatography of each of these materials (hexanes / ethyl acetate 2:1 for the fast moving product and hexanes / ethyl acetate 1:1 for the slow moving spot) provided the 2'-silyl protected thiocyanate **16** (0.341 g, 34%), as well as the 2'-hydroxy thiocyanate **17** (0.392 g, 44%).

Alternate procedure for preparation of **17**: Silyl ether **16** (0.63 g, 0.62 mmol) was dissolved in acetonitrile (10 mL), cooled to 0°C and treated with 1M HCl (1.25 mL, 1.25 mmol) for 30 minutes. The reaction mixture was stripped to a residue under vacuum, dissolved in acetonitrile and stripped to a residue again. This residue was taken up in a minimal amount of CH₂Cl₂ and passed through a short plug of silica gel (hexanes/ethyl acetate 2:1 - 1:1) to provide the alcohol **17** (0.521 g, 94%) as a white solid.

2'-triethylsilyl thiocyanate [16]

35
40
45

[0088] ¹H NMR (CDCl₃ 300 MHz)δ: 8.13 (d, 2H, H_{arom.}), 7.72 (d, 2H, H_{arom.}), 7.63-7.29 (m, 11H, H_{arom.}), 7.09 (d, 1H, J = 9.0, H_{NNH}), 6.45 (s, 1H, H₁₀), 6.24 (t, 1H, J = 8.6, H₁₃), 5.70 (m, 2H, H₃+H₂), 5.02 (d, 1H, J = 5.8, H₅), 4.68 (d, 1H, J = 2.1, H₂'), 4.37 (d, 1H, J = 8.2, H₂₀), 4.21 (dt, 1H, J = 9.7, 2.1, H₆), 4.15 (d, 1H, J = 8.1, H₂₀), 3.71 (d, 1H, J = 6.9, H₃), 2.59 (dd, 1H, J = 15.4, 8.4), 2.55 (s, 3H, H_{4Ac}), 2.37 (dd, 1H, J = 15.4, 9.6), 2.21 (s, 3H, H_{10Ac}), 2.18-2.07 (m, 2H), 1.88 (s, 6H, H₁₈+H₁₉), 1.21 (s, 3H, H₁₆), 1.12 (s, 3H, H₁₇), 0.79 (t, 9H), 0.63-0.33 (m, 6H).

¹³C NMR (CDCl₃, 75.469 MHz)δ: 204.26, 171.48, 170.43, 169.60, 167.12, 166.98, 141.08, 138.41, 134.13, 133.89, 133.26, 131.85, 130.28, 129.06, 128.93, 128.81, 128.75, 128.09, 127.09, 126.49, 112.01, 82.78, 79.49, 79.01, 76.11, 75.36, 74.98, 73.75, 71.10, 55.67, 52.84, 45.39, 44.06, 43.03, 40.97, 36.03, 26.08, 22.73, 21.80, 20.79, 16.13, 14.53, 6.58, 4.44.

LRESIMS m/z Calcd. for C₅₄H₆₄N₂O₁₃SSi [M-H]⁻ 1008, found 1008.

IR (cm⁻¹): 3441.46, 2956.01, 2878.14, 2155.82, 1746.50, 1731.59, 1667.86, 1484.42, 1270.35, 1240.33, 1107.41, 1070.34, 971.27, 710.42

2'-hydroxy thiocyanate [17]

50
55

[0089] ¹H NMR (CDCl₃ 300 MHz)δ: 8.12 (d, 2H, H_{arom.}), 7.71 (d, 2H, H_{arom.}), 7.64-7.32 (m, 11H, H_{arom.}), 7.01 (d, 1H, J = 8.9, H_{NNH}), 6.41 (s, 1H, H₁₀), 6.19 (t, 1H, J = 8.5, H₁₃), 5.76 (dd, 1H, J = 8.9, 2.5, H₃'), 5.70 (d, 1H, J = 7.0, H₂'), 4.98 (d, 1H, J = 7.3, H₅), 4.77 (d, 1H, J = 2.5, H₂'), 4.35 (d, 1H, J = 8.2, H₂₀), 4.19-4.09 (m, 2H, H₆+H₂₀), 3.69 (d, 1H, J = 6.9, H₃), 3.62 (br, 1H, H_{OH}), 2.54 (dd, 1H, J = 15.4, 8.5), 2.41 (s, 3H, H_{4Ac}), 2.35-2.24 (m, 2H), 2.21 (s, 3H, H_{10Ac}), 1.87 (s, 3H, H₁₈), 1.77 (s, 3H, H₁₉), 1.19 (s, 3H, H₁₆), 1.12 (s, 3H, H₁₇).


¹³C NMR (CDCl₃, 75.469 MHz)δ: 204.08, 172.72, 170.66, 169.61, 167.17, 167.07, 140.63, 138.01, 133.93, 133.67, 133.53, 132.06, 130.26, 129.11, 128.88, 128.76, 128.44, 127.13, 127.06, 111.91, 82.85, 79.46, 78.87, 76.14, 75.27, 73.79, 73.27, 72.08, 55.10, 52.87, 45.22, 44.03, 42.99, 40.75, 35.91, 26.18, 22.39, 21.48, 20.80, 16.21, 14.51, 14.26.

LRESIMS m/z Calcd. for C₄₈H₅₀N₂O₁₃S [M-H]⁻ 894, found 894.

IR (cm⁻¹): 3432.14, 2990.13, 2155.51, 1728.73, 1661.84, 1270.10, 1239.85, 1070.49, 970.27, 710.95.

Example 14**2'-O-(triethylsilyl)-7-deoxy-6 β -methyl sulfoxide-paclitaxel 18**

5 [0090]



[0091] Thiomethyl ether **8** (2.09 g, 2.09 mmol) was dissolved in methylene chloride (30 mL), cooled to -40°C (acetonitrile/dry ice) and treated with m-CPBA (0.36 g, ~2.09 mmol) in small portions over two hours. The reaction was allowed to warm to room temperature then washed with excess satd. NaHCO₃. Concentration followed by MPLC (acetonitrile / ether 1:1) in portions provided the slow eluting sulfoxide **18** (1.62 g, 76%) as a white solid contaminated with a trace of the faster eluting minor diastereomer. Additionally (0.38 g 18%) of the faster eluting minor diastereomer contaminated with a small amount of starting material, and a trace of the slower eluting sulfoxide was also recovered.

¹H NMR (CDCl₃ 300 MHz)δ: 8.13 (d, 2H, H_{arom.}), 7.73 (d, 2H, H_{arom.}) 7.64-7.31 (m, 11H, H_{arom.}), 7.10 (d, 1H, J = 9.0, HNH), 6.48 (s, 1H, H₁₀), 6.22 (t, 1H, J = 8.7, H₁₃), 5.75 (d, 1H, J = 6.9, H₂), 5.69 (d, 1H, J = 8.9, H₃), 5.26 (d, 1H, J = 6.2, H₅), 4.67 (d, 1H, J = 2.0, H_{2'}), 4.43 (d, 1H, J = 8.0, H₂₀), 4.22 (d, 1H, J = 7.9, H₂₀), 3.77 (d, 1H, J = 6.8, H₃), 3.52 (br, 1H, H₆), 2.58 (s, 3H, H_{CH3S}), 2.52 (s, 3H, H_{4Ac}), 2.43-2.24 (m, 2H), 2.21 (s, 3H, H_{10Ac}), 2.18-2.12 (m, 2H), 1.90 (s, 3H, H₁₈), 1.89 (s, 3H, H₁₉), 1.34-1.24 (m, 2H), 1.21 (s, 3H, H₁₆), 1.12 (s, 3H, H₁₇) 0.80 (t, 9H), 0.51-0.35 (m, 6H).

¹³C NMR (CDCl₃, 75.469 MHz)δ: 204.70, 171.57, 170.26, 169.93, 167.18, 167.04, 141.33, 138.42, 134.15, 133.87, 133.23, 131.86, 130.28, 128.81, 128.68, 128.10, 127.23, 127.10, 126.49, 82.84, 79.70, 78.85, 75.63, 74.96, 73.74, 71.19, 59.69, 55.72, 52.39, 43.05, 42.99, 37.30, 35.99, 34.16, 31.65, 26.08, 22.70, 21.87, 20.82, 16.96, 14.62, 6.58, 4.44.


LRESIMS m/z Calcd. for C₅₄H₆₇NO₁₄SSi [M+H]⁺ 1013, found 1013.

IR (cm⁻¹): 3440.47, 2955.72, 1732.05, 1667.24, 1484.18, 1371.92, 1239.95, 1070.56, 970.24, 710.87

Elemental calcd. for: C₅₄H₆₇NO₁₄SSi: C, 63.95; H, 6.66; N, 1.38; S, 3.16. Found: C, 63.88; H, 6.89; N, 1.26; S, 3.06.

Example 15**7-deoxy-6 β -methyl sulfoxide-paclitaxel diastereomers 19 and 19a**

40 [0092]



[0093] Silyl ether **18** (1.0 g, 0.99 mmol) was dissolved in acetonitrile (40 mL), cooled to 0°C and treated with 1M HCl (1.97 mL, 1.97 mmol) for 10 minutes. The reaction mixture was stripped to a residue under vacuum, dissolved in acetonitrile and stripped to a residue again. This residue was chromatographed over silica gel (acetonitrile / ether 1:1) to provide the alcohol **19** (0.363 g, 41%) as a white solid. Mixed fractions containing a small amount of the faster eluting minor diastereomer (**19a**) amounted to (0.438 g 49%).


¹H NMR (CDCl₃ 300 MHz)δ: 8.13 (d, 2H, H_{arom.}), 7.77 (d, 2H, H_{arom.}), 7.73-7.30 (m, 11H, H_{arom.}), 7.23 (d, 1H, J = 9.0, H_{NH}), 6.45 (s, 1H, H₁₀), 6.17 (t, 1H, J = 8.6, H₁₃), 5.78-5.73 (m, 2H, H₂ + H₃), 5.22 (d, 1H, J = 6.2, H₅), 4.75 (dd, 1H, J = 5.9, 2.7, H₂), 4.37 (d, 1H, J = 8.1, H₂₀), 4.18 (d, 1H, J = 8.0, H₂₀), 4.01 (d, 1H, J = 6.1, H_{OH}), 3.74 (d, 1H, J = 6.7, H₃), 3.51 (br, 1H, H₆), 2.53 (s, 3H, H_{CH3S}), 2.36 (s, 3H, H_{4Ac}), 2.32-2.27 (m, 2H), 2.22 (s, 3H, H_{10Ac}), 1.94 (s, 3H, H₁₈), 1.84 (s, 3H, H₁₉), 1.41-1.24 (m, 4H), 1.20 (s, 3H, H₁₆), 1.12 (s, 3H, H₁₇).

¹³C NMR (CDCl₃, 75.469 MHz)δ: 204.51, 172.69, 170.50, 169.96, 167.22, 167.10, 141.01, 138.24, 133.92, 133.81, 133.39, 131.94, 130.26, 129.12, 129.00, 128.87, 128.69, 128.28, 127.23, 127.11, 82.75, 79.60, 78.70, 75.48, 73.80, 73.35, 71.82, 59.41, 55.17, 52.43, 43.16, 42.98, 37.00, 35.87, 33.93, 31.65, 26.16, 22.72, 22.35, 20.84, 16.94, 14.62.

LRESIMS m/z Calcd. for C₄₈H₅₃NO₁₄S [M-H]⁻ 899, found 899.

IR (cm⁻¹): 3424.70, 2952.86, 1731.93, 1662.46, 1486.09, 1372.19, 1238.92, 1107.55, 1025.47, 711.09

Elemental calcd. for: C₄₈H₅₃NO₁₄S: C, 64.06; H, 5.94; N, 1.56; S, 3.56. Found: C, 64.12; H, 6.04; N, 1.44; S, 3.41.

Example 16**2'-O-(triethylsilyl)-7-deoxy-6β-methyl sulfone-paclitaxel [20]****[0094]**

[0095] Thiomethyl ether **8** (1.50 g, 1.50 mmol) was dissolved in CH₂Cl₂ (50 mL), cooled to 0°C and treated with m-cpba (1.09 g, @ 50%, 3.15 mmol) in portions over 30 minutes. The reaction was allowed to warm to 25°C and stirred for an additional 30 minutes. The mixture was washed with saturated NaHCO₃, brine, dried over MgSO₄, and concentrated to a residue. This residue was dissolved in a minimal amount of CH₂Cl₂ and passed through a short plug of silica gel using hexanes / ethyl acetate 2:1 as eluent. Concentration of the clean fractions provided the sulfone **20** (1.396 g 90.2%) as a white solid.

¹H NMR (CDCl₃ 300 MHz)δ: 8.11 (d, 2H, H_{arom.}), 7.74 (d, 2H, H_{arom.}), 7.64-7.29 (m, 11H, H_{arom.}), 7.10 (d, 1H, J = 9.0, H_{NH}), 6.52 (s, 1H, H₁₀), 6.22 (t, 1H, J = 8.7, H₁₃), 5.79 (d, 1H, J = 6.5, H₂), 5.70 (dd, 1H, J = 9.0, 1.5, H₃), 5.31 (d, 1H, J = 4.1, H₅), 4.69 (d, 1H, J = 2.0, H₂), 4.42 (d, 1H, J = 7.8, H₂₀), 4.21 (d, 1H, J = 7.8, H₂₀), 3.88 (m, 1H, H₆), 3.81 (d, 1H, J = 6.3, H₃), 2.86 (s, 3H, H_{CH3S}), 2.53 (s, 3H, H_{4Ac}), 2.42-2.29 (m, 2H), 2.21 (s, 3H, H_{10Ac}), 2.19-2.03 (m, 2H), 1.99 (s, 3H, H₁₈), 1.90 (s, 3H, H₁₉), 1.22 (s, 3H, H₁₆), 1.14 (s, 3H, H₁₇), 0.81 (t, 9H), 0.54-0.33 (m, 6H).

¹³C NMR (CDCl₃, 75.469 MHz)δ: 203.82, 171.61, 170.14, 169.57, 167.15, 166.99, 141.48, 138.38, 134.17, 133.92, 133.28, 131.88, 130.23, 129.01, 128.89, 128.81, 128.78, 128.08, 127.09, 126.49, 82.41, 79.63, 78.50, 75.63, 74.89, 73.56, 71.09, 59.08, 55.71, 52.08, 43.13, 41.79, 39.60, 35.88, 32.83, 26.08, 22.75, 21.82, 20.76, 18.96, 14.71, 14.18, 6.58, 4.44.


LRESIMS m/z Calcd. for C₅₄H₆₇NO₁₅SSi [M+H]⁺ 1029, found 1029.

IR (cm⁻¹): 3511.73, 3440.87, 2956.04, 1722.25, 1666.84, 1484.52, 1271.15, 1239.88, 1124.97, 968.97, 711.52

Elemental calcd. for C₅₄H₆₇NO₁₅SSi: C, 62.95; H, 6.55; N, 1.36; S, 3.11. Found: C, 63.16; H, 6.75; N, 1.31; S, 3.11.

Example 17**7-deoxy-6 β -methyl sulfone-paclitaxel [21]**

[0096]



[0097] Silyl ether sulfone **20** (1.21 g, 1.17 mmol) was dissolved in acetonitrile (30 mL), cooled to 0°C and treated with 1M HCl (2.35 mL, 2.35 mmol) for 35 minutes. The reaction mixture was stripped to a residue under vacuum, dissolved in acetonitrile (60 mL) and stripped to a residue again. This residue was taken up in a minimal amount of CH₂Cl₂ and passed through a short plug of silica gel (hexanes / ethyl acetate 1:1 - 1:2) to provide the hydroxy sulfone **21** (0.975 g, 91%) as a white solid.

¹H NMR (CDCl₃ 300 MHz)δ: 8.08 (d, 2H, H_{arom.}), 7.73 (d, 2H, H_{arom.}), 7.64-7.31 (m, 11H, H_{arom.}), 7.16 (d, 1H, J = 8.9, H_{NH}), 6.45 (s, 1H, H₁₀), 6.22 (t, 1H, J = 8.5, H₁₃), 5.77 (s, 1H, H₃), 5.75 (s, 1H, H₂), 5.29 (s, 1H, H₅), 4.78 (s, 1H, H₂), 4.38 (d, 1H, J = 7.9, H₂₀), 4.17 (d, 1H, J = 7.9, H₂₀), 3.86-3.80 (m, 2H, H₆+H_{OH}), 3.76 (d, 1H, J = 6.2, H₃), 2.81 (s, 3H, H_{CH3S}), 2.36 (s, 3H, H_{4Ac}), 2.33-2.22 (m, 2H), 2.19 (s, 3H, H_{10Ac}), 2.08-2.00 (m, 2H), 1.95 (s, 3H, H₁₈), 1.72 (s, 3H, H₁₉), 1.18 (s, 3H, H₁₆), 1.11 (s, 3H, H₁₇).


¹³C NMR (CDCl₃, 75.469 MHz)δ: 203.57, 172.37, 170.69, 169.64, 167.16, 166.91, 141.00, 138.17, 133.98, 133.74, 133.56, 132.02, 130.19, 129.01, 128.85, 128.76, 128.31, 127.14, 127.12, 82.30, 79.64, 78.30, 77.20, 75.39, 73.63, 73.36, 71.72, 59.02, 55.04, 52.13, 43.03, 41.92, 39.53, 35.77, 32.54, 26.17, 22.36, 21.34, 20.77, 18.94, 14.76.

LRESIMS m/z Calcd. for C₄₈H₅₃NO₁₅S [M+H]⁺ 915, found 915.

IR (cm⁻¹): 3440.07, 2934.55, 1733.69, 1722.20, 1661.98, 1486.49, 1312.56, 1239.34, 1071.66, 967.83, 711.97

Example 18**7-deoxy-6b-thiomethylbaccatin (22)**

[0098]

**22**

[0099] 7-deoxy-6b-thiomethylpaclitaxel **8** (2.740 g, 3.010 mmol) was dissolved in methylene chloride (24 mL), cooled to 0°C under nitrogen. Tetrabutyl ammonia borohydride (1.595 g, 6.199 mmol) was added in one portion. The reaction mixture was then warmed up to room temperature and kept stirring for 6.5 hours. The reaction mixture was cooled to 0°C, 24.3 mL of 1M acetic acid was then added. After the foam stopped, diluted with EtOAc, washed with NaHCO₃, water and brine. The solution was dried over MgSO₄, filtered and concentrated. The residue was chromatographed over silica gel (hexanes/ ethyl acetate 3:1, 1:1, 1:1.5). The pure fractions were combined together and stripped to a residue, dissolved in a minimal amount of methylene chloride and precipitated with hexane. This suspension was stripped to a solid residue under vacuum to provide the baccatin **22** (1.693 g) as a white solid in 89% yield.


EP 0 960 107 B1

¹H-NMR (CDCl₃, 300.133MHz) δ: 8.11 (d, 2H, J = 7.0), 7.63-7.45 (m, 3H), 5.68(d, 1H, J = 6.8), 4.98 (d, 1H, J = 6.4), 4.90-4.80 (m, 1H), 4.32(d, 1H, J = 8.0), 4.07 (d, 1H, J = 8.1), 3.83 (d, 1H, J = 6.7), 3.45-3.39 (m, 1H), 2.45-1.08 (m, 27H, include singlets at 2.29, 2.22, 2.07, 2.05, 1.89, 1.10, 1.08, 3H each)
¹³C-NMR (CDCl₃, 75.469 MHz) δ: 205.22, 171.03, 169.84, 167.23, 144.54, 133.75, 132.52, 130.14, 129.42, 128.69, 85.23, 80.31, 78.83, 75.63, 75.56, 74.66, 67.95, 53.29, 43.91, 42.67, 41.97, 40.15, 38.81, 26.36, 22.72, 22.57, 20.94, 20.60, 16.72, 15.17
 LRESIMS m/z Calcd. for C₃₂H₄₀O₁₀S [M+H]⁺ 616, found 616
 IR (cm⁻¹): 3468.95, 2929.54, 1712.12, 1372.52, 1237.60, 1071.26, 710.72

Example 19

2'-O-(triethylsilyl)-3'-NH-Boc-7-deoxy-6b-thiomethylpaclitaxel (23)

[0100]




23

[0101] 7-deoxy-6b-thiomethylbaccatin **22** (0.70 g, 1.135 mmol) was dissolved in tetrahydrofuran (28 mL), cooled to -40°C and treated with lithium bis(trimethylsilyl)amide (1.7 mL, 1.702 mmol) for 15 minutes. A solution of (3R, 4S)-1-t-butoxycarbonyl-4-phenyl-3-triethylsilyloxy-2-azetidinone (0.857 g, 2.27 mmol) in THF (2.3 mL) was then added. After stirring for 15 minutes at -40°C, the reaction mixture was warmed up to 0°C and allowed to stir overnight. The reaction mixture was diluted with EtOAc, washed with NaHCO₃, water and brine. The solution was dried over MgSO₄, filtered and concentrated. The residue was chromatographed over silica gel (hexanes/ ethyl acetate 4:1, 3:1) to provide 1.043 g of the desired product **23** as a white powder in 92 % yield.
¹H-NMR (CDCl₃, 300.133MHz) δ: 8.13 (d, 2H, J = 7.1), 7.62-7.27 (m, 8H), 6.49 (s, 1H), 6.26 (t, 1H, J = 8.8), 5.74 (d, 2H, J = 6.9), 5.46 (d, 1H, J = 9.6), 5.27 (d, 1H, J = 9.3), 4.99 (d, 1H, J = 6.4), 4.53(d, 1H, J = 2.0), 4.33(d, 1H, J = 8.0), 4.09 (d, 1H, J = 8.0), 3.80 (d, 1H, J = 6.8), 3.45-3.39 (m, 1H), 2.52-0.25 (m, 50H, include singlets at 2.51, 2.22, 2.08, 1.90, 1.89, 1.25, 1.14, 3H each, at 1.29, 9H and triplet at 0.80, 9H)
¹³C-NMR (CDCl₃, 75.469 MHz) δ: 205.06, 171.62, 170.09, 169.80, 167.27, 155.26, 141.29, 133.70, 133.19, 130.26, 129.27, 128.77, 128.61, 127.77, 126.47, 85.33, 80.37, 79.94, 79.06, 75.87, 75.52, 75.31, 73.96, 71.16, 53.06, 43.49, 43.15, 41.89, 40.40, 35.68, 31.65, 28.21, 26.08, 22.84, 22.71, 21.84, 20.86, 16.86, 15.02, 14.51, 6.55, 4.33
 LRESIMS m/z Calcd. for C₅₂H₇₁NO₁₄SSi [M+H]⁺ 993, found 993
 IR (cm⁻¹): 3446.18, 2957.23, 1732.32, 1715.97, 1494.56, 1369.48, 1271.31, 1242.18, 1164.38, 1110.84, 1069.72, 710.30

Example 20**3'-NH-Boc-7-deoxy-6b-thiomethylpaclitaxel (24)**

[0102]

**24**

[0103] The triethylsilyl ether **23** (1.01 g, 1.016 mmol) was dissolved in acetonitrile (12 mL), cooled to 0°C and treated with 1M HCl (2.03 mL, 2.032 mmol) for 1 hour. The reaction mixture was diluted with EtOAc, washed with NaHCO₃, water and brine. The solution was dried over MgSO₄, filtered and concentrated. The residue was chromatographed over silica gel (hexanes/ ethyl acetate 3:1, 2:1, 1:1). The pure fractions were combined together and stripped to a residue, dissolved in a minimal amount of methylene chloride and precipitated with hexane. This suspension was

stripped to a solid residue under vacuum to provide the thiomethyl ether **24** (0.779 g) as a white solid in 87% yield.
¹H-NMR (CDCl₃, 300.133MHz) δ: 8.11 (d, 2H, J = 7.3), 7.64-7.28 (m, 8H), 6.47 (s, 1H), 6.18 (t, 1H, J = 8.6), 5.73 (d, 1H, J = 6.7), 5.39 (d, 1H, J = 9.5), 5.25 (d, 1H, 9.1), 4.96 (d, 1H, J = 5.9), 4.61 (bs., 1H.), 4.32(d, 1H, J = 8.0), 4.08 (d, 1H, J = 8.0), 3.75 (d, 1H, J = 6.6), 3.42-3.35 (m, 2H), 2.44-1.14 (m, 35H, include singlets at 2.36, 2.23, 2.07, 1.89, 1.82, 1.22, 1.14, 3H each and 1.33 9H)


¹³C-NMR (CDCl₃, 75.469 MHz) δ: 204.72, 172.65, 170.33, 169.75, 167.22, 155.36, 140.62, 138.47, 133.79, 130.21, 129.21, 128.89, 128.75, 128.12, 126.82, 85.48, 80.42, 80.28, 78.77, 75.83, 75.68, 75.62, 74.00, 73.74, 72.16, 56.17, 53.10, 43.28, 43.11, 41.60, 39.97, 35.60, 31.63, 28.25, 26.18, 22.53, 21.38, 20.86, 17.23, 14.86 and 14.63

LRESIMS m/z Calcd. for C₄₆H₅₇NO₁₄S [M+H]⁺ 879, found 879

IR (cm⁻¹): 3446.08, 2979.41, 1735.61, 1715.79, 1370.28, 1241.55, 1168.26, 1107.14, 1069.88, 710.38

Example 21**3'-NH-Boc-7-deoxy-6b-methylsulfoxidepaclitaxel (25 and 26)**

[0104]

**25 and 26**
(diastereomers at Sulfur)

[0105] A solution of 3-chloroperoxybenzoic acid (0.136 g, 0.393 mmol) in methylene chloride (2 mL) at 25°C was added dropwise via a syringe to a solution of 3'-NH-Boc-7-deoxy-6b-methylsulfoxidepaclitaxel **24** (0.346 g, 0.393 mmol) in methylene chloride (5 mL) at -78°C over 2 minutes. The reaction mixture was stirred at -78°C for 5 minutes and then

warmed up to -15°C. TLC shows the reaction finished in 20 minutes. The reaction was quenched with DMSO (2 mL) and stirred for 5 minutes at -15°C. The reaction mixture was warmed up and diluted with EtOAc, washed with NaHCO₃, water and brine. The solution was dried over MgSO₄, filtered and concentrated. The residue was chromatographed over silica gel (methylene chloride/acetonitrile 10:1, 10:2, 10:3) to provide the pure minor sulfoxide **25** (8 mg, 2%) as a white solid. Mixed fractions containing a small amount of slower eluting major sulfoxide amounted to (32 mg, 9%), the major sulfoxide containing some of the minor (46 mg, 13%) and the pure slower eluting major sulfoxide **26** (119 mg, 34%)

minor:

¹H-NMR (CDCl₃, 300.133MHz) δ: 8.10 (d, 2H, J = 7.3), 7.63-7.25 (m, 8H), 6.47 (s, 1H), 6.20 (t, 1H, J = 8.9), 5.71 (d, 1H, J = 7.2), 5.45 (d, 1H, J = 9.5), 5.26-5.12 (m, 2H), 4.61 (bs, 1H), 4.32 (d, 1H, J = 8.3), 4.14 (d, 1H, J = 8.2), 3.74 (d, 1H, J = 7.0), 3.51 (bs, 1H), 3.25 (m, 1H), 2.58-1.15 (m, 35H, include singlets at 2.58, 2.40, 2.20, 1.90, 1.85, 1.23, 1.15, 3H each and 1.32, 9H)

¹³C-NMR (CDCl₃, 75.469 MHz) δ: 204.38, 170.54, 169.48, 167.33, 140.75, 134.00, 133.63, 130.41, 129.10, 128.99, 128.30, 126.94, 82.68, 80.72, 80.48, 79.17, 75.56, 73.97, 72.38, 62.15, 52.98, 44.83, 43.24, 38.66, 35.88, 33.60, 28.40, 26.27, 22.66, 21.62, 20.98, 15.58, 14.65

LRESIMS m/z Calcd. for C₄₆H₅₇NO₁₅S [M-H]⁻ 895, found 895

major:

¹H-NMR (CDCl₃, 300.133MHz) δ: 8.10 (d, 2H, J = 7.3), 7.64-7.28 (m, 8H), 6.47 (s, 1H), 6.18 (t, 1H, J = 8.6), 5.74 (d, 1H, J = 6.8), 5.42 (d, 1H, J = 9.2), 5.28-5.23 (m, 2H), 4.59 (bs, 1H), 4.41 (d, 1H, J = 8.0), 4.16 (d, 1H, J = 8.1), 3.76 (d, 1H, J = 6.6), 3.54-3.48 (m, 2H), 2.56-1.13 (m, 35H, include singlets at 2.56, 2.35, 2.22, 1.89, 1.83, 1.23, 1.13, 3H each and 1.32, 9H)

¹³C-NMR (CDCl₃, 75.469 MHz) δ: 204.66, 170.57, 170.13, 167.41, 141.35, 134.12, 133.50, 130.40, 129.21, 129.10, 129.03, 128.32, 126.99, 82.94, 80.44, 79.83, 78.94, 75.66, 73.97, 72.23, 59.58, 52.64, 43.33, 43.20, 37.38, 35.84, 34.05, 28.42, 26.26, 22.50, 21.67, 21.01, 17.01, 14.84


LRESIMS m/z Calcd. for C₄₆H₅₇NO₁₅S [M-H]⁻ 895, found 895

IR (cm⁻¹): 3441.71, 2979.89, 1731.97, 1716.10, 1370.03, 1272.20, 1240.27, 1169.47, 1107.78, 1071.34, 1025.53, 710.95

Example 22

2'-O-(triethylsilyl)-3'-NH-ethylcarbonate-7-deoxy-6b-thiomethylpaclitaxel (27)

[0106]



27

[0107] 7-deoxy-6b-thiomethylbaccatin **22** (0.60 g, 0.973 mmol) was dissolved in tetrahydrofuran (24 mL), cooled to -40°C and treated with lithium bis(trimethylsilyl)amide (1.5 mL, 1.459 mmol) for 15 minutes. A solution of (3R, 4S)-1-ethylcarbonyl-4-phenyl-3-triethylsilyloxy-2-azetidine (0.683 g, 1.946 mmol) in THF (2 mL) was then added. After stirring for 15 minutes at -40°C, the reaction mixture was warmed up to 0°C and allowed to stir overnight. The reaction mixture was diluted with EtOAc, washed with NaHCO₃, water and brine. The solution was dried over MgSO₄, filtered and concentrated. The residue was chromatographed over silica gel (hexanes/ ethyl acetate 4:1, 3:1, 2:1) to provide 0.743 g of the desired product **27** as a white powder in 79 % yield.


¹H-NMR (CDCl₃, 300.133MHz) δ: 8.13 (d, 2H, J = 7.1), 7.62-7.25 (m, 8H), 6.49 (s, 1H), 6.28 (t, 1H, J = 8.6), 5.74 (d, 2H, J = 7.0), 5.60 (d, 1H, J = 9.4), 5.27 (d, 1H, J = 7.8), 4.98 (d, 1H, J = 6.5), 4.55 (d, 1H, J = 2.3), 4.33 (d, 1H, J = 8.0), 4.09 (d, 1H, J = 8.0), 3.97 (d, 2H, J = 7.1), 3.75 (d, 1H, J = 6.8), 3.45-3.38 (m, 1H), 2.50-0.27 (m, 44H, include singlets at 2.50, 2.22, 2.08, 1.90, 1.87, 1.26, 1.14, 3H each and triplet at 0.77, 9H)

¹³C-NMR (CDCl₃, 75.469 MHz) δ: 205.05, 171.41, 169.80, 167.30, 141.15, 138.87, 133.73, 133.23, 130.29, 129.26,

128.74, 128.68, 127.94, 126.44, 85.31, 80.37, 79.20, 79.06, 75.87, 75.52, 75.27, 73.92, 71.09, 61.32, 53.07, 43.56, 43.14, 41.94, 40.45, 35.72, 31.65, 26.16, 22.80, 21.87, 20.86, 16.80, 15.05, 14.48, 6.54, 4.34
 LRESIMS m/z Calcd. for C₅₂H₇₁NO₁₄SSi [M+H]⁺ 965, found 965
 IR (cm⁻¹): 3445.26, 2956.24, 1730.91, 1718.04, 1275.07, 1243.34, 1112.19, 1070.70, 710.04

Example 23**3'-NH-ethylcarbonate-7-deoxy-6b-thiomethylpaclitaxel (28)**

[0108]

**28**

[0109] The triethylsilyl ether **27** (0.7198 g, 0.745 mmol) was dissolved in acetonitrile (12 mL), cooled to 0°C and treated with 1M HCl (1.49 mL, 1.49 mmol) for 1 hour and 20 minutes. The reaction mixture was diluted with EtOAc, washed with NaHCO₃, water and brine. The solution was dried over MgSO₄, filtered and concentrated. The residue was chromatographed over silica gel (hexanes/ ethyl acetate 3:1, 2:1, 1:1). The pure fractions were combined together and stripped to a residue, dissolved in a minimal amount of methylene chloride and precipitated with hexane. This suspension was stripped to a solid residue under vacuum to provide the thiomethyl ether **28** (0.546 g) as a white solid in 85% yield.

¹H-NMR (CDCl₃, 300.133MHz) δ: 8.11 (d, 2H, J = 7.3), 7.63-7.25 (m, 8H), 6.46 (s, 1H), 6.21 (t, 1H, J = 8.4), 5.72 (d, 1H, J = 6.7), 5.58 (d, 1H, J = 9.4), 5.30 (d, 1H, J = 8.7), 4.96 (d, 1H, J = 5.8), 4.62 (bs., 1H), 4.31 (d, 1H, J = 8.0), 4.09 (d, 1H, J = 8.0), 4.02 (q, 2H, J = 7.1), 3.71 (d, 1H, J = 6.6), 3.48 (bs, 1H), 3.41-3.34 (m, 1H), 2.38-1.12 (m, 29H, include singlets at 2.35, 2.23, 2.07, 1.89, 1.80, 1.23, 1.14, 3H each)


¹³C-NMR (CDCl₃, 75.469 MHz) δ: 204.63, 170.50, 169.76, 167.21, 140.45, 133.82, 130.23, 129.18, 128.92, 128.73, 128.23, 126.85, 85.54, 80.47, 78.80, 75.65, 73.98, 73.79, 71.93, 61.48, 56.48, 53.12, 43.26, 43.09, 41.56, 39.90, 35.64, 31.65, 29.77, 26.28, 22.72, 22.52, 21.31, 20.87, 17.32, 14.83, 14.69, 14.54, 14.18

LRESIMS m/z Calcd. for C₄₄H₅₃NO₁₄S [M+H]⁺ 851, found 851

IR (cm⁻¹): 3445.58, 2929.17, 1730.58, 1716.34, 1372.28, 1241.39, 1107.63, 1069.72, 868.26, 710.95

Example 24**2'-O-(triethylsilyl)-7-deoxy-6b-thioethylpaclitaxel (29)**

[0110]

**29**

[0111] Thiol **12** (0.5 g, 0.508 mmol) was dissolved in benzene (9 mL) and degassed under house vacuum for 20 minutes, then backfilled with nitrogen. Iodoethane (61 μ L, 0.762 mmol) and DBU (0.15 mL, 1.016 mmol) were then added and the reaction was stirred at room temperature for 20 minutes. The precipitated salts were filtered off on a short pass of silica gel and washed with 2:1 hexanes/ethyl acetate. The filtrate was stripped to a residue and chromatographed on silica gel (hexanes/ethyl acetate 4:1, 3:1) to provide 0.474 g of the thioethyl ether **29** as a white solid in

92 % yield

$^1\text{H-NMR}$ (CDCl_3 , 300.133MHz) δ : 8.14 (d, 2H, J = 7.1), 7.74 (d, 2H, J = 7.0), 7.63-7.28 (m, 11H), 7.09 (d, 1H, J = 8.8), 6.48 (s, 1H), 6.24 (t, 1H, J = 8.4), 5.75-5.68 (m, 2H), 4.96 (d, 1H, J = 6.4), 4.68 (d, 1H, 2.0), 4.33 (d, 1H, J = 8.0), 4.11 (d, 1H, J = 8.1), 3.74 (d, 1H, 6.8), 3.54-3.47 (m, 1H), 2.59-0.33 (m, 43H, include singlets at 2.53, 2.21, 1.90, 1.21, 1.12, 3H each and triplet at 0.79, 9H)

$^{13}\text{C-NMR}$ (CDCl_3 , 75.469 MHz) δ : 205.03, 171.54, 170.17, 169.81, 167.20, 166.96, 140.89, 138.53, 134.16, 133.74, 133.48, 131.82, 130.28, 129.26, 128.83, 128.75, 128.03, 127.11, 126.51, 85.48, 80.42, 78.98, 75.81, 75.45, 74.98, 73.98, 71.25, 55.75, 53.12, 43.45, 43.13, 41.39, 39.86, 35.90, 26.17, 25.77, 22.93, 21.82, 20.86, 16.94, 14.60, 14.54, 6.58, 4.44


LRESIMS m/z Calcd. for $\text{C}_{55}\text{H}_{69}\text{NO}_{13}\text{SSi}$ $[\text{M}+\text{H}]^+$ 1011, found 1011

IR (cm^{-1}): 3411.39, 2957.41, 1747.37, 1732.29, 1715.79, 1669.13, 1484.14, 1371.83, 1270.69, 1241.17, 1108.41, 1069.67, 968.92, 710.50

Example 25

7-deoxy-6b-thioethylpaclitaxel (**30**)

[0112]



30

[0113] The triethylsilyl ether **29** (0.463 g, 0.457 mmol) was dissolved in acetonitrile (21 mL), cooled to 0°C and treated with 1M HCl (0.9 mL, 0.915 mmol) for 20 minutes. The reaction mixture was diluted with EtOAc, washed with NaHCO_3 , water and brine. The solution was dried over MgSO_4 , filtered and concentrated. The residue was chromatographed over silica gel (hexanes/ ethyl acetate 2:1, 1:1). The pure fractions were combined together and stripped to a residue, dissolved in a minimal amount of methylene chloride and precipitated with hexane. This suspension was stripped to a solid residue under vacuum to provide the thioethyl ether **30** (0.368 g) as a white solid in 90% yield.

$^1\text{H-NMR}$ (CDCl_3 , 300.133MHz) δ : 8.12 (d, 2H, J = 7.1), 7.74 (d, 2H, J = 7.1), 7.63-7.30 (m, 11H), 7.05 (d, 1H, J = 9.0), 6.43 (s, 1H), 6.17 (t, 1H, J = 8.4), 5.78 (dd, 1H, J = 2.5, 9.0), 5.72 (d, 1H, J = 6.7), 4.92 (d, 1H, J = 5.8), 4.79-4.76 (m, 1H), 4.36 (d, 1H, J = 8.0), 4.09 (d, 1H, J = 7.9), 3.74 (d, 1H, 6.5), 3.65 (d, 1H, J = 4.8, disappear with D_2O), 3.50-3.43 (m, 1H), 2.68-1.12 (m, 28H, include. singlets at 2.37, 2.27, 1.88, 1.74, 1.12, 3H each)


$^{13}\text{C-NMR}$ (CDCl_3 , 75.469 MHz) δ : 204.64, 172.38, 170.54, 169.77, 167.16, 166.92, 140.30, 138.09, 133.94, 133.82, 133.73, 132.02, 130.23, 129.22, 129.04, 128.77, 128.38, 127.13, 127.10, 85.69, 80.45, 78.72, 75.64, 75.58, 74.02, 73.39, 72.10, 54.93, 55.14, 43.19, 43.09, 40.82, 39.61, 35.76, 31.65, 26.29, 25.64, 22.72, 22.58, 21.30, 20.87, 17.42, 14.61, 14.18

LRESIMS m/z Calcd. for $\text{C}_{49}\text{H}_{55}\text{NO}_{13}\text{S}$ $[\text{M}-\text{H}]^+$ 897, found 897

IR (cm^{-1}): 3435.69, 2930.07, 1733.39, 1718.09, 1664.00, 1654.44, 1487.03, 1372.82, 1270.69, 1239.54, 1106.80, 1069.56, 968.04, 711.06

Example 26**2'-tert-butyldimethylsilyl-6- β -thiobenzyl-7-deoxypaclitaxel(31)**


5 [0114]



20 [0115] A solution of 2'-tert-butyldimethylsilyl-6- β -thio-7-deoxy-paclitaxel (**12a**) (461.0 mg, 0.530 mmoles) in anhydrous benzene (4.5 mL) was treated with DBU (300.0 μ L, 2.00 mmoles), then with benzyl bromide (125.0 μ L, 1.05 mmoles) and stirred at ambient temperature under nitrogen until the reaction was complete according to analysis by TLC. The reaction mixture was diluted with ethyl acetate and washed with water followed by brine. The solution was dried over anhydrous Na_2SO_4 , filtered and concentrated *in vacuo*. Purification by column chromatography on silica eluting with 75% hexanes/ethyl acetate afforded 361 mg (71.1%) of compound with formula **31** as a white, amorphous powder which exhibited the following physical properties: ^1H NMR (CDCl_3 , 300 MHz) δ 8.14 (d, J = 7.8 Hz, 2H), 7.74 (d, J = 7.7 Hz, 2H), 7.72-7.23 (m, 16H), 7.08 (d, J = 9.0 Hz, 1H), 6.42 (s, 1H), 6.24 (t, J = 8.3 Hz, 1H), 5.74 (m, 2H), 4.87 (d, J = 6.2 Hz, 1H), 4.33 (d, J = 8.0 Hz, 1H), 4.13 (d, J = 8.0 Hz, 1H), 3.77-3.67 (m, 3H), 3.45-3.38 (m, 1H), 2.55 (s, 3H), 2.40-2.32 (m, 2H), 2.23 (s, 3H), 2.17-2.09 (m, 1H), 1.92 (s, 3H), 1.87 (s, 3H), 1.92-1.87 (m, 3H), 1.21 (s, 3H), 1.13 (s, 3H), 0.81 (s, 9H), -0.04 (s, 3H), -0.29 (s, 3H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 205.49, 175.74, 171.87, 170.49, 170.27, 167.57, 141.34, 138.88, 138.28, 134.63, 134.19, 134.01, 132.39, 130.77, 129.81, 129.50, 129.32, 129.11, 128.56, 127.68, 127.57, 127.00, 86.09, 80.83, 79.30, 76.37, 76.10, 75.82, 74.52, 71.76, 56.23, 53.49, 43.74, 43.64, 41.38, 39.68, 36.35, 26.68, 26.12, 25.62, 23.45, 22.37, 21.39, 18.74, 17.92, 15.14, -4.61, -5.21.

35 **Example 27****6- β -thiobenzyl-7-deoxypaclitaxel (32).**

40 [0116]




45 [0117] A solution of compound **31** (344 mg, 0.320 mmoles) in THF (5 mL) was cooled to -10°C under nitrogen and treated with TBAF (1 M in THF, 150 μ L, 0.150 mmoles). After stirring for 10 mins., the reaction was judged to be approximately 66% completed on the basis of TLC analysis and an additional amount of TBAF (50 μ L, 0.050 mmoles) was added. After another 5 mins., the mixture diluted with ethyl acetate and washed with water, then brine. The solution was dried over anhydrous Na_2SO_4 , filtered and concentrated *in vacuo*. Chromatography on silica eluting with 75% hexanes/ethyl acetate afforded 123 mg (40%) of compound with formula **32** as a white, amorphous solid which exhibited

the following physical properties: ^1H NMR (CDCl_3 , 300 MHz) δ 8.12 (d, J = 7.7 Hz, 2H), 7.76 (d, J = 7.9 Hz, 2H), 7.64-7.21 m, 16H), 7.11 (d, J = 9.1 Hz, 1H), 6.36 (s, 1H), 6.15 (t, J = 7.0 Hz, 1H), 5.80 (dd, J = 2.4 Hz, J = 8.9 Hz, 1H), 5.72 (d, J = 6.0 Hz, 1H), 4.83 (d, J = 5.6 Hz, 1H), 4.78 (d, J = 2.6 Hz, 1H), 4.31 (d, J = 7.9 Hz, 1H), 4.12 (d, J = 7.6 Hz, 1H), 3.75-3.65 (m, 3H), 3.38-3.31 (m, 1H), 2.35 (s, 3H), 2.31-2.26 (m, 2H), 2.23 (s, 3H), 2.00 (s, 1H), 1.89 (s, 3H), 1.87-1.80 (m, 2H), 1.64 (s, 3H), 1.19 (s, 3H), 1.12 (s, 3H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 205.19, 172.83, 170.85, 170.28, 168.87, 167.52, 140.88, 138.67, 138.16, 134.26, 132.50, 130.71, 129.77, 129.47, 129.24, 129.12, 128.80, 127.66, 86.20, 80.82, 79.05, 78.85, 76.15, 74.54, 73.90, 72.38, 55.53, 53.51, 43.54, 40.91, 39.47, 36.28, 26.76, 25.61, 22.99, 21.82, 21.39, 18.74, 18.21, 15.09; LRMS (ESI): 958.3 ($[\text{M}-1$), 100%).

Example 28

2'-tert-butyltrimethylsilyl-6- β -thiomethyl methyl keto-7-deoxypaclitaxel (33).

[0118]




[0119] A solution of 2'-tert-butyltrimethylsilyl-6- β -thio-7-deoxy-paclitaxel (**12a**) (416.0 mg, 0.423 mmoles) in anhydrous benzene (4.0 mL) was treated with DBU (300.0 μL , 2.00 mmoles), then with α -chloroacetone (90.0 μL , 1.13 mmoles) and stirred at ambient temperature under for 10 mins. The reaction mixture was diluted with ethyl acetate and washed with water followed by brine. The solution was dried over anhydrous Na_2SO_4 , filtered and concentrated *in vacuo*. Purification by column chromatography on silica eluting with 75% hexanes/ethyl acetate to 50% hexanes/ethyl acetate afforded 330 mg (75.0%) of compound with formula **33** as a white, amorphous powder which exhibited the following physical properties: ^1H NMR (CDCl_3 , 300 MHz) δ 8.15 (d, J = 7.8 Hz, 2H), 7.73 (d, J = 7.0 Hz, 2H), 7.61-7.34 (bm, 11H), 7.08 (d, J = 8.9 Hz, 1H), 6.46 (s, 1H), 6.25 (t, J = 9.0 Hz, 1H), 5.75-5.72 (m, 2H), 4.94 (d, J = 6.7 Hz, 1H), 4.66 (d, J = 1.9 Hz, 1H), 4.34 (d, J = 8.0 Hz, 1H), 4.12 (d, J = 8.3 Hz, 1H), 3.73 (d, J = 7.0 Hz, 1H), 3.59-3.51 (m, 1H), 3.24 (d, J = 14.1 Hz, 1H), 3.15 (d, J = 14.0 Hz, 1H), 2.57 (s, 3H), 2.47-2.34 (m, 1H), 2.27 (s, 3H), 2.21 (s, 3H), 2.19-2.04 (m, 1H), 1.91 (s, 3H), 1.89 (s, 3H), 1.86-1.75 (m, 3H), 1.21 (s, 3H), 1.19 (s, 3H), 0.79 (s, 9H), -0.04 (s, 3H), -0.30 (s, 3H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 205.48, 204.38, 171.88, 170.56, 170.22, 167.54, 153.91, 141.42, 138.81, 134.62, 134.17, 133.84, 132.36, 130.76, 129.81, 129.29, 128.54, 127.54, 129.99, 88.22, 80.67, 79.28, 76.27, 76.00, 75.78, 74.51, 71.76, 56.21, 53.44, 44.22, 43.59, 41.92, 41.46, 40.46, 36.45, 28.37, 26.65, 26.10, 23.36, 22.34, 21.33, 18.70, 17.11, 15.14, -4.66, -5.24.

Example 29

6- β -thiomethyl methyl keto-7-deoxypaclitaxel (34).

[0120]




[0121] A solution of compound **33** (330 mg, 0.317 mmoles) in anhydrous THF (5.0 mL) was cooled to -10°C under nitrogen and treated with TBAF (1M in THF, 250 µL, 0.250 mmoles). The mixture was removed from the cooling bath and stirred at ambient temperature for 15 mins. The mixture was diluted with ethyl acetate and washed with water, then brine. The solution was dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. Chromatography on silica eluting with 75% hexanes/ethyl acetate afforded 178 mg of impure material that was subjected to chromatography on silica eluting with 90% hexanes/ethyl acetate to give 93 mg (31.7%) of compound with formula **34** as a white, amorphous solid which exhibited the following physical properties: ¹H NMR (CDCl₃, 300 MHz) δ 8.13 (d, J = 8.1 Hz, 2H), 7.75 (d, J = 8.1 Hz, 2H), 7.62-7.36 (bm, 11H), 7.08 (d, J = 8.9 Hz, 1H), 6.42 (s, 1H), 6.18 (t, J = 8.4 Hz, 1H), 5.80 (dd, J = 9.0 Hz, J = 2.4 Hz 1H), 5.72 (d, J = 6.6 Hz, 1H), 4.91 (d, J = 6.2 Hz, 1H), 4.79 (d, J = 2.5 Hz, 1H), 4.32 (d, J = 8.0 Hz, 1H), 4.11 (d, J = 8.3 Hz, 1H), 3.72 (d, J = 6.8 Hz, 1H), 3.53-3.47 (m, 1H), 3.24 (d, J = 18.6 Hz, 1H), 3.15 (d, J = 13.2 Hz, 1H), 2.45 (m, 1H), 2.38 (s, 3H), 2.32 (s, 1H), 2.28 (s, 1H), 2.25 (s, 3H), 2.22 (s, 3H), 2.03 (s, 1H), 1.88 (s, 3H), 1.78 (s, 3H), 1.75 (m, 1H), 1.21 (s, 3H), 1.13 (s, 3H); ¹³C NMR (CDCl₃, 75 MHz) δ 205.27, 204.35, 173.03, 170.86, 170.26, 168.87, 167.69, 167.53, 141.07, 138.66, 134.27, 134.22, 134.09, 132.48, 130.72, 130.62, 129.78, 129.50, 129.26, 129.22, 128.80, 127.65, 127.60, 85.41, 80.68, 79.15, 76.10, 73.85, 74.59, 73.85, 72.50, 55.55, 53.49, 44.07, 43.53, 41.83, 41.08, 40.35, 36.32, 28.43, 26.75, 22.96, 21.89, 21.35, 17.38, 15.10, 14.75; LRMS (ESI): 926.4 ((M+1)⁺, 100%).

Example 30

2'-O-(triethylsilyl)-7-deoxy-6b-thioacetoneitrilepaclitaxel (**35**)

[0122]




[0123] Thiol **12** (0.8 g, 0.813 mmol) was dissolved in benzene (15 mL) and degassed under house vacuum for 20 minutes, then backfilled with nitrogen. Iodoacetoneitrile (88 µL, 1.219 mmol) and DBU (0.24 mL, 1.626 mmol) were then added and the reaction was stirred at room temperature for 30 minutes. The precipitated salts were filtered off on a short pass of silica gel and washed with 2:1 hexanes/ethyl acetate. The filtrate was stripped to a residue and chromatographed on silica gel (hexanes/ethyl acetate 3:1, 2:1) to provide 0.6954 g of the thioacetoneitrile ether **35** as a white solid in 84 % yield.

¹H-NMR (CDCl₃, 300.133MHz) δ: 8.08 (d, 2H, J = 7.0), 7.67 (d, 2H, J = 7.0), 7.57-7.19 (m, 11H), 7.04 (d, 1H, J = 8.9), 6.40 (s, 1H), 6.18 (t, 1H, J = 8.7), 5.68-5.63 (m, 2H), 4.98 (d, 1H, J=7.0), 4.62(d, 1H, J = 2.0), 4.31(d, 1H, J = 8.1), 4.08 (d, 1H, J = 7.9), 3.76-3.61(m, 2H), 3.28-3.16 (m, 2H), 2.50-0.30 (m, 38H, include. singlets at 2.48, 2.15, 1.84, 1.82, 1.15, 1.06, 3H each and triplet at 0.74, 9H)

¹³C-NMR (CDCl₃, 75.469 MHz) δ: 204.85, 171.56, 170.18, 169.76, 167.17, 167.00, 141.14, 138.46, 134.16, 133.81, 133.23, 131.84, 130.93, 130.28, 129.18, 128.88, 128.80, 128.76, 128.06, 127.10, 126.50, 116.34, 84.52, 80.12, 78.97, 75.91, 75.61, 74.97, 73.99, 71.21, 68.22, 55.74, 52.96, 43.85, 43.08, 40.67, 40.31, 38.80, 35.99, 31.65, 30.43, 28.99, 26.13, 23.82, 23.04, 22.79, 22.71, 21.81, 20.82, 16.56, 16.40, 14.59, 14.18, 14.11, 11.02, 6.58, 4.44

LRMSIMS m/z Calcd. for C₅₅H₆₆N₂O₁₃SSi [M+H]⁺ 1022, found 1022

Example 31**6b-thioacetoneitrile-7-deoxypaclitaxel (36)****[0124]**


[0125] The triethylsilyl ether **35** (0.675 g, 0.660 mmol) was dissolved in acetonitrile (31 mL), cooled to 0°C and treated with 1M HCl (1.3 mL, 1.319 mmol) for 30 minutes. The reaction mixture was diluted with EtOAc, washed with NaHCO₃, water and brine. The solution was dried over MgSO₄, filtered and concentrated. The residue was chromatographed over silica gel (hexanes/ ethyl acetate 2:1, 1:1). The pure fractions were combined together and stripped to a residue, dissolved in a minimal amount of methylene chloride and precipitated with hexane. This suspension was stripped to a solid residue under vacuum to provide the thioether **36** (0.585 g) as a white solid in 97% yield.

¹H-NMR (CDCl₃, 300.133MHz) δ: 8.07 (d, 2H, J = 7.1), 7.68 (d, 2H, J = 7.0), 7.59-7.26 (m, 11H), 6.95 (d, 1H, J = 8.9), 6.36 (s, 1H), 6.14 (t, 1H, J = 8.5), 5.73 (dd, 1H, J = 2.4, 8.9), 5.66 (d, 1H, J = 6.8), 4.96(d, 1H, J=6.5), 4.74-4.71 (m, 1H), 4.29 (d, 1H, J = 8.0), 4.07 (d, 1H, J = 8.1), 3.73-3.66 (m, 2H), 3.53 (d, 1H, J = 4.9, disappear with D₂O), 3.27-3.15 (m, 2H), 2.44-1.06 (m, 23H, include. singlets at 2.33, 2.15, 1.81, 1.72, 1.14, 1.06, 3H each)

¹³C-NMR (CDCl₃, 75.469 MHz) δ: 204.59, 172.64, 170.56, 169.80, 167.13, 140.68, 138.10, 133.90, 133.71, 133.64, 132.08, 130.28, 129.21, 129.13, 128.86, 128.81, 128.45, 127.14, 127.10, 116.37, 84.74, 80.16, 78.78, 76.03, 75.51, 74.06, 73.33, 72.18, 55.03, 52.99, 43.67, 43.08, 40.63, 40.02, 35.90, 26.29, 22.50, 21.46, 20.87, 16.80, 16.53, 14.68

LRESIMS m/z Calcd. for C₄₉H₅₂N₂O₁₃S [M+H]⁺ 908, found 908

IR (cm⁻¹): 3432.48, 2953.79, 2245.30, 1733.46, 1721.24, 1661.98, 1486.70 1372.15, 1271.12, 2240.36, 1107.31, 1070.11, 1023.99, 969.96, 711.34

Example 32**6b-cyanomethylsulfoxo-7-deoxypaclitaxel (37 & 38)****[0126]**

[0127] A solution of 3-chloroperoxybenzoic acid (0.380 g, 1.10 mmol) in methylene chloride (5 mL) at 25°C was added dropwise via a syringe to a solution of **36** (1.0 g, 1.10 mmol) in methylene chloride (20 mL) at -78°C over 2 minutes. The reaction mixture was stirred at -78°C for 5 minutes and then warmed up to -15°C. TLC shows the reaction finished in 20 minutes. The reaction was quenched with DMSO and stirred for 5 minutes at -15°C. The reaction mixture was warmed up and diluted with EtOAc, washed with NaHCO₃, water and brine. The solution was dried over MgSO₄, filtered and concentrated. The residue was chromatographed over silica gel (methylene chloride/acetonitrile 10:1, 10:2) to provide the pure minor sulfoxide **37** (190 mg, 19%) as a white solid, the pure slower eluting major sulfoxide **38**

(373 mg, 37%) and an additional taxane (64.5 mg, 6%).

minor:

¹H-NMR (CDCl₃, 300.133MHz) δ: 8.06 (d, 2H, J = 7.1), 7.68 (d, 2H, J = 7.0), 7.59-7.19 (m, 11H), 6.98 (d, 1H, J = 8.7), 6.40 (s, 1H), 6.12 (t, 1H, J = 8.9), 5.68 (dd, 1H, J = 2.8, 8.7), 5.63 (d, 1H, J = 7.2), 5.20 (d, 1H, J = 8.4), 4.72 (d, 1H, J = 2.4), 4.30 (d, 1H, J = 8.3), 4.13 (d, 1H, J = 8.4), 3.78-3.58 (m, 5H), 2.42-1.07 (m, 23H, include. singlets at 2.36, 2.13, 1.83, 1.76, 1.13, 1.07, 3H each)

¹³C-NMR (CDCl₃, 75.469 MHz) δ: 204.26, 173.03, 170.81, 170.05, 167.47, 167.23, 140.96, 138.23, 134.12, 133.96, 133.54, 132.19, 130.44, 129.21, 129.08, 129.08, 128.93, 128.55, 127.34, 127.18, 111.59, 81.94, 80.28, 79.13, 78.04, 75.45, 74.15, 73.43, 72.12, 60.43, 55.38, 52.83, 44.77, 43.16, 38.72, 36.07, 33.67, 26.35, 22.63, 21.70, 20.99, 15.84, 14.78

LRESIMS m/z Calcd. for C₄₉H₅₂N₂O₁₄S [M-H]⁺ 924, found 924

IR (cm⁻¹): 3425.79, 2983.27, 2932.21, 2250.06, 1733.09, 1722.54, 1658.92, 1486.12, 1372.10, 1272.22, 1239.25, 1178.82, 1069.44, 1025.83, 972.55, 711.71

major:

¹H-NMR (CDCl₃, 300.133MHz) δ: 8.12 (d, 2H, J = 7.1), 7.73 (d, 2H, J = 7.0), 7.65-7.25 (m, 11H), 7.04 (d, 1H, J = 8.9), 6.41 (s, 1H), 6.18 (t, 1H, J = 8.2), 5.79-5.72 (m, 2H), 5.27 (d, 1H, J = 5.9), 4.78 (s, 1H), 4.44 (d, 1H, J = 8.1), 4.24 (d, 1H, J = 8.0), 3.99-3.93 (m, 1H), 3.86-3.50 (m, 4H), 2.42-1.11 (m, 23H, include. singlets at 2.36, 2.20, 1.88, 1.80, 1.21, 1.11, 3H each)

¹³C-NMR (CDCl₃, 75.469 MHz) δ: 204.44, 172.85, 170.70, 170.12, 167.37, 167.25, 141.56, 138.28, 134.18, 133.88, 133.44, 132.22, 130.42, 229.30, 129.19, 129.09, 128.96, 128.59, 127.32, 127.26, 111.26, 82.67, 79.60, 78.79, 75.55, 74.19, 73.42, 72.16, 57.92, 55.22, 52.34, 43.19, 43.11, 37.90, 36.10, 33.38, 26.38, 22.48, 21.71, 20.99, 17.63, 14.97


LRESIMS m/z Calcd. for C₄₉H₅₂N₂O₁₄S [M-H]⁺ 924, found 924

IR (cm⁻¹): 3424.86, 2983.48, 2930.13, 2250.05, 1734.98, 1719.49, 1656.30, 1518.89, 1486.80, 1372.55, 1271.46, 1239.21, 1107.38, 1070.63, 1025.18, 969.56, 711.41

Example 33

2'-triethylsilyl-6b-(2-thioacetic acid methyl ester)-7-deoxypaclitaxel (39).


[0128]



[0129] A solution of 2'-triethylsilyl-6- α -trifluoromethanesulfonyl-7-deoxypaclitaxel (I) (437.5 mg, 0.39 mmoles) in anhydrous benzene (10 mL) was treated with methyl thioglycolate (0.11 mL, 1.19 mmoles) and DBU (0.24 mL, 1.59 mmole) and stirred for 20 mins. at ambient temperature under nitrogen. The solution was transferred to a silica column packed with hexanes and eluted with 60% hexanes/ethyl acetate to give 371.8 mg (88.4%) of compound with formula 39 as a white, amorphous powder which exhibited the following physical properties: LRMS (ESI): 1073.6 ((M+NH₄)⁺, 40%), 1056.0 ((M+1)⁺, 100%).

Example 34**6b-thioacetyl methyl ester-7-deoxypaclitaxel (40).**


[0130]



[0131] A solution of compound with formula 39 (370.0 mg, 0.350 mmoles) in acetonitrile (9.0 mL) was cooled to 0°C under nitrogen and treated with 1N HCl (0.7 mL, 0.700 mmoles). After stirring at ambient temperature for 1.5 hrs., the mixture was concentrated *in vacuo*. Chromatography on silica eluting with 60% hexanes/ethyl acetate afforded 303.6 mg (92.1%) of compound with formula 40 as a white, amorphous solid which exhibited the following physical properties: ¹H NMR (CDCl₃, 300 MHz) δ 8.12 (d, J = 8.56 Hz, 2H), 7.73 (d, J = 8.59 Hz, 2H), 7.63-7.30 (bm, 11H), 7.04 (d, J = 8.97 Hz, 1H), 6.42 (s, 1H), 6.17 (m, 1H), 5.78 (dd, J = 2.43 Hz, J = 8.94 Hz, 1H), 5.70 (d, J = 6.78 Hz, 1H), 4.98 (d, J = 6.25 Hz, 1H), 4.77 (dd, J = 2.65 Hz, J = 4.71 Hz, 1H), 4.31 (d, J = 8.03 Hz, 1H), 4.10 (d, J = 7.01 Hz, 1H), 3.74-3.64 (m, 2H), 3.69 (s, 3H), 3.19 (dd, J = 14.76 Hz, J = 20.01 Hz, 2H), 2.40 (m, 1H), 2.38 (s, 3H), 2.30 (s, 1H), 2.28 (s, 1H), 2.21 (s, 3H), 2.03 (s, 1H), 1.87 (s, 3H), 1.76 (s, 3H), 1.66 (s, 2H), 1.19 (s, 3H), 1.12 (s, 3H); ¹³C NMR (CDCl₃, 75 MHz) δ 204.64, 172.49, 170.68, 170.44, 169.69, 167.13, 167.00, 140.39, 138.08, 133.82, 133.77, 133.72, 132.03, 130.24, 129.22, 129.05, 128.77, 128.38, 127.11, 85.03, 80.32, 78.73, 75.72, 75.56, 74.02, 73.33, 72.13, 54.95, 53.07, 52.56, 43.53, 43.06, 40.48, 40.36, 35.79, 32.96, 22.52, 21.33, 20.85, 16.98, 14.60; LRMS (ESI): 942.4 ((M+1)⁺, 42%), 286.3 (100%), 161.4 (60%), 105.3 (70%)

Example 35**2'-O-(triethylsilyl)-7-deoxy-6b-allyl thioacetatepaclitaxel (41)**

[0132]




[0133] Thiol 12 (0.66 g, 0.670 mmol) was dissolved in benzene (11 mL) and degassed under house vacuum for 20 minutes, then backfilled with nitrogen. Allyl chloroacetate (93.5 uL, 1.005 mmol) and DBU (0.198 mL, 1.341 mmol) were then added and the reaction was stirred at room temperature for 20 minutes. The precipitated salts were filtered off on a short pass of silica gel and washed with 2:1 hexanes/ethyl acetate. The filtrate was stripped to a residue and chromatographed on silica gel (hexanes/ethyl acetate 3:1, 2:1) to provide 0.66 g of the desired product 41 as a white solid in 91% yield

¹H-NMR (CDCl₃, 300.133MHz) δ: 8.14 (d, 2H, J = 7.0), 7.73 (d, 2H, J = 7.0), 7.63-7.29 (m, 11H), 7.10 (d, 1H, J = 8.9), 6.47 (s, 1H), 6.23 (t, 1H, J = 9.3), 5.97-5.84 (m, 1H), 5.74-5.68 (m, 2H), 5.36-5.22 (m, 2H), 5.01 (d, 1H, J = 6.9), 4.67 (d, 1H, J = 2.0), 4.60 (d, 1H, J = 6.9), 4.34 (d, 1H, J = 8.0), 4.11 (d, 1H, J = 8.1), 3.79-3.71 (m, 2H), 3.27-3.15 (m, 2H),

2.52-0.35 (m, 38H, include. singlets at 2.52, 2.21, 1.89, 1.88, 1.25, 1.15, 3H each and triplet at 0.80, 9H)
 ^{13}C -NMR (CDCl_3 , 75.469 MHz) δ : 204.98, 171.55, 170.04, 169.94, 169.71, 167.19, 167.02, 140.89, 138.49, 134.14, 133.74, 133.35, 131.84, 131.80, 130.28, 129.27, 128.84, 128.76, 128.71, 128.04, 127.10, 126.50, 118.86, 84.77, 80.28, 78.96, 75.72, 75.585, 74.96, 73.96, 71.27, 66.06, 55.75, 53.08, 43.82, 43.10, 40.98, 40.48, 35.93, 33.19, 31.65, 26.14, 22.84, 22.72, 21.79, 20.85, 16.45, 14.55, 14.18 6.58, 4.43
 LRESIMS m/z Calcd. for $\text{C}_{58}\text{H}_{71}\text{NO}_{15}\text{SSi}$ $[\text{M}+\text{H}]^+$ 1081, found 1081
 IR (cm^{-1}): 3442.25, 2956.06, 2878.21, 1731.90, 1668.09, 1484.27, 1371.75, 1272.40, 1241.49, 1127.26, 1069.92, 979.99, 711.04

Example 36**7-deoxy-6b- allyl thioacetatepaclitaxel (42)**

[0134]



[0135] The triethylsilyl ether **41** (0.650 g, 0.600 mmol) was dissolved in acetonitrile (8 mL), cooled to 0°C and treated with 1M HCl (1.2 mL, 1.20 mmol) for 1 hour. The reaction mixture was diluted with EtOAc, washed with NaHCO_3 , water and brine. The solution was dried over MgSO_4 , filtered and concentrated. The residue was chromatographed over silica gel (hexanes/ ethyl acetate 2:1, 1:1). The pure fractions were combined together and stripped to a residue, dissolved in a minimal amount of methylene chloride and precipitated with hexane. This suspension was stripped to a solid residue under vacuum to provide the thioethyl ether **42** (0.474 g) as a white solid in 82% yield.

^1H -NMR (CDCl_3 , 300.133MHz) δ : 8.12 (d, 2H, $J = 7.2$), 7.74 (d, 2H, $J = 7.1$), 7.64-7.25 (m, 11H), 7.04 (d, 1H, $J = 9.0$), 6.43 (s, 1H), 6.17 (t, 1H, $J = 8.4$), 5.94-5.83 (m, 1H), 5.78 (dd, 1H, $J = 2.4, 9.0$), 5.71 (d, 1H, $J = 6.8$), 5.36-5.21 (m, 2H), 4.98(d, 1H, $J = 6.3$), 4.78-4.76 (m, 1H), 4.59 (d, 2H, $J = 5.6$), 4.21(d, 1H, $J = 8.0$), 4.10 (d, 1H, $J = 8.0$), 3.75-3.68 (m, 2H), 3.62 (d, 1H, $J = 4.8$), 3.27-3.15 (m, 2H), 2.45-1.12 (m, 23H, include. singlets at 2.37, 2.21, 1.87, 1.76, 1.19, 1.12, 3H each)


^{13}C -NMR (CDCl_3 , 75.469 MHz) δ : 204.62, 172.47, 170.41, 169.86, 169.65, 167.16, 166.96, 140.37, 138.09, 133.82, 133.76, 133.73, 132.02, 131.78, 130.25, 129.22, 129.05, 128.79, 128.76, 128.39, 127.11, 118.89, 84.99, 80.31, 78.77, 75.69, 75.57, 74.00, 73.35, 72.12, 66.08, 54.94, 53.11, 43.60, 43.05, 40.51, 40.30, 35.79, 33.09, 31.65, 26.28, 22.72, 22.51, 21.30, 20.85, 16.88, 14.62, 14.18

LRESIMS m/z Calcd. for $\text{C}_{52}\text{H}_{57}\text{NO}_{15}\text{S}$ $[\text{M}+\text{H}]^+$ 967, found 967

IR (cm^{-1}): 3449.31, 2930.08, 1733.76, 1663.85, 1372.03, 1273.56, 1241.51, 1108.57, 1070.60, 711.53

Example 37**2'-O-(triethylsilyl)-7-deoxy-6b-thioacetamidopaclitaxel (43)**

5 [0136]



[0137] Thiol **12** (0.8 g, 0.813 mmol) was dissolved in benzene (15 mL) and degassed under house vacuum for 20 minutes, then backfilled with nitrogen. Iodoacetamide (226 μ L, 1.219 mmol) and DBU (0.24 mL, 1.626 mmol) were then added and the reaction was stirred at room temperature for 35 minutes. The precipitated salts were filtered off on a short pass of silica gel and washed with 2:1 hexanes/ethyl acetate. The filtrate was stripped to a residue and chromatographed on silica gel (hexanes/ethyl acetate 1:1, 1:2, 1:3) to provide 0.720 g of the thioacetamide ether **43** as a white solid in 85 % yield.

¹H-NMR (CDCl₃, 300.133MHz) δ : 8.14 (d, 2H, J = 7.1), 7.73 (d, 2H, J = 7.1), 7.63-7.28 (m, 11H), 7.10 (d, 1H, J = 8.9), 6.78 (broad s, 1H), 6.44 (s, 1H), 6.23 (t, 1H, J = 8.7), 5.70 (t, 2H, J = 8.1), 5.43 (broad s, 1H), 4.92 (d, 1H, J = 6.6), 4.67 (d, 1H, J = 2.0), 4.34 (d, 1H, J = 8.0), 4.12 (d, 1H, J = 8.0), 3.72 (d, 1H, J = 6.8), 3.57-3.52 (m, 1H), 3.26-3.11 (m, 2H), 2.52-0.32 (m, 38H, include singlets at 2.52, 2.20, 1.88, 1.86, 1.20, 1.00, 3H each and triplet at 0.80, 9H)


¹³C-NMR (CDCl₃, 75.469 MHz) δ : 204.86, 171.52, 171.38, 170.08, 169.75, 167.09, 166.98, 141.06, 138.36, 134.07, 133.76, 133.19, 131.80, 130.23, 129.12, 128.82, 128.75, 128.71, 128.02, 127.05, 126.43, 84.54, 79.94, 78.84, 75.56, 75.46, 74.86, 73.98, 71.13, 55.66, 52.76, 43.60, 43.02, 41.58, 41.11, 35.87, 35.72, 26.07, 22.77, 21.77, 20.80, 16.61, 14.53, 6.52, 4.34

LRESIMS m/z Calcd. for C₅₅H₆₈N₂O₁₄SSi [M+H]⁺ 1040, found 1040

IR (cm⁻¹): 3442.50, 2956.22, 1734.02, 1717.28, 1667.60, 1486.49, 1371.71, 1272.58, 1241.77, 1112.59, 710.89

35 **Example 38****7-deoxy-6b-thioacetamidopaclitaxel (44)**

40 [0138]



50

[0139] The triethylsilyl ether **43** (0.70 g, 0.672 mmol) was dissolved in acetonitrile (112 mL), cooled to 0°C and treated with 1M HCl (1.3 mL, 1.344 mmol) for 30 minutes. The reaction mixture was diluted with EtOAc, washed with NaHCO₃, water and brine. The solution was dried over MgSO₄, filtered and concentrated. The residue was chromatographed over silica gel (hexanes/ethyl acetate 1:2, 1:3, 1:6). The pure fractions were combined together and stripped to a residue, dissolved in a minimal amount of methylene chloride and precipitated with hexane. This suspension was stripped to a solid residue under vacuum to provide the thioacetamide ether **44** (0.514 g) as a white solid in 83% yield.

¹H-NMR (CDCl₃, 300.133MHz) δ : 8.13 (d, 2H, J = 7.4), 7.74 (d, 2H, J = 7.2), 7.64-7.33 (m, 11H), 7.04 (d, 1H, J = 9.0),

6.73 (bs, 1H), 6.40 (s, 1H), 6.18 (t, 1H, J = 8.6), 5.79 (d, 1H, J = 9.0), 5.71 (d, 1H, J = 6.8), 5.45 (bs, 1H), 4.91(d, 1H, J = 6.0), 4.79 (d, 1H, J = 2.3), 4.33(d, 1H, J = 8.0), 4.12 (d, 1H, J = 8.0), 3.74 (d, 1H, J = 6.7), 3.57-3.48 (m, 2H), 3.26-3.10 (m, 2H), 2.47-1.12 (m, 23H, include. singlets at 2.38, 2.21, 1.86, 1.77, 1.21, 1.12, 3H each)

¹³C-NMR (CDCl₃, 75.469 MHz) δ: 204.82, 172.98, 171.88, 170.59, 170.05, 167.42, 167.18, 140.96, 138.32, 134.00, 133.96, 133.79, 132.15, 130.40, 129.19, 129.10, 128.97, 128.88, 128.45, 127.34, 127.28, 84.95, 80.17, 78.77, 75.83, 75.70, 74.35, 73.54, 72.23, 55.25, 52.96, 43.38, 43.26, 41.28, 40.67, 35.98, 35.55, 26.41, 22.65, 21.63, 21.03, 17.53, 14.81


LRESIMS m/z Calcd. for C₄₉H₅₄N₂O₁₄S [M-H]⁺ 926, found 926

IR (cm⁻¹): 3435.95, 2930.50, 1734.17, 1717.17, 1670.34, 1372.53, 1241.32, 1070.36, 711.33

Example 39

2'-tertbutyldimethylsilyl-6-β-methylthiomethylthio ether-7-deoxy paclitaxel(45).

[0140]




[0141] A solution of 2'-tert-butylidimethylsilyl-6-β-thio-7-deoxy-paclitaxel (12a) (311.0 mg, 0.357 mmoles) in anhydrous benzene (3.0 mL) was treated with DBU (300.0 μL, 2.00 mmoles), then with chloromethyl methyl sulfide (60.0 μL, 0.715 mmoles) and stirred at ambient temperature under for 60 mins. The reaction mixture was diluted with ethyl acetate and washed with water followed by brine. The solution was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. Purification by column chromatography on silica eluting with 75% hexanes/ethyl acetate to 50% hexanes/ethyl acetate afforded 178.0 mg (47.0%) of compound with formula 45 as a white, amorphous powder which exhibited the following physical properties: ¹H NMR (CDCl₃, 300 MHz) δ 8.15 (d, J = 7.8 Hz, 2H), 7.73 (d, J = 7.8 Hz, 2H), 7.72-7.26 (m, 11H), 7.09 (d, J = 8.9 Hz, 1H), 6.49 (s, 1H), 6.26 (t, J = 8.8 Hz, 1H), 5.77-5.73 (m, 2H), 4.99 (d, J = 6.8 Hz, 1H), 4.66 (d, J = 2.1 Hz, 1H), 4.35 (d, J = 8.1 Hz, 1H), 4.15-4.09 (m, 2H), 3.76 (d, J = 6.9 Hz, 1H), 3.66-3.55 (m, 2H), 2.58 (s, 3H), 2.54-2.36 (m, 2H), 2.21 (s, 3H), 2.13 (s, 3H), 1.91 (s, 3H), 1.90 (s, 3H), 1.21 (s, 3H), 1.12 (s, 3H), 0.80 (s, 9H), -0.04 (s, 3H), -0.30 (s, 3H).

Example 40

6-β-methylthiomethylthio ether-7-deoxy paclitaxel(46).

[0142]




[0143] A solution of compound 45 (202 mg, 0.193 mmoles) in anhydrous THF (4.0 mL) was cooled to -10°C under

nitrogen and treated with TBAF (1M in THF, 250 μ L, 0.250 mmoles). The mixture was removed from the cooling bath and stirred at ambient temperature for 5 mins. The mixture was diluted with ethyl acetate and washed with water, then and stirred at ambient temperature for 5 mins. The mixture was diluted with ethyl acetate and washed with water, then brine. The solution was dried over anhydrous Na_2SO_4 , and concentrated *in vacuo*. Chromatography on silica eluting with 75% hexanes/ethyl acetate to 50% hexanes/ethyl acetate afforded 132.0 mg (75.0%) of compound with formula 46 as a white, amorphous solid which exhibited the following physical properties: ^1H NMR (CDCl_3 , 300 MHz) δ 8.14 (d, J = 7.8 Hz, 2H), 7.74 (m, 2H), 7.65-7.26 (m, 11H), 7.08 (d, J = 9.0 Hz, 1H), 6.45 (s, 1H), 6.19 (t, J = 8.6 Hz, 1H), 5.80 (dd, J = 9.0 Hz, J = 3.0 Hz, 1H), 5.73 (d, J = 6.8 Hz, 1H), 4.96 (d, J = 6.0 Hz, 1H), 4.79 (d, J = 2.6 Hz, 1H), 4.34 (d, J = 8.1 Hz, 1H), 4.13 (d, J = 8.1 Hz, 1H), 3.83-3.75 (m, 2H), 3.65-3.55 (m, 2H), 2.43 (m, 1H), 2.39 (s, 3H), 2.32 (s, 1H), 2.29 (s, 1H), 2.22 (s, 3H), 2.13 (s, 3H), 1.89 (s, 3H), 1.88-1.78 (m, 3H), 1.78 (s, 3H), 1.21 (s, 3H), 1.13 (s, 3H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 205.35, 172.95, 170.93, 170.28, 167.58, 140.98, 138.63, 134.27, 134.21, 132.47, 130.72, 129.77, 129.48, 129.26, 129.21, 128.80, 127.65, 127.60, 100.68, 85.98, 80.85, 79.21, 76.13, 74.62, 73.89, 72.48, 55.53, 53.62, 44.12, 43.54, 41.37, 39.08, 38.00, 36.31, 26.76, 23.01, 21.86, 21.36, 17.44, 15.11, 14.92; LRMS (ESI): 930.4 (($M+1$) $^+$, 100%).

Example 41

2'-tertbutyldimethylsilyl-6- β -methylthiomethylether-7-deoxy paclitaxel (47).


[0144]



[0145] A solution of 2'-*tert*-butyldimethylsilyl-6- β -thio-7-deoxy-paclitaxel (12a) (440.0 mg, 0.447 mmoles) in anhydrous benzene (4.0 mL) was treated with DBU (270.0 μ L, 1.80 mmoles), then with bromomethyl methyl ether (75.0 μ L, 0.894 mmoles) and stirred at ambient temperature under for 10 mins. The reaction mixture was diluted with ethyl acetate and washed with water followed by brine. The solution was dried over anhydrous Na_2SO_4 , filtered and concentrated *in vacuo*. Purification by column chromatography on silica eluting with 75% hexanes/ethyl acetate to 50% hexanes/ethyl acetate afforded 450.0 mg (96.4%) of compound with formula 47 as a white, amorphous powder which exhibited the following physical properties: ^1H NMR (CDCl_3 , 300 MHz) δ 8.15 (d, J = 6.9 Hz, 2H), 7.45 (dd, J = 1.5 Hz, J = 6.9 Hz, 2H), 7.61-7.31 (m, 11H), 7.06 (d, J = 8.9 Hz, 1H), 6.48 (s, 1H), 6.26 (m, 1H), 5.75-5.72 (m, 2H), 4.99 (d, J = 7.0 Hz, 1H), 4.68-4.52 (m, 3H), 4.34 (d, J = 7.7 Hz, 1H), 4.13 (m, 2H), 3.74 (m, 2H), 3.32 (s, 3H), 2.57 (s, 3H), 2.56-2.36 (m, 2H), 2.21 (s, 3H), 2.18-2.08 (m, 1H), 2.04 (s, 3H), 1.90 (s, 3H), 1.22 (s, 3H), 1.13 (s, 3H), 0.79 (s, 9H).

Example 42**6-b-methylthiomethylether-7-deoxy paclitaxel (48).**


[0146]



[0147] A solution of compound with formula 47 (450 mg, 0.438 mmoles) in anhydrous THF (4.0 mL) was cooled to -10°C under nitrogen and treated with TBAF (1M in THF, 200 µL, 0.200 mmoles). The mixture was removed from the cooling bath and stirred at ambient temperature for 10 mins. The reaction was judged to be incomplete by TLC analysis, so additional TBAF (100 µL, 0.100 mmoles) was added and the reaction was stirred at ambient temperature for another 10 mins. The mixture was diluted with ethyl acetate and washed with saturated NaHCO₃ solution, water, then brine. The solution was dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. Chromatography on silica eluting with 75% hexanes/ethyl acetate to 50% hexanes/ethyl acetate afforded 200.2 mg (50.0%) of compound with formula 48 as a white, amorphous solid which exhibited the following physical properties: ¹H NMR (CDCl₃, 300 MHz) δ 8.13 (d, J = 7.7 Hz, 2H), 7.75-7.72 (m, 2H), 7.64-7.26 (m, 11H), 7.12 (d, J = 9.0 Hz, 1H), 6.43 (s, 1H), 6.17 (t, J = 8.1 Hz, 1H), 5.79 (dd, J = 9.0 Hz, J = 2.5 Hz, 1H), 5.72 (d, J = 6.9 Hz, 1H), 4.96 (d, J = 6.2 Hz, 1H), 4.78 (dd, J = 5.0 Hz, J = 2.6 Hz, 1H), 4.64 (d, J = 11.7 Hz, 1H), 4.53 (d, J = 11.8 Hz, 1H), 4.31 (d, J = 8.0 Hz, 1H), 4.10 (d, J = 8.0 Hz, 1H), 3.78 (d, J = 5.0 Hz, 1H), 3.73 (d, J = 6.7 Hz, 1H), 3.70-3.63 (m, 1H), 3.30 (s, 3H), 2.45 (m, 1H), 2.37 (s, 3H), 2.31 (s, 1H), 2.28 (s, 1H), 2.21 (s, 3H), 1.99 (s, 1H), 1.92-1.84 (m, 2H), 1.88 (s, 3H), 1.76 (s, 3H), 1.19 (s, 3H), 1.13 (s, 3H); ¹³C NMR (CDCl₃, 75 MHz) δ 205.30, 172.97, 170.93, 170.23, 167.58, 140.85, 138.63, 134.24, 132.49, 130.72, 129.79, 129.50, 129.23, 128.81, 127.61, 86.03, 80.82, 79.20, 76.09, 75.98, 75.52, 74.55, 73.85, 72.56, 56.36, 55.50, 54.02, 53.65, 44.15, 43.54, 41.96, 39.54, 36.30, 26.74, 23.00, 21.84, 21.35, 17.26, 15.06; LRMS (ESI): 914.4 ((M+1)⁺, 100%).


Example 43**2'-O-(triethylsilyl)-6b-thioethenyl-7-deoxypaclitaxel (49) and 6b-thioethenyl-7-deoxypaclitaxel (50)**

[0148]



[0149] Thiol 12 (0.90 g, 0.912 mmol) was dissolved in toluene (27 mL) and degassed under house vacuum for 20 minutes, then backfilled with nitrogen. Vinyl sulfoxide (0.128 mL, 0.957 mmol) and DBU (0.20 mL, 1.368 mmol) were then added and the reaction was stirred at room temperature for 3 hours. The reaction mixture was then placed in an oil bath and reflux for 5 hours and 30 minutes. The reaction mixture was then cooled and diluted with EtOAc, washed with NaHCO₃, water and brine. The solution was dried over MgSO₄, filtered and concentrated. The residue was chro-

matographed on silica gel (hexanes/ethyl acetate 3:1, 2:1) to provide 0.43 g of the impure vinyl sulfide **49** in 47% yield which was used directly for the next step reaction.



LRESIMS *m/z* Calcd. for C₅₅H₆₇NO₁₃Si [M+H]⁺ 1009, found 1009

[0150] The triethylsilyl ether **49** (0.43 g, 0.426 mmol) was dissolved in acetonitrile (16 mL), cooled to 0°C and treated with 1M HCl (0.85 mL, 0.851 mmol) for 1 hour and 20 minutes. The reaction mixture was diluted with EtOAc, washed with NaHCO₃, water and brine. The solution was dried over MgSO₄, filtered and concentrated. The residue was chromatographed over silica gel (hexanes/ ethyl acetate 2:1, 1.5:1) to provide the vinylsulfide **50** (0.265g/ 70%) as a white solid. Also recovered were some mixed fractions (44 mg, 12%) and a slower eluting compound (32 mg, 8%).

¹H-NMR (CDCl₃, 300.133MHz) δ: 8.12 (d, 2H, J = 7.0), 7.74 (d, 2H, J = 7.0), 7.64-7.30 (m, 11H), 7.04 (d, 1H, J = 9.0), 6.43 (s, 1H), 6.32-6.23 (m, 1H), 6.18 (t, 1H, J = 8.1), 5.79 (dd, 1H, J = 2.4, 9.0), 5.73 (d, 1H, J = 6.7), 5.29-5.17 (m, 2H), 4.98(d, 1H, J = 5.8), 4.79-4.77 (m, 1H), 4.32 (d, 1H, J = 8.0), 4.12 (d, 1H, J = 7.9), 3.78-3.71 (m, 2H), 3.64 (d, 1H, J = 4.8), 2.42-1.13 (m, 23H, include, singlets at 2.38, 2.21, 1.89, 1.75, 1.20, 1.13, 3H each)

¹³C-NMR (CDCl₃, 75.469 MHz) δ: 204.48, 172.46, 170.60, 169.76, 167.16, 167.01, 140.41, 138.12, 133.94, 133.86, 133.75, 132.06, 130.51, 130.26, 129.23, 129.08, 128.80, 128.42, 127.14, 127.13, 114.25, 85.26, 80.31, 78.74, 75.80, 75.63, 74.02, 73.40, 72.13, 54.98, 53.06, 43.20, 43.11, 40.29, 40.16, 35.82, 34.48, 32.00, 29.79, 26.31, 22.57, 22.22, 21.37, 20.88, 17.48, 14.67


LRESIMS *m/z* Calcd. for C₄₉H₅₃N₀O₁₃S [M+H]⁺ 895, found 895

IR (cm⁻¹): 3432.06, 2932.39, 1732.82, 1717.31, 1663.32, 1372.00, 1271.17, 1240.10, 1107.20, 1069.66, 1025.06, 968.22, 710.50

Example 44

2'-O-(triethylsilyl)-6b-thiophenyl-7-deoxy-paclitaxel (**51**).

[0151]




[0152] A solution of 2'-triethylsilyl-6-α-trifluoromethanesulfonyl-7-deoxy-paclitaxel (**7**) (261.1 mg, 0.237 mmoles) in anhydrous benzene (4.4 mL) was treated with thiophenol (73.0 μL, 0.711 mmoles) and DBU (142.0 μL, 0.949 mmoles) and stirred for 40 mins, at ambient temperature under nitrogen. The solution was transferred to a silica column packed with hexanes and eluted with 70% hexanes/ethyl acetate to give 210.6 mg (83.8%) of compound with formula **51** as a white, amorphous powder which exhibited the following physical properties: ¹H NMR (CDCl₃, 300 MHz) δ 8.14 (d, J = 7.1 Hz, 2H), 7.72 (d, J = 7.1 Hz, 2H), 7.63-7.18 (bm, 16H), 7.10 (d, J = 8.8 Hz, 1H), 6.45 (s, 1H), 6.22 (m, 1H), 5.74 (d, J = 6.9 Hz, 1H), 5.68 (d, J = 8.9 Hz, 1H), 5.00 (d, J = 6.8 Hz, 1H), 4.67 (d, J = 2.0 Hz, 1H), 4.34 (d, J = 7.9 Hz, 1H), 4.14 (d, J = 8.1 Hz, 1H), 3.94 (m, 1H), 3.73 (d, J = 6.9 Hz, 1H), 2.51 (s, 3H), 2.47-2.34 (m, 2H), 2.20 (s, 3H), 2.17 (m, 1H), 1.97-1.92 (m, 1H), 1.95 (s, 3H), 1.88 (s, 3H), 1.20 (s, 3H), 1.13 (s, 3H), 0.81 (t, J = 7.87 Hz, 9H), 0.53-0.32 (bm,

6H); LRMS (ESI): 1060 ((M+1)⁺, 10%).

Example 45

6b-thiophenyl-7-deoxy-paclitaxel (52).

[0153]




[0154] A solution of compound with formula 51 (206 mg, 0.195 mmoles) in acetonitrile (5.0 mL) was cooled to 0°C under nitrogen and treated with 1N HCl (0.40 mL, 0.389 mmoles). After stirring at ambient temperature for 1.25 hrs., the mixture was concentrated *in vacuo*. Chromatography on silica eluting with 50% hexanes/ethyl acetate afforded 151.8 mg (82.3%) of compound with formula 52 as a white, amorphous solid which exhibited the following physical properties: ¹H NMR (CDCl₃, 300 MHz) δ 8.12 (d, J = 7.3 Hz, 2H), 7.72 (d, J = 7.2 Hz, 2H), 7.61-7.18 (bm, 16H), 7.04 (d, J = 9.0 Hz, 1H), 6.41 (s, 1H), 6.17 (m, 1H), 5.78-5.72 (m, 2H), 4.95 (d, J = 6.3 Hz, 1H), 4.76 (dd, J = 2.6 Hz, J = 5.0 Hz, 1H), 4.32 (d, J = 8.0 Hz, 1H), 4.12 (d, J = 8.0 Hz, 1H), 3.92 (ddd, J = 4.5 Hz, J = 5.4 Hz, J = 9.8 Hz, 1H), 3.73 (d, J = 6.5 Hz, 1H), 3.66 (d, J = 5.0 Hz, 1H), 2.41 (m, 1H), 2.35 (s, 3H), 2.30 (s, 1H), 2.28 (s, 1H), 2.20 (s, 3H), 1.98 (s, 1H), 1.88 (m, 1H), 1.75 (s, 3H), 1.69 (s, 3H), 1.19 (s, 3H), 1.13 (s, 3H); ¹³C NMR (CDCl₃, 75 MHz) δ 204.64, 172.52, 170.48, 169.67, 167.15, 167.06, 140.24, 138.07, 134.62, 133.85, 133.80, 133.70, 132.04, 131.57, 130.24, 129.25, 129.18, 129.06, 128.77, 128.39, 127.26, 127.11, 84.74, 80.38, 78.72, 77.29, 75.60, 73.98, 73.33, 72.17, 60.47, 54.99, 53.20, 43.59, 43.55, 43.06, 40.70, 35.79, 26.26, 22.52, 21.35, 21.11, 20.86, 17.05, 14.57, 14.26; LRMS (ESI): 944.8 ((M-1)⁻, 10%).

Example 46

2'-O-(tertbutyldimethylsilyl)-6-b-thio-(2-thienyl)-7-deoxypaclitaxel(53).

[0155]




[0156] A solution of 2'-*tert*-butyldimethylsilyl-6- α -trifluoromethanesulfonyl-7-deoxy-paclitaxel (7a) (500.0 mg, 0.454 mmoles) in anhydrous benzene (15.0 mL) was treated with thiophenethiol (50.0 μ L, 0.500 mmoles) and DBU (85.0 μ L, 0.540 mmoles) and stirred for 50 mins. at ambient temperature under nitrogen. The solution was concentrated *in vacuo* and subjected to column chromatography on silica eluting with 70% hexanes/ethyl acetate to give 476.4 mg (98.4%) of compound with formula 53 as a white, amorphous powder which exhibited the following physical properties: ¹H NMR (CDCl₃, 300 MHz) δ 8.12 (d, J = 7.2 Hz, 2H), 7.69 (d, J = 7.2 Hz, 2H), 7.58-7.28 (bm, 12H), 7.13 (d, J = 2.4 Hz, 1H), 7.03 (d, J = 9.0 Hz, 1H), 6.93 (dd, J = 3.4 Hz, J = 5.4 Hz, 1H), 6.43 (s, 1H), 6.21 (m, 1H), 5.71 (m, 2H), 4.99 (d, J = 7.1

Hz, 1H), 4.62 (d, J = 2.1 Hz, 1H), 4.34 (d, J = 8.1 Hz, 1H), 4.12 (d, J = 8.1 Hz, 1H), 3.74-3.67 (m, 2H), 2.52 (s, 3H), 2.41-2.31 (m, 2H), 2.18 (s, 3H), 2.13-2.05 (m, 2H), 2.01 (s, 1H), 1.93 (s, 3H), 1.84 (s, 3H), 1.17 (s, 3H), 1.09 (s, 3H), 0.76 (s, 9H), -0.076 (s, 3H), -0.33 (s, 3H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 205.10, 171.52, 170.35, 169.84, 167.36, 167.16, 140.87, 138.49, 135.63, 134.30, 133.90, 133.56, 132.95, 132.03, 130.66, 130.46, 129.45, 129.00, 128.97, 128.20, 127.95, 127.22, 126.64, 84.51, 80.60, 79.11, 77.46, 75.86, 75.80, 75.44, 74.02, 71.39, 60.62, 55.85, 53.39, 48.02, 44.20, 43.25, 40.84, 36.09, 26.28, 25.74, 23.04, 21.97, 21.27, 21.03, 19.45, 18.37, 16.53, 14.73, 14.43; LRMS (ESI): 1067.5 ((M+1)⁺, 100%), 400.3 (60%).

Example 47**6-b-thio-(2-thienyl)-7-deoxypaclitaxel (54)**


[0157]



[0158] A solution of compound **53** (456.4 mg, 0.428 mmoles) in THF (21.4 mL) was cooled to -10°C under nitrogen and treated with TBAF (1M in THF, 0.40 mL, 0.40 mmoles). After stirring in the cold for 10 mins., the mixture was diluted with ethyl acetate (100 mL) and washed with brine (20 mL). The solution was dried over anhydrous Na_2SO_4 , and concentrated *in vacuo*. Chromatography on silica eluting with 60% hexanes/ethyl acetate afforded 381 mg (93.5%) of compound with formula **54** as a white, amorphous solid which exhibited the following physical properties: ^1H NMR (CDCl_3 , 300 MHz) δ 8.05 (d, J = 7.1 Hz, 2H), 7.65 (d, J = 7.1 Hz, 2H), 7.55-7.26 (bm, 12H), 7.07 (dd, J = 1.2 Hz, J = 3.5 Hz, 1H), 6.96 (d, J = 8.9 Hz, 1H), 6.88 (dd, J = 3.6 Hz, J = 5.3 Hz, 1H), 6.34 (s, 1H), 6.10 (t, J = 8.1 Hz, 1H), 5.70 (dd, J = 2.4 Hz, J = 9.0 Hz, 1H), 5.65 (d, J = 6.9 Hz, 1H), 4.90 (d, J = 6.7 Hz, 1H), 4.69 (dd, J = 2.6 Hz, J = 5.0 Hz, 1H), 4.27 (d, J = 8.1 Hz, 1H), 4.05 (d, J = 8.0 Hz, 1H), 3.67-3.57 (bm, 2H), 2.28 (s, 3H), 2.24 (s, 1H), 2.21 (s, 1H), 2.14 (s, 3H), 1.97 (s, 1H), 1.84 (s, 3H), 1.63 (s, 3H), 1.12 (s, 3H), 1.06 (s, 3H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 204.66, 172.57, 170.43, 169.67, 167.11, 140.24, 138.10, 135.52, 133.81, 133.75, 132.53, 132.06, 130.57, 130.27, 129.31, 129.08, 128.80, 128.41, 127.80, 127.12, 84.48, 80.46, 78.76, 77.31, 75.73, 75.60, 73.96, 73.33, 72.21, 64.46, 55.01, 53.27, 55.01, 53.27, 47.56, 43.89, 43.07, 40.28, 35.83, 26.27, 22.51, 21.37, 21.09, 20.89, 19.21, 16.72, 14.54; LRMS (ESI): 952.4 ((M+1)⁺, 100%).

Example 48**2'-O-(tertbutyldimethylsilyl)-6-b-(2-thioacetic acid)-7-deoxy-paclitaxel (55)**

[0159]



[0160] A solution of compound **42** (121.5 mg, 0.126 mmoles) in DCM (2.0 mL) was treated with palladium acetate (3.3 mg, 0.015 mmoles), triphenylphosphine (23 mg, 0.700 mmoles) and 2-ethyl hexanoic acid (0.5 M solution in ethyl acetate, 0.38 mL, 0.188 mmoles). The mixture was stirred at ambient temperature for 23 hrs., then diluted with DCM (20 mL) and washed with 1 N HCl, water, then brine (5.0 mL each). The solution was dried over anhydrous Na₂SO₄, and concentrated *in vacuo*.

Chromatography on silica eluting with 50% hexanes/ethyl acetate plus 1% formic acid afforded 114.8 mg (98.2%) of compound with formula **55** as a white, amorphous solid which exhibited the following physical properties: ¹H NMR (CDCl₃, 300 MHz) δ 8.06 (d, J = 7.1 Hz, 2H), 7.67 (d, J = 7.0 Hz, 2H), 7.59-7.21 m, 12H), 6.35 (s, 1H), 6.08 (t, J = 8.9 Hz, 2H), 5.70-5.65 (m, 2H), 4.93 (d, J = 6.0 Hz, 1H), 4.71 (m, 1H), 4.24 (d, J = 8.0 Hz, 1H), 4.08-3.96 (m, 2H), 3.64 (m, 2H), 3.15-3.03 (dd, J = 14.7 Hz, J = 21.5 Hz, 2H), 2.50 (bs, 1H), 2.36-2.20 (m, 3H), 2.29 (s, 3H), 2.15 (s, 3H), 1.97 (s, 1H), 1.81 (s, 3H), 1.77-1.75 (m, 1H), 1.73 (s, 3H), 1.13 (s, 3H), 1.06 (s, 3H); ¹³C NMR (CDCl₃, 75 MHz) δ 205.02, 172.88, 172.48, 170.62, 170.45, 167.95, 166.98, 151.85, 140.77, 138.24, 133.86, 133.81, 132.35, 132.24, 130.35, 129.63, 129.15, 128.93, 128.85, 128.75, 128.44, 128.16, 127.29, 127.19, 85.50, 80.50, 78.27, 75.88, 75.76, 74.53, 73.28, 72.25, 55.30, 55.21, 53.15, 43.29, 40.90, 40.79, 35.87, 35.58, 26.33, 22.60, 21.69, 21.24, 21.05, 17.20, 14.66; LRMS (ESI): 928.5 ((M+1)⁺, 100%).

[0161] The compounds of this invention exhibit antitumor activities in *in vivo* and/or *in vitro* models. For example, the following test describes the *in vitro* test used to evaluate some representative compounds of this invention.

Cytotoxicity

[0162] The epoxide taxane derivatives possessed cytotoxicity *in vitro* against human colon carcinoma cells HCT-116. Cytotoxicity was assessed in HCT-116 human colon carcinoma cells by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphenyl)-2H-tetrazolium, inner salt) assay as reported in T.L. Riss, et. al., "Comparison of MTT, XTT, and a novel tetrazolium compound MTS for *in vitro* proliferation and chemosensitivity assays," *Mol. Biol. Cell* 3 (Suppl.):184a, 1992. Cells were plated at 4,000 cell/well in 96 well microtiter plates and 24 hours later drugs were added and serially diluted. The cells were incubated at 37° for 72 hours at which time the tetrazolium dye, MTS at 333 µg/ml (final concentration), in combination with the electron coupling agent phenazine methosulfate at 25 µM (final concentration) was added. A dehydrogenase enzyme in live cells reduces the MTS to a form that absorbs light at 492nm which can be quantitated spectrophotometrically. The greater the absorbance the greater the number of live cells. The results are expressed as an IC₅₀, which is the drug concentration required to inhibit cell proliferation (i.e. absorbance at 450nm) to 50% of that of untreated control cells. The IC₅₀ values for compounds evaluated in this assay are evaluated in Table I.

Table I.

Compound	Cytotoxicity Assay IC ₅₀ (nM) against HCT 116 Human colon tumor cell line ¹
9	1.1
11	1.84
13	26.12
15	1.80
17	3.80
19	50.9
19a	>111
21	>109
24	0.2
26	0.66
28	0.7
30	0.9
32	5.27
34	1.2

¹Cytotoxicity was determined after a 72 h exposure by MTS assay.

Table I. (continued)

Compound	Cytotoxicity Assay IC ₅₀ (nM) against HCT 116 Human colon tumor cell line ¹
36	4.4
38	28.0
40	2.5
42	9.0
44	11.0
46	3.5
48	1.9
50	0.3
52	0.58
54	1.1
55	>107.8

¹Cytotoxicity was determined after a 72 h exposure by MTS assay.

[0163] The following results describes the in vivo tests used to evaluate representative compounds of this invention.

Mice M109 Model (In-Vivo)

[0164] Balb/c x DBA/2 F₁ hybrid mice were implanted intraperitoneally, as described by William Rose in *Evaluation of Madison 109 Lung Carcinoma as a Model for Screening Antitumor Drugs*, Cancer Treatment Reports, 65, No. 3-4 (1981), with 0.5 mL of a 2% (w/v) brei of M109 lung carcinoma.

[0165] Mice were treated with compounds under study by receiving intraperitoneal injections of various doses on days 5 and 8 post-implant. Mice were followed daily for survival until approximately 75 days post-tumor implant. One group of mice per experiment remained untreated and served as the control group.

[0166] Median survival times of compound-treated (T) mice were compared to the median survival time of the control (C) mice. The ratio of the two values for each compound-treated group of mice was multiplied by 100 and expressed as a percentage (i.e. % T/C) in the following Table II for representative compounds.

Paclitaxel & Derivatives vs ip M109-Table II		
Compd	O.D. ^a m/kg/i	Deriv. Maximum % T/C
17	50	194
19	200	169
21	200	147
34	25	168
40	60	103
42	50	106
52	16	114
54	25	148
55	80	107

^a Optimal dose (mg/kg/inj) if active, otherwise, maximal tolerated dose (MTD) or highest dose tested.

M5076: Taxane derivatives were tested in the M5076 murine sarcoma model using the general materials and methods described by Rose, W.C. in *Anticancer Research* 6: 557-562, 1986, for subcutaneous M5076 implants, with the following modifications: treatments were administered intravenously on Days 1, 3, 5, 7, and 9 post-tumor implant using eight mice per treatment and untreated control group. Activity was determined based on an increase in lifespan (as described in the preceding reference) of $\geq 135\%$, and, in particular, on a delay in tumor growth equivalent to at least 1 gross log cell kill (LCK). The latter was calculated as described in Rose, W.C. and Basler, G.A. in *In Vivo* 4: 391-396, 1990. The results are provided in Table III.

Paclitaxel & Derivatives vs Sc M5076-Table III		
Compd	O.D. ^a m/kg/i	Deriv. Maximum T-C in LCK
9	50	1.1
11	36	0.5
13	40	0.5
15	48	0.3
17	35	0.7
19	75	0.4
21	65	0
24	13	1.2
28	50	1.1
30	20	0.4
36	50	1.1
38	70	0
44	20	0
46	60	0
48	25	0.2
50	30	1.0

^a Optimal dose (mg/kg/inj) if active, otherwise, maximal tolerated dose (MTD) or highest dose tested.

[0167] Thus, another aspect of the instant invention concerns a method for inhibiting human and/or other mammalian tumors which comprises administering to a tumor bearing host an antitumor effective amount of a compound of formula I.

[0168] For treating a variety of tumors, the compound of formula I of the present invention may be used in a manner similar to that of paclitaxel, e.g. see Physician's Desk Reference, 49th Edition, Medical Economics, p 682, 1995. The dosage, mode and schedule of administration for the compound of this invention are not particularly restricted; an oncologist skilled in the art of cancer treatment will be able to ascertain, without undue experimentation, an appropriate treatment protocol for administering the compound of the present invention. Thus the compound of formula I may be administered via any suitable route of administration, parenterally or orally. Parenteral administration includes intravenous, intraperitoneal, intramuscular, and subcutaneous administration.

[0169] The doses utilized to implement the methods in accordance with the invention are the ones that make it possible to administer prophylactic treatment or to evoke a maximal therapeutic response. The doses vary, depending on the type of administration, the particular product selected, and the personal characteristics of the subject to be treated. In general, the doses are the ones that are therapeutically effective for the treatment of disorders caused by abnormal cell proliferation. The products in accordance with the invention can be administered as often as necessary in order to obtain the desired therapeutic effect. Some patients may respond rapidly to relatively high or low doses, and then require mild maintenance or no maintenance dose at all. Via the iv route, the dosage may be, for example, in the range of about 20 to about 500 mg/m² over 1 to 100 hours. Via the oral route, the dosage may be in the range of 5-1000mg/kg/day of body weight. The actual dose used will vary according to the particular composition formulated, the route of administration, and the particular site, host and type of tumor being treated. Many factors that modify the action of the drug will be taken into account in determining the dosage including age, weight, sex, diet and the physical condition of the patient.


[0170] The present invention also provides pharmaceutical formulations (compositions) containing an antitumor effective amount of compound of formula I in combination with one or more pharmaceutically acceptable carriers, excipients, diluents or adjuvants. The compositions can be prepared in accordance with conventional methods. Examples of formulating paclitaxel or derivatives thereof may be found in, for example, United States Patents Nos. 4,960,790 and 4,814,470, and such examples may be followed to formulate the compound of this invention. For example, compound of formula I may be formulated in the form of tablets, pills, powder mixtures, capsules, injectables, solutions, suppositories, emulsions, dispersions, food premix, and in other suitable forms. It may also be manufactured in the form of sterile solid compositions, for example, freeze dried and, if desired, combined with other pharmaceutically acceptable excipients. Such solid compositions can be reconstituted with sterile water, physiological saline, or a mixture of water and an organic solvent, such as propylene glycol, ethanol, and the like, or some other sterile injectable medium

immediately before use for parenteral administration.

[0171] Typical of pharmaceutically acceptable carriers are, for example, mannitol, urea, dextrans, lactose, potato and maize starches, magnesium stearate, talc, vegetable oils, polyalkylene glycols, ethyl cellulose, poly(vinylpyrrolidone), calcium carbonate, ethyl oleate, isopropyl myristate, benzyl benzoate, sodium carbonate, gelatin, potassium carbonate, silicic acid. The pharmaceutical preparation may also contain nontoxic auxiliary substances such as emulsifying, preserving, wetting agents, and the like as for example, sorbitan monolaurate, triethanolamine oleate, polyoxyethylene monostearate, glyceryl tripalmitate, dioctyl sodium sulfosuccinate, and the like.

Claims

1. A compound of formula I, or a pharmaceutically acceptable salt thereof



X⁻ is halide;

base is NH₃, (HOC₂H₄)₃N, N(CH₃)₃, CH₃N(C₂H₄)₂NH, NH₂(CH₂)₆NH₂, N-methylglucamine, NaOH or KOH;

R^F and R^G are independently -H or -C₁-C₃ alkyl, or R^F and R^G taken together with the nitrogen of NR^FR^G form a pyrrolidino, piperidino, morpholino or N-methylpiperizino groups;

Rⁿ is -H, -CH₃, -CH₂CH(CH₃)₂, -CH(CH₃)CH₂CH₃, -CH(CH₃)₂, -CH₂phenyl, -(CH₂)₃NH₂, -(CH₂)₄NH₂, -CH₂CH₂COOH, -(CH₂)₃NHC(=NH)NH₂, the residue of the amino acid proline, -OC(O)CH=CH₂, -C(O)CH₂CH₂C(O)NHCH₂CH₂SO₃-Y⁺ or -OC(O)CH₂CH₂C(O)NHCH₂CH₂CH₂SO₃-Y⁺;

Y⁺ is Na⁺ or N⁺(Bu)₄;

R² is phenyl or substituted phenyl;

R⁴ is C₁₋₄ alkyl, C₃₋₅ cycloalkyl or -O-(C₁-C₄ alkyl);

L is O or S;

R⁶ and R^{6'} are independently hydrogen, -SH, -S-[C₁₋₆ alkyl(OH)_m], -S-ethenyl, -S-substituted ethenyl, -S(O)_nCH₂CN, -S(O)_nCH₂C(O)Q, -SCH₂ halogen, -SC(O)-[C₁₋₆ alkyl(OH)_m], -SC(O)O(C₁-C₆ alkyl), -SC(O)N(W)₂, -SC(S)-(C₁-C₆ alkyl), -SC(S)O(C₁-C₆ alkyl), -SC(S)N(W)₂, -S(O)_n-[C₁₋₆ alkyl(OH)_m], -S(C₁-C₆ alkyl)₂⁺X⁻, -S(O)₂OH, -S(O)₂NH[C₁₋₆ alkyl(OH)_m], -S(O)₂N[C₁₋₆ alkyl(OH)_m]₂, -S-S-[C₁₋₆ alkyl(OH)_m], -S-S-substituted phenyl, -S(O)-CN, -S(O)₂-CN, -SCH₂O[C₁₋₆ alkyl(OH)_m], -SCH(C₁-C₆ alkyl)O[C₁₋₆ alkyl(OH)_m], -SCH₂OCH₂OCH₃, -SCH₂S[C₁₋₆ alkyl(OH)_m], -SCH₂S(O)[C₁₋₆ alkyl(OH)_m], -SCH₂S(O)₂[C₁₋₆ alkyl(OH)_m], -S-heteroaryl or -SCN; with the proviso that R⁶ and R^{6'} are not both hydrogen;

m is 0, 1, 2 or 3;

n is 0, 1, or 2;

S-substituted ethenyl is -S-C(R^H)=C(R^J)(R^K), wherein two of R^H, R^J and R^K are each H and the other of R^H, R^J and R^K is C₁₋₃ alkyl, CN, COOC₁₋₃ alkyl, S(O)₂CH₃ or C(O)CH₃;

W is H or C₁₋₆ alkyl;

Q is -[C₁₋₆ alkyl(OH)_m], -O(C₁₋₆ alkyl), -OCH₂CCl₃, -N(W)₂ or -C(O)OH;

R⁷ is hydrogen, hydroxy or when taken together with R¹⁹ forms a cyclopropane ring;

R⁹ and R^{9'} are independently hydrogen or hydroxy or R⁹ and R^{9'} together form an oxo (keto) group;

R¹⁰ is hydrogen, hydroxy or -OC(O)-(C₁-C₆ alkyl);

R¹⁴ is hydrogen or hydroxy; and

R¹⁹ is methyl or when taken together with R⁷ forms a cyclopropane ring.

2. A compound of claim 1 or a pharmaceutically acceptable salt thereof wherein:

R is phenyl, p-fluorophenyl, p-chlorophenyl, p-hydroxyphenyl, p-tolyl, isopropyl, isopropenyl, isobutenyl, isobutyl, cyclopropyl, furyl, or thienyl;

R² is phenyl;

L is O;

R^{6'} is hydrogen;

R⁶ is -SH, -S-[C₁₋₆ alkyl(OH)_m], -S-ethenyl, -S-substituted ethenyl, -S(O)_nCH₂CN, -S(O)_nCH₂C(O)Q, -SCH₂ halogen, -SC(O)-[C₁₋₆ alkyl(OH)_m], -SC(O)O(C₁₋₆ alkyl), -SC(O)N(W)₂, -SC(S)-(C₁₋₆ alkyl), -SC(S)O (C₁₋₆ alkyl), -SC(S)N(W)₂, -S(O)_n-[C₁₋₆ alkyl(OH)_m], -S(C₁₋₆ alkyl)₂⁺ X⁻, -S(O)₂OH, -S(O)₂NH[C₁₋₆ alkyl (OH)_m], -S(O)₂N[C₁₋₆ alkyl(OH)_m]₂, -S-S-[C₁₋₆ alkyl(OH)_m], -S-S-substituted phenyl, -S(O)-CN, -S(O)₂-CN, -SCH₂O[C₁₋₆ alkyl(OH)_m], -SCH(C₁₋₆ alkyl)O[C₁₋₆ alkyl(OH)_m], -SCH₂OCH₂OCH₃, -SCH₂S[C₁₋₆ alkyl (OH)_m], -SCH₂S(O) [C₁₋₆ alkyl(OH)_m], -SCH₂S(O)₂[C₁₋₆ alkyl(OH)_m], -S-heteroaryl or -SCN;

R⁹ and R^{9'} together form an oxo (keto) group;

R¹⁰ is hydroxy or -OC(O)CH₃; and

R¹⁴ is hydrogen.

3. A compound of claim 2 or pharmaceutically acceptable salts thereof wherein:

R⁶ is -SH, -S-[C₁₋₆ alkyl(OH)_m], -S(O)_n-[C₁₋₆ alkyl(OH)_m], -S-ethenyl, -S-substituted ethenyl, -SCH₂CN, -S(O) CH₂CN, -SCH₂C(O)Q, -SC(O)-[C₁₋₆ alkyl(OH)_m], -SCH₂O[C₁₋₆ alkyl(OH)_m], -SCH(C₁₋₆ alkyl)O [C₁₋₆ alkyl (OH)_m], -SCH₂OCH₂OCH₃, -SCH₂S[C₁₋₆ alkyl(OH)_m], -SCH₂S(O)[C₁₋₆ alkyl(OH)_m], -SCH₂S(O)₂[C₁₋₆ alkyl (OH)_m], or -SCN.

4. A compound of claim 3 or pharmaceutically acceptable salts thereof wherein:

R^B is -NHC(O)-Ph or -NHC(O)O-(C₁₋₆ alkyl);

R^D is hydroxy;

R⁴ is methyl;

R⁶ is -S-[C₁₋₆ alkyl(OH)_m], -S-ethenyl, -S-substituted ethenyl, -SCH₂CN, -S(O)CH₂CN, -SCH₂C(O)Q, -S(O) (C₁₋₆ alkyl), -SC(O)-[C₁₋₆ alkyl(OH)_m], -SCH₂OCH₃, -SCH₂OCH₂OCH₃, -SCH₂S(C₁₋₆ alkyl), -SCH₂S(O)(C₁₋₆ alkyl), or -SCN; and

R⁷ is hydrogen or when taken together with R¹⁹ forms a cyclopropane ring.

5. A compound of claim 4 or pharmaceutically acceptable salts thereof wherein:

R⁷ is hydrogen; and

R¹⁹ is methyl.

6. A compound of claim 5 or pharmaceutically acceptable salts thereof wherein:

R is phenyl;

R⁶ is -S-methyl, -S-ethyl, -S-ethenyl, -SCH₂CN, -S(O)CH₂CN, -SCH₂C(O)-(C₁₋₆ alkyl), -S(O)-(C₁₋₆ alkyl), -SC (O)-[C₁₋₆ alkyl(OH)_m], -SCH₂OCH₃, -SCH₂OCH₂OCH₃, -SCH₂SCH₃, -SCH₂S(O)(CH₃), or -SCN; and

R¹⁰ is -OC(O)CH₃.

7. A compound of claim 1, wherein:

R is phenyl or substituted phenyl;

R^B is -NHC(O)Ph or -NHC(O)O(C₁₋₆ alkyl);

R^D is hydroxy;

R^2 is phenyl;

R^4 is methyl;

L is O;

R^6 is hydrogen;

R^6 is -SH, -S(C₁₋₃ alkyl), -SCN, -S-ethenyl, -SCH₂CN, -SCH₂CH₂OH, -SCH₂(O)-[C₁₋₆ alkyl (OH)_m] or -S-(2-thienyl);

R^7 is hydrogen;

R^9 and R^9 together form an oxo (keto) group;

R^{10} is -OC(O)CH₃ or OH;

R^{14} is hydrogen; and

R^{19} is methyl.

8. A compound of claim 7 wherein:

R is phenyl, p-chlorophenyl, p-methylphenyl, p-fluorophenyl or p-hydroxyphenyl.


9. A pharmaceutical formulation which comprises an antitumor effective amount of a compound of formula I as claimed in any one of claims 1-8.

10. A compound of formula I as claimed in any of claims 1-8 for use as a medicament.

11. Use of a compound of formula I as claimed in any one of claims 1-8 for manufacturing a medicament for inhibiting tumor growth in a mammalian host.

Patentansprüche

1. Verbindung der Formel I oder ein pharmazeutisch verträgliches Salz davon



in der:

R ein Aryl-, substituierter Aryl-, C₁₋₆-Alkyl-, C₂₋₆-Alkenyl-, C₃₋₆-Cycloalkyl- oder Heteroarylrest ist;
 R^B ein —NHC(O)-Arylrest, -NHC(O)-substituierter Arylrest, -NHC(O)-Heteroarylrest, -NHC(O)OCH₂Ph, -NHC

(O)O(C₁₋₆-Alkylrest) oder —NHC(O)O-(C₃₋₆-Cycloalkylrest) ist;

R^D eine Hydroxylgruppe, -OC(O)R^X, -OC(O)OR^X, OP(O)(OH)₂, OCH₂OP(O)(OH)₂, -OCH₂OCH₂OP(=O)(OH)₂, OP(O)(OH)₂-Base, OCH₂OP(O)(OH)₂-Base, -OCH₂OCH₂OP(=O)(OH)₂-Base, -(OCH₂)_mOC(=O)CH₂NHR^X, -(OCH₂)_mOC(=O)CH(R^m)NR⁶R⁷, -OCOCH₂CH₂NH₃⁺HCOO⁻, -OCOCH₂CH₂COOH, -OCO(CH₂)₃COOH, -OC(O)(CH₂)_aNR^FR^G, wobei a 0 - 3 ist, -OC(O)CH₂CH₂C(O)OCH₂CH₂OH oder -OC(O)-Z-C(O)-R' ist;

R^X eine Benzoyl-, Acetyl-, Phenylacetyl-, Formyl-, Mono-, Di- und Trihalogenacetylgruppe ist;

Z —CH₂CH₂—, —CH₂CH₂CH₂—, —CH=CH—, eine 1,2-Cyclohexan- oder 1,2-Phenylengruppe ist;

R'—OH, —OH-Base, —NR'₂R'₃, —OR'₃, —SR'₃ oder —OCH₂C(O)NR'₄R'₅ ist;

R'₂—H oder —CH₃ ist;

R'₃—(CH₂)_jNR'₆R'₇ oder (CH₂)_nN⁺R'₆R'₇R'₈X⁻ ist, wobei j 1 - 3 ist;

R'₄—H oder ein —C₁-C₄-Alkylrest ist;

R'₅—H, ein C₁-C₄-Alkylrest, eine Benzyl-, Hydroxyethylgruppe, -CH₂CO₂H oder eine Dimethylaminoethylgruppe ist;

R'₆ und R'₇ unabhängig —H, —CH₃, —CH₂CH₃, eine Benzylgruppe sind oder R'₆ und R'₇ zusammen mit dem Stickstoffatom von NR'₆R'₇ eine Pyrrolidin-, Piperidin-, Morpholin- oder N-Methylpiperizingruppe bilden;

R'₈—CH₃, -CH₂CH₃ oder eine Benzylgruppe ist;

X⁻ ein Halogenid ist;

Base NH₃, (HOC₂H₄)₃N, N(CH₃)₃, CH₃N(C₂H₄)₂NH, NH₂(CH₂)₆NH₂, N-Methylglucamin, NaOH oder KOH ist;

R^F und R^G unabhängig —H oder ein —C₁-C₃-Alkylrest sind oder R^F und R^G zusammen mit dem Stickstoffatom von NR^FR^G eine Pyrrolidin-, Piperidin-, Morpholin- oder N-Methylpiperizingruppe bilden;

R^m —H, -CH₃, -CH₂CH(CH₃)₂, -CH(CH₃)CH₂CH₃, -CH(CH₃)₂, eine —CH₂-Phenylgruppe, -(CH₂)₃NH₂, -(CH₂)₄NH₂, -CH₂CH₂COOH, -(CH₂)₃NHC(=NH)NH₂, der Rest der Aminosäure Prolin, -OC(O)CH=CH₂, -C(O)CH₂CH₂C(O)NHCH₂CH₂CH₂SO₃⁻Y⁺ oder -OC(O)CH₂CH₂C(O)NHCH₂CH₂CH₂SO₃⁻Y⁺ ist;

Y⁺ Na⁺ oder N⁺(Bu)₄ ist;

R² eine Phenyl- oder substituierte Phenylgruppe ist;

R⁴ ein C₁₋₄-Alkyl-, C₃₋₅-Cycloalkyl- oder —O-(C₁-C₄-Alkylrest) ist;

L O oder S ist;

R⁶ und R⁶ unabhängig ein Wasserstoffatom, -SH, ein Rest -S-[C₁₋₆-Alkyl(OH)_m], eine -S-Ethenyl-, -S-substituierte Ethenylgruppe, -S(O)_nCH₂CN, -S(O)_nCH₂C(O)Q, ein Rest -SCH₂-Halogen, -SC(O)-[C₁₋₆-Alkyl(OH)_m], -SC(O)O(C₁-C₆-Alkyl), -SC(O)N(W)₂, -SC(S)-(C₁-C₆-Alkyl), -SC(S)O(C₁-C₆-Alkyl), -SC(S)N(W)₂, -S(O)_n-[C₁₋₆-Alkyl(OH)_m], -S(C₁-C₆-Alkyl)₂X⁻, -S(O)₂OH, -S(O)₂NH[C₁₋₆-Alkyl(OH)_m], -S(O)₂N[C₁₋₆-Alkyl(OH)_m]₂, -S-S-[C₁₋₆-Alkyl(OH)_m], eine —S-S-substituierte Phenylgruppe, -S(O)-CN, -S(O)₂-CN, -SCH₂O(C₁₋₆-Alkyl(OH)_m), -SCH(C₁-C₆-Alkyl)O[C₁₋₆-Alkyl(OH)_m], -SCH₂OCH₂OCH₃, -SCH₂S[C₁₋₆-Alkyl(OH)_m], -SCH₂S(O)[C₁₋₆-Alkyl(OH)_m], -SCH₂S(O)₂[C₁₋₆-Alkyl(OH)_m], -S-Heteroarylrest oder —SCN ist; mit der Maßgabe, dass R⁶ und R⁶ nicht beide ein Wasserstoffatom sind;

m 0, 1, 2 oder 3 ist;

n 0, 1 oder 2 ist;

eine S-substituierte Ethenylgruppe —S-C(R^H)=C(R^J)(R^K) ist, wobei zwei der Reste R^H, R^J und R^K jeweils H sind und der andere von R^H, R^J und R^K ein C₁₋₃-Alkyl-, CN, COOC₁₋₃-Alkylrest, S(O)₂CH₃ oder C(O)CH₃ ist;

W H oder ein C₁₋₆-Alkylrest ist;

Q—[C₁₋₆-Alkyl(OH)_m], -O(C₁₋₆-Alkyl), -OCH₂CCl₃, -N(W)₂ oder -C(O)OH ist;

R⁷ ein Wasserstoffatom, eine Hydroxylgruppe ist oder zusammen mit R¹⁹ einen Cyclopropanring bildet;

R⁹ und R⁹ unabhängig ein Wasserstoffatom oder eine Hydroxylgruppe sind oder R⁹ und R⁹ zusammen eine

Oxo(Keto)-Gruppe bilden;

R¹⁰ ein Wasserstoffatom, eine Hydroxylgruppe oder ein —OC(O)-(C₁-C₆-Alkylrest) ist;

R¹⁴ ein Wasserstoffatom oder eine Hydroxylgruppe ist; und

R¹⁹ eine Methylgruppe ist oder zusammen mit R⁷ einen Cyclopropanring bildet.

2. Verbindung nach Anspruch 1 oder ein pharmazeutisch verträgliches Salz davon, wobei:

R eine Phenyl-, p-Fluorphenyl-, p-Chlorphenyl-, p-Hydroxyphenyl-, p-Tolyl-, Isopropyl-, Isopropenyl-, Isobutenyl-, Isobutyl-, Cyclopropyl-, Furyl- oder Thienylgruppe ist;

R² eine Phenylgruppe ist;

L O ist;

R⁶ ein Wasserstoffatom ist;

R⁶ -SH, -S-[C₁₋₆-Alkyl(OH)_m], eine -S-Ethenyl-, oder -S-substituierte Ethenylgruppe, -S(O)_nCH₂CN, -S(O)_nCH₂C(O)Q, -SCH₂Halogen, -SC(O)-[C₁₋₆-Alkyl(OH)_m], -SC(O)O(C₁-C₆-Alkyl), -SC(O)N(W)₂, -SC(S)

- $-(C_1-C_6-Alkyl)$, $SC(S)O(C_1-C_6-Alkyl)$, $-SC(S)N(W)_2$, $-S(O)_n-[C_{1-6}-Alkyl(OH)_m]$, $-S(C_1-C_6-Alkyl)_2^+X^-$, $-S(O)_2OH$,
 $-S(O)_2NH[C_{1-6}-Alkyl(OH)_m]$, $-S(O)_2N[C_{1-6}-Alkyl(OH)_m]_2$, $-S-S-[C_{1-6}-Alkyl(OH)_m]$, $-S-S$ -substituierter Phenyl-,
 $-S(O)-CN$, $-S(O)_2-CN$, $-SCH_2O[C_{1-6}-Alkyl(OH)_m]$, $-SCH(C_1-C_6-Alkyl)O[C_{1-6}-alkyl(OH)_m]$, $-SCH_2OCH_2OCH_3$,
 $-SCH_2S[C_{1-6}-Alkyl(OH)_m]$, $-SCH_2S(O)[C_{1-6}-Alkyl(OH)_m]$, $-SCH_2S(O)_2[C_{1-6}-Alkyl(OH)_m]$, $-S$ -Heteroarylrest
 5 oder $-SCN$ ist;
 R^9 und R^9 zusammen eine Oxo(Keto)-Gruppe bilden;
 R^{10} eine Hydroxylgruppe oder $-OC(O)CH_3$ ist; und
 R^{14} ein Wasserstoffatom ist.
- 10 3. Verbindung nach Anspruch 2 oder pharmazeutisch verträgliche Salze davon, wobei
 R^6 $-SH$, $-S-[C_{1-6}-Alkyl(OH)_m]$, $-S(O)_n-[C_{1-6}-Alkyl(OH)_m]$, eine $-S$ -Ethenyl- oder $-S$ -substituierte Ethenylgruppe,
 $-SCH_2CN$, $-S(O)CH_2CN$, $-SCH_2C(O)Q$, $-SC(O)-[C_{1-6}-Alkyl(OH)_m]$, $-SCH_2O[C_{1-6}-Alkyl(OH)_m]$, $-SCH(C_1-C_6-Alkyl)$
 $O[C_{1-6}-Alkyl(OH)_m]$, $-SCH_2OCH_2OCH_3$, $-SCH_2S[C_{1-6}-Alkyl(OH)_m]$, $-SCH_2S(O)[C_{1-6}-Alkyl(OH)_m]$, $-SCH_2S(O)_2$
 $[C_{1-6}-Alkyl(OH)_m]$ oder $-SCN$ ist.
- 15 4. Verbindung nach Anspruch 3 oder pharmazeutisch verträgliche Salze davon, wobei:
 R^B $-NHC(O)PH$ oder ein $-NHC(O)O-(C_{1-6}-Alkylrest)$ ist;
 R^D eine Hydroxylgruppe ist;
 20 R^4 eine Methylgruppe ist;
 R^6 $-S-[C_{1-6}-Alkyl(OH)_m]$, eine $-S$ -Ethenyl- oder $-S$ -substituierte Ethenylgruppe, $-SCH_2CN$, $-S(O)CH_2CN$,
 $-SCH_2C(O)Q$, $-S(O)(C_{1-6}-Alkyl)$, $-SC(O)-[C_{1-6}-Alkyl(OH)_m]$, $-SCH_2OCH_3$, $-SCH_2OCH_2OCH_3$, $-SCH_2S(C_{1-6}-Alkyl)$,
 $-SCH_2S(O)(C_{1-6}-Alkylrest)$ oder $-SCN$ ist; und
 R^7 ein Wasserstoffatom ist oder zusammen mit R^{19} einen Cyclopropanring bildet.
- 25 5. Verbindung nach Anspruch 4 oder pharmazeutisch verträgliche Salze davon, wobei:
 R^7 ein Wasserstoffatom ist; und
 R^{19} eine Methylgruppe ist.
- 30 6. Verbindung nach Anspruch 5 oder pharmazeutisch verträgliche Salze davon, wobei:
 R eine Phenylgruppe ist;
 R^6 eine $-S$ -Methyl-, $-S$ -Ethyl- oder $-S$ -Ethenylgruppe, $-SCH_2CN$, $-S(O)CH_2CN$, $-SCH_2C(O)-(C_{1-6}-Alkyl)$, $-S(O)$
 35 $-(C_{1-6}-Alkyl)$, $-SC(O)-[C_{1-6}-Alkyl(OH)_m]$, $-SCH_2OCH_3$, $-SCH_2OCH_2OCH_3$, $-SCH_2SCH_3$, $-SCH_2S(O)(CH_3)$ oder
 $-SCN$ ist; und
 R^{10} $-OC(O)CH_3$ ist.
- 40 7. Verbindung nach Anspruch 1, in der
 R eine Phenyl- oder substituierte Phenylgruppe ist;
 R^B $-NHC(O)Ph$ oder ein $-NHC(O)O(C_{1-6}-Alkylrest)$ ist;
 R^D eine Hydroxylgruppe ist;
 R^2 eine Phenylgruppe ist;
 R^4 eine Methylgruppe ist;
 45 L O ist;
 R^6 ein Wasserstoffatom ist;
 R^6 $-SH$, $-S(C_{1-3}-Alkyl)$, $-SCN$, $-S$ -Ethenyl, $-SCH_2CN$, $-SCH_2CH_2OH$, $-SCH_2(O)-[C_{1-6}-Alkyl(OH)_m]$ oder
 $-S$ -(2-Thienylgruppe) ist;
 R^7 ein Wasserstoffatom ist;
 50 R^9 und R^9 zusammen eine Oxo(Keto)-Gruppe bilden;
 R^{10} $-OC(O)CH_3$ oder OH ist;
 R^{14} ein Wasserstoffatom ist; und
 R^{19} eine Methylgruppe ist.
- 55 8. Verbindung nach Anspruch 7, in der
 R eine Phenyl-, p-Chlorphenyl-, p-Methylphenyl-, p-Fluorphenyl- oder p-Hydroxyphenylgruppe ist.
9. Arzneimittel, umfassend eine antitumorwirksame Menge einer Verbindung der Formel I nach einem der Ansprüche


1 - 8.

10. Verbindung der Formel I nach einem der Ansprüche 1 - 8 zur Verwendung als Medikament.

5 11. Verwendung einer Verbindung der Formel I nach einem der Ansprüche 1 - 8 zur Herstellung eines Medikaments zur Hemmung des Tumorwachstums in einem menschlichen Wirt.

Revendications

10 1. Composé de la formule I, ou un sel pharmaceutiquement acceptable de celui-ci



où:

30 R est aryle, aryle substitué, alkyle C₁₋₆, alcényle C₂₋₆, cycloalkyle C₃₋₆, ou hétéroaryle;

R^B est -NHC(O)-aryle, -NHC(O)-aryle substitué, -NHC(O)-hétéroaryle, -NHC(O)OCH₂Ph, -NHC(O)O-(alkyle C₁₋₆), ou -NHC(O)O-(cycloalkyle C₃₋₆);

35 R^D est hydroxy, -OC(O)R^x, -OC(O)OR^x, OP(O)(OH)₂, OCH₂OP(O)(OH)₂, -OCH₂OCH₂OP(=O)(OH)₂, base OP(O)(OH)₂, base OCH₂OP(O)(OH)₂, base -OCH₂OCH₂OP(=O)(OH)₂, -OCH₂)_mOC=OCH₂NHR^x, -(OCH₂)_mOC(=O)CH(R'')NR'₆R'₇, -OCOCH₂CH₂NH₃⁺HCOO⁻, -OCOCH₂CH₂COOH, -OCO(CH₂)₃COOH, -OC(O)(CH₂)_aNR^FR^G, où a est 0-3, -OC(O)CH₂CH₂C(O)OCH₂CH₂OH ou -OC(O)-Z-C(O)-R';

40 R^x est benzyle, acétyle, phénylacétyle, formyle, mono-, di-, et trihaloacétyle,

Z est -CH₂CH₂-, -CH₂CH₂CH₂-, -CH=CH-, 1,2-cyclohexane ou 1,2-phénylène;

45 R' est -OH, base -OH, -NR'₂R'₃, -OR'₃, -SR'₃, ou -OCH₂C(O)NR'₄R'₅;

R'₂ est -H ou -CH₃;

R'₃ est -(CH₂)_jNR'₆R'₇ ou (CH₂)_nN⁺R'₆R'₇R'₈X⁻, où j est 1-3;

50 R'₄ est -H ou -alkyle C₁₋₄;

R'₅ est -H, -alkyl C₁₋₄, benzyle, hydroxyéthyle, -CH₂CO₂H ou diméthylaminoéthyle;

55 R'₆ et R'₇ sont indépendamment -H, -CH₃, -CH₂CH₃, benzyle ou R'₆ et R'₇ avec l'azote de NR'₆R'₇ forment un groupe pyrrolidino, pipéridino, morpholino, ou N-méthylpipéridino;

R'₈ est -CH₃, -CH₂CH₃ ou benzyle;

X⁻ est halogénure;

base est NH₃, (OCH₂H₄)₃N, N(CH₃)₃, CH₃N(C₂H₄)₂NH, NH₂(CH₂)₆NH₂, N-méthylglucamine, NaOH ou KOH;

R^F et R^G sont indépendamment -H ou -alkyle C₁-C₃, ou bien R^F et R^G pris ensemble avec l'azote de NR^FR^G forment des groupes pyrrolidino, pipéridino, morpholino ou N-méthylpipéridino;

Rⁿ est -H, -CH₃, -CH₂CH(CH₃)₂, -CH(CH₃)CH₂CH₃, -CH(CH₃)₂, -CH₂phényle, -(CH₂)₃NH₂, -(CH₂)₄NH₂, -CH₂CH₂COOH, -(CH₂)₃NHC(=NH)NH₂, le résidu de l'acide aminé proline, -OC(O)CH=CH₂, -C(O)CH₂CH₂C(O)NHCH₂CH₂SO₃-Y⁺ ou -OC(O)CH₂CH₂C(O)NHCH₂CH₂CH₂SO₃-Y⁺;

Y⁺ est Na⁺ ou N⁺(Bu)₄;

R² est phényle ou phényle substitué;

R⁴ est alkyle C₁₋₄, cycloalkyle C₃₋₅ ou -O-(alkyle C₁-C₄);

L est O ou S;

R⁶ et R^{6'} sont indépendamment hydrogène, -SH, -S-[alkyle C₁₋₆(OH)_m], -S-éthényle, éthényle -S-substitué, -S(O)_nCH₂CN, -S(O)_nCH₂C(O)Q, -SCH₂ halogène, -SC(O)-[alkyle C₁₋₆(OH)_m], -SC(O)O(alkyle C₁-C₆), -SC(O)N(W)₂, -SC(S)-(alkyle C₁-C₆), -SC(S)O(alkyle C₁-C₆), -SC(S)N(W)₂, -S(O)_n-[alkyle C₁₋₆(OH)_m], -S(alkyle C₁-C₆)₂X⁻, -S(O)₂OH, -S(O)₂NH[alkyle C₁₋₆(OH)_m], -S(O)₂N[alkyle C₁₋₆(OH)_m]₂, -S-S-[alkyle C₁₋₆(OH)_m], phényle -S-S-substitué, -S(O)-CN, -S(O)₂-CN, -SCH₂O[alkyle C₁₋₆(OH)_m], -SCH(alkyle C₁-C₆)O[alkyle C₁-C₆(OH)_m], -SCH₂OCH₂OCH₃, -SCH₂S[alkyle C₁-C₆(OH)_m], -SCH₂S(O)[alkyle C₁-C₆(OH)_m], -SCH₂S(O)₂[alkyle C₁-C₆(OH)_m], -S-hétéroaryle ou -SCN; à condition que R⁶ et R^{6'} ne soient pas tous deux hydrogène;

m est 0, 1, 2 ou 3;

n est 0, 1, ou 2;

éthényle S-substitué est -S-C(R^H)=C(R^J)(R^K), où deux de R^H, R^I et R^K sont chacun H et l'autre de R^H, R^J et R^K est alkyle C₁₋₃, CN, COOalkyle C₁₋₃, S(O)₂CH₃ ou C(O)CH₃;

W est H ou alkyle C₁₋₆;

Q est -[alkyle C₁₋₆(OH)_m], -O(alkyle C₁₋₆), -OCH₂CCl₃, -N(W)₂ ou -C(O)OH;

R⁷ est hydrogène, hydroxy ou bien quand ils sont pris ensemble avec R¹⁹, forme un cycle cyclopropane;

R⁹ et R^{9'} sont indépendamment hydrogène ou hydroxy ou bien R⁹ et R^{9'} forment ensemble un groupe oxo (céto);

R¹⁰ est hydrogène, hydroxy ou -OC(O)-(alkyle C₁-C₆);

R¹⁴ est hydrogène ou hydroxy; et

R¹⁹ est méthyle ou bien quand il est pris ensemble avec R⁷ forme un cycle cyclopropane.

2. Composé de la revendication 1 ou son sel pharmaceutiquement acceptable
où:

R est phényle, p-fluorophényle, p-chlorophényle, p-hydroxyphényle, p-tolyle, isopropyle, isopropényle, isobutényle, isobutyle, cyclopropyle, furyle ou thiényle;

R² est phényle;

L est O;

R^{6'} est hydrogène;

R⁶ est -SH, -S-[alkyle C₁₋₆(OH)_m], -S-éthényle, éthényle-S-substitué, -S(O)_nCH₂CN, -S(O)_nCH₂C(O)Q, -SCH₂ halogène -SC(O)-[alkyle C₁₋₆(OH)_m], -SC(O)O(alkyle C₁₋₆)-SC(O)N(W)₂, -SC(S)-(alkyle C₁₋₆), SC(S)O(alkyle C₁₋₆), -SC(S)N(W)₂, -S(O)_n-[alkyle C₁₋₆(OH)_m], -S(alkyle C₁₋₆)₂⁺X⁻, -S(O)₂OH, -S(O)₂NH-[alkyle C₁₋₆(OH)_m], -S(O)₂N[alkyle C₁₋₆(OH)_m]₂, -S-S-[alkyle C₁₋₆(OH)_m], phényle -S-S substitué, -S(O)-CN, -S(O)₂-CN, -SCH₂O[alkyle C₁₋₆(OH)_m], -SCH(alkyle C₁₋₆)O[alkyle C₁₋₆(OH)_m], -SCH₂OCH₂OCH₃, -SCH₂S[alkyle C₁₋₆(OH)_m], -SCH₂S(O)[alkyle C₁₋₆(OH)_m], -SCH₂S(O)₂[alkyle C₁₋₆(OH)_m], -S-hétéroaryle ou -SCN;

R⁹ et R^{9'} forment ensemble un groupe oxo (céto);

R¹⁰ est hydroxy ou -OC(O)CH₃; et

R¹⁴ est hydrogène.

3. Composé de la revendication 2 ou son sel pharmaceutiquement acceptables où:

R⁶ est -SH, -S-[alkyle C₁₋₆(OH)_m], -S(O)_n-[alkyle C₁₋₆(OH)_m], -S-éthényle, éthényle -S- substitué, -SCH₂CN, -S(O)CH₂CN, -SCH₂C(O)Q, -SC(O)-[alkyle C₁₋₆(OH)_m], -SCH₂O[alkyle C₁₋₆(OH)_m], -SCH(alkyle C₁₋₆)O[alkyle C₁₋₆(OH)_m], -SCH₂OCH₂OCH₃, -SCH₂S[alkyle C₁₋₆(OH)_m], -SCH₂S(O)[alkyle C₁₋₆(OH)_m], -SCH₂S(O)₂[alkyle C₁₋₆(OH)_m], ou -SCN.

4. Composé de la revendication 3 ou ses sels pharmaceutiquement acceptables où:

R^B est -NHC(O)-Ph ou -NHC(O)O-(alkyle C₁₋₆);

R^D est hydroxy;

R⁴ est méthyle;

R⁶ est -S-[alkyle C₁₋₆(OH)_m], -S-éthényle, éthényle -S-substitué, -SCH₂CN, -S(O)CH₂CN, -SCH₂C(O)Q, -S(O)(alkyle C₁₋₆), -SC(O)-[alkyle C₁₋₆(OH)_m], -SCH₂OCH₃, -SCH₂OCH₂OCH₃, -SCH₂S(alkyle C₁₋₆), -SCH₂S(O)(alkyle C₁₋₆), ou -SCN; et

R⁷ est hydrogène ou bien quand ils sont pris ensemble avec R¹⁹, forme un cycle cyclopropane.

5. Composé de la revendication 4 ou ses sels pharmaceutiquement acceptables où:

R⁷ est hydrogène; et

R¹⁹ est méthyle.

6. Composé de la revendication 5 ou ses sels pharmaceutiquement acceptables où:

R est phényle;

R⁶ est -S-méthyle, -S-éthyle, -S-éthényle, -SCH₂CN, -S(O)CH₂CN, -SCH₂C(O)-(alkyle C₁₋₆), -S(O)-(alkyle C₁₋₆), -SC(O)-[alkyle C₁₋₆(OH)_m], -SCH₂OCH₃, -SCH₂OCH₂OCH₃, -SCH₂SCH₃, -SCH₂S(O)(CH₃), ou -SCN; et

R¹⁰ est -OC(O)CH₃.

7. Composé de la revendication 1, où:

R est phényle ou phényle substitué;

R^B est -NHC(O)Ph ou -NHC(O)O(alkyle C₁₋₆),

R^D est hydroxy;

R² est phényle;

5 R⁴ est méthyle;

L est O;

10 R⁶ est hydrogène;

R⁶ est -SH, -S(alkyle C₁₋₃), -SCN, -S-éthényle, -SCH₂CN, -SCH₂CH₂OH, -SCH₂(O)-[alkyle C₁₋₆(OH)_m] ou -S-(2-thiényle);

15 R⁷ est hydrogène;

R⁹ et R^{9'} forment ensemble un groupe oxo(céto);

R¹⁰ est -OC(O)CH₃ ou OH;

20 R¹⁴ est hydrogène; et

R¹⁹ est méthyle.

25 8. Composé de la revendication 7 où:

R est phényle, p-chlorophényle, p-méthylphényle, p-fluorophényle ou p-hydroxyphényle.

9. Formulation pharmaceutique qui comprend une quantité efficace antitumorale d'un composé de la formule I selon l'une quelconque des revendications 1-8.

30 10. Composé de la formule I selon l'une quelconque des revendications 1-8 pour une utilisation comme médicament.

11. Utilisation d'un composé de formule I selon l'une quelconque des revendications 1-8 pour la fabrication d'un médicament pour inhiber la croissance des tumeurs chez un hôte mammalien.

THIS PAGE BLANK (USPTO)